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Myrthe van Herk-Sukel
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the Eindhoven Cancer Registry-PHARMO linkage
The crab is the symbol for cancer and the pink colour represents 
breast cancer awareness.  The crab is composed of many smaller 
crabs referring to the complexity of cancer and its treatment. 
The medicines used to treat breast cancer are symbolised 
by the pipette and snake; the symbol of medicine. 
The numbers and figures stand for the large, population-
based data sources used for this research.
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Breast cancer epidemiology
In	the	Netherlands,	breast	cancer	is	the	most	frequent	(30%)	of	all	cancers	in	women1.	In	
2008,	around	13,000	women	were	newly	diagnosed	with	the	disease1.	Worldwide,	breast	
cancer	accounted	for	almost	1.4	million	new	cancer	patients	in	20082.	
Incidence	 rates	 of	 breast	 cancer	 have	 been	 increasing	 in	 the	Netherlands	 since	 19603.	
This	increase	can	be	explained	by	several	factors:	the	increased	detection	of	(early)	breast	
cancer	due	to	the	introduction	and	increased	use	of	mammography	and	cytology	since	
the	1980s,	 the	 implementation	of	 the	mass	breast	 cancer	 screening	program	between	
1991	and	1996,	and	a	change	 in	adverse	way	of	 the	 risk	 factors	 for	breast	 cancer	over	
the	years.	Many	known	risk	factors	are	related	to	endogenous	hormones:	young	age	at	
menarche,	 higher	 age	 at	menopause,	 high	 age	 at	 first	 childbirth,	 lower	 parity,	 shorter	
lactation	and	obesity4.	Changes	in	adverse	way	of	these	reproductive	patterns	and	other	
lifestyle	factors,	such	as	physical	activity5,	have	almost	certainly	played	an	important	role	
in	the	increase	of	breast	cancer	incidence.	
In	2008,	3,300	patients	died	of	breast	cancer	in	the	Netherlands,	making	it,	together	with	
lung	cancer,	the	most	important	cause	of	cancer	death	among	women1.	However,	breast	
cancer	survival	has	improved	for	several	decades:	in	the	1970s	5-year	relative	survival	was	
less	than	50%,	while	for	patients	diagnosed	in	2000-2002	this	was	80%6.	Factors	related	
to	the	increased	survival	are,	among	other	things,	early	detection	through	breast	cancer	
awareness	and	screening,	resulting	in	a	more	favourable	stage	distribution,	and	improved	
(adjuvant)	treatment7.
With	 the	 incidence	 rates	 of	 breast	 cancer	 increasing	 and	 survival	 rates	 improving,	 the	
number	of	prevalent	breast	cancer	patients	will	continue	to	rise.	In	2005	it	was	estimated	that	
119,000	patients	in	the	Netherlands	were	ever	diagnosed	with	breast	cancer6.	Breast	cancer	
prevalence	rises	with	approximately	5%	annually8,	and	in	2015	the	number	of	(ex-)breast	
cancer	patients	might	increase	to	about	194,0009.	This	number	is	expected	to	continue	to	rise	
also	due	to	demographic	developments	(age	distribution	skewed	toward	old	age).	A	large	
proportion	of	these	women	will	still	require	some	form	of	health	care,	either	for	diagnosis	
and	treatment,	surveillance	during	follow-up,	or	because	of	recurrences,	metastases	or	new	
primary	malignancies.	Breast	 cancer	 survivors	are	at	high	 risk	of	developing	 subsequent	
primary	cancers	either	in	the	breast	or	in	another	organ10-12.
12
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Developments in systemic breast cancer treatment
Recent	decades	have	brought	a	dramatic	 increase	 in	 the	number	of	new	agents	being	
investigated	and	approved	for	the	treatment	of	patients	with	breast	cancer.	The	majority	
of	 these	agents	represent	a	new	category	of	 targeted	compounds:	drugs	that	 interfere	
with	 specific	 targeted	molecules	 needed	 for	 carcinogenesis	 and	 tumour	growth13.	The	
treatment	of	patients	with	breast	cancer	with	targeted	drugs	has	a	long	record	starting	
with	 the	 approval	 of	 tamoxifen	 for	 the	 treatment	 of	 hormone	 (oestrogen)	 receptor	
positive	metastatic	breast	cancer	in	the	seventies	of	the	last	century14.	Since	then,	the	list	
of	 oncology	drug	 targets	 in	breast	 cancer	patients	has	 expanded	 including	aromatase	
(aromatase	 inhibitors),	 epidermal	 growth	 factor	 receptor	 2	 (trastuzumab)	 and	 vascular	
endothelial	 growth	 factor	 (bevacizumab)15.	 These	 targeted	 drugs	 together	 with	 the	
conventional	chemotherapeutics	that	interfere	with	rapidly	dividing	cells,	result	in	many	
systemic	treatment	options	to	choose	from	when	treating	the	breast	cancer	patient.	
New morbidities after breast cancer diagnosis and treatment 
Current	 systemic	 breast	 cancer	 treatment	 is	 often	 dispensed	 next	 to	 surgery	 and	
radiotherapy	 and	 mainly	 consists	 of	 chemotherapeutics	 administered	 concurrently	
or	 in	 specified	 sequential	 regimens	 followed	 by	 hormonal	 therapy	 in	 patients	 with	
hormone	 positive	 breast	 cancer.	These	 approaches	 can	 increase	 the	 efficacy	 of	 breast	
cancer	treatment,	but,	at	the	same	time,	may	generate	new	morbidities	that	need	to	be	
recognized.	
Each	type	of	breast	cancer	treatment	may	create	various	morbidities.	Radiation	therapy	
may	have	both	localized	side	effects	(such	as	skin	irritation	after	external	radiation)	and	
more	 general	 side	 effects	 (such	 as	 fatigue).	 Morbidities	 after	 radiotherapy	 are	 often	
temporary,	 but	 late	 effects,	 such	 as	 cardiovascular	 disease,	may	 occur16,	 17.	Morbidities	
after	surgical	treatment	are	decreased	due	to	the	less	invasive	diagnostic	and	treatment	
techniques,	such	as	sentinel	lymph	node	biopsy	and	lumpectomy.	However,	lymphoedema	
remains	a	clinically	relevant	complication18.	Ovarian	ablation	in	premenopausal	women	
with	 hormone	 receptor-positive	 breast	 cancer	 by	 e.g.	 luteinizing	 hormone	 releasing	
hormone	 (LHRH)	 agonists,	 causes	 menopause-related	 symptoms	 such	 as	 increased	
risk	of	bone	 loss	 and	 cardiovascular	 events19.	 Endocrine	 treatment	with	 tamoxifen	 can	
cause,	next	to	menopause-related	symptoms,	much	more	serious	rare	morbidities	such	
as	endometrial	cancer,	cataract	and	thromboembolism20.	The	most	common	late	effect	
associated	with	aromatase	inhibitors	is	bone	loss21.	Long-term	risks	after	chemotherapy	
depend	on	the	specific	treatment	received.	Next	to	menopause-related	symptoms	in	pre-
menopausal	women	due	to	amenorrhea,	cardiotoxicity	is	a	complication	that	is	rare	after	
chemotherapeutic	treatment	with	some	agents,	but	may	occur	in	>20%	of	patients	treated	
with	doxorubicin,	daunorubicin	or	fluorouracil22,	23.	Moreover,	the	risk	of	cardiotoxicity	with	
Myrthe van Herk-Sukel
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the	targeted	drug	trastuzumab	has	been	reported	to	be	4%	with	monotherapy	and	27%	
when	 administered	 in	 combination	with	 anthracyclines24.	Other	 chemotherapy	 related	
long-term	treatment	complications	are	acute	leukaemia	and	myelodysplasia	depending	
on	the	type	of	cytotoxic	drugs	received25	and	impaired	cognitive	functioning	depending	
on	chemotherapy	dose	and	duration26.
So,	new	morbidities	resulting	from	breast	cancer	treatment	may	be	acute,	late,	reversible,	
or	 persistent.	 Acute,	 short-term	 side	 effects	 occur	 during	 treatment	 and	 many	 are	
reversible	 and	 treatable.	 Long-term	 morbidities	 occur	 during	 treatment	 and	 may	 or	
may	 not	 be	 permanent.	 Late	 effects	may	 emerge	weeks	 or	months	 after	 treatment	 is	
completed	 or	 even	 sometimes	 not	 be	 evident	 until	many	 years	 later.	 Serious	 late	 and	
long-term	irreversible	morbidities	are	of	most	concern	especially	as	they	are	potentially	
life	shortening.
Need for a new data source for pharmacoepidemiological studies in breast 
cancer patients
Efforts	to	treat	breast	cancer	are	all	aimed	at	maximizing	the	changes	for	a	healthy	 life	
while,	at	 the	same	time,	minimizing	new	morbidities.	Documenting	how	breast	cancer	
is	treated	and	how	these	treatments	affect	the	patient,	becomes	crucial	for	determining	
whether	these	interventions	are	tolerable	and	acceptable	and	provide	significant	clinical	
benefits.	While	effectiveness	and	safety	of	breast	cancer	therapies	are	thoroughly	studied	
in	randomized	clinical	trials,	few	data	are	available	on	these	parameters	in	a	daily	practice	
setting.	Daily	clinical	practice	differs	 from	the	experimental	 setting	with	 respect	 to	 the	
heterogeneity	of	patients,	their	age,	treatments	and	co-medication.	Moreover,	important	
side	effects	may	not	be	detectable	in	clinical	trials	since	the	frequency	of	many	adverse	
events	 is	 low	and	adverse	effects	of	cancer	 therapies	may	occur	many	years	after	drug	
administration.27-29
With	the	increasing	number	of	patients	who	were	ever	diagnosed	with	breast	cancer	and	
the	increase	in	the	number	of	new	agents	being	approved	for	the	treatment	of	patients	
with	breast	 cancer,	 there	 is	a	need	 for	a	new	data	 source	 that	 facilitates	post-approval	
drug	utilization,	(cost-)effectiveness	and	safety	studies	on	anti-cancer	drugs	among	breast	
cancer	patients.	Linkage	of	cancer	registry	data	to	an	administrative	healthcare	database	
that	includes	information	on	drug	use	and	(co-)morbidities	makes	this	type	of	research	in	
breast	cancer	patients	possible.	
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Outline
The	main	objectives	of	the	studies	described	in	this	thesis	were:
1.	 To	explore	whether	the	linkage	of	the	Eindhoven	Cancer	Registry	and	PHARMO	Record	
Linkage	System	would	create	a	good	data	source	for	pharmacoepidemiological	studies	
in	cancer	patients.
2.	 To	 assess	 systemic	 breast	 cancer	 treatment	 in	 daily	 clinical	 practice,	 including	
chemotherapy	and	endocrine	therapy.	
3.	 To	define	incidence	of	morbidities	after	breast	cancer	diagnosis	and	treatment.
PART I 
To	create	a	unique	source	for	numerous	types	of	pharmacoepidemiological	studies	in	
cancer	patients	we	investigated	whether	the	linkage	of	the	Eindhoven	Cancer	Registry	
(ECR)	and	the	PHARMO	Record	Linkage	System	(PHARMO	RLS)	was	 feasible	and	valid	
(Chapter 2.3).	This	linkage	included	all	cancer	sites;	however,	as	the	size	of	the	created	
ECR-PHARMO	cohort	was	too	small	to	study	rare	cancers,	the	study	population	for	this	
thesis	included	the	largest	study	cohort:	breast	cancer	patients.	
PART II 
Trends	 in	 the	 use	 of	 adjuvant	 systemic	 treatment	 (chemotherapy	 and/or	 hormonal	
therapy)	 in	 daily	 clinical	 practice	 were	 determined	 using	 solely	 data	 from	 the	 ECR	
(Chapter 3).	 Expanding	data	 from	 the	 included	breast	 cancer	 cohort	with	data	 from	
the	PHARMO	RLS	allowed	us	to	 investigate	the	type	of	chemotherapy	regimens	used	
with	detailed	 information	on	the	administered	 intravenous	chemotherapies	obtained	
from	the	PHARMO	in-hospital	pharmacy	database	(Chapter 4).	Data	from	the	PHARMO	
community	 pharmacy	 database	 was	 used	 to	 determine	 the	 treatment	 pattern	 of	
endocrine	therapy	use	of	breast	cancer	patients	living	in	the	ECR-PHARMO	catchment	
area	(Chapter 5).
PART III
In	this	part	of	the	thesis	we	determined	the	incidence	of	morbidities	after	breast	cancer	
diagnosis	 and	 treatment.	 First,	 we	 assessed	 the	 incidence	 of	 cardiovascular	 events	
among	breast	cancer	patients	after	chemotherapy	(Chapter 6).	Second,	the	incidence	of	
myocardial	infarction,	ischaemic	stroke	and	pulmonary	embolism	after	hospitalisation	
for	 breast	 cancer	 was	 determined	 (Chapter 7).	 For	 the	 latter,	 solely	 data	 from	 the	
20
Myrthe van Herk-Sukel
C h a p t e r  11
PHARMO	RLS	were	 used	 as	 this	 resulted	 in	 a	 larger	 cohort	 of	 breast	 cancer	 patients	
(with	less	detailed	information	on	the	disease)	which	was	desirable	to	be	able	to	study	
these	rare	events.
PART IV
Finally,	 this	thesis	ends	with	an	overview	of	 linked	databases	comparable	to	the	 linked	
ECR-PHARMO	 cohort	 (Chapter 8.2).	 In	 the	 general	 discussion	 the	main	 results	 of	 the	
studies	on	breast	cancer	treatment	and	related	morbidities	are	considered.	We	conclude	
with	future	perspectives	for	research	with	the	linked	ECR-PHARMO	cohort	and	possible	
expansion	of	this	cohort.
Myrthe van Herk-Sukel
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Eindhoven Cancer Registry
The	Eindhoven	Cancer	Registry	 (ECR)	 is	a	population-based	registry,	maintained	by	the	
Comprehensive	Cancer	Centre	South,	which	was	started	in	1955	as	part	of	a	programme	
for	nation-wide	cancer	registration	in	the	area	of	southeastern	North	Brabant1.	Data	on	all	
new	cancer	patients	are	collected	directly	from	pathology	reports	and	patients’	medical	
records.	The	registry	was	started	in	three	hospitals	in	Eindhoven	and	gradually	expanded	
to	include	the	south	eastern	part	of	the	province	of	North	Brabant,	the	northern	part	of	
the	province	of	Limburg	 (since	1970)	 	and	 the	middle	and	southwestern	part	of	North	
Brabant	 since	 1986	 (except	 the	 small	 most	 western	 part)	 (Figure	 1).	 Other	 regional	
registries	had	discontinued	their	activities,	until	a	successful	nationwide	program	was	re-
established	since	1984.	Since	1989	 the	whole	Dutch	population	 is	 covered	by	 regional	
cancer	registries,	which	established	the	National	Cancer	Registry.
Figure 1. The current area of the Eindhoven Cancer Registry of the Comprehensive Cancer Centre South
The	area	in	the	population-based	ECR	is	now	served	by	10	general	hospitals	at	16	locations	
and	two	large	radiotherapy	institutes	and	covers	a	demographic	region	with	2.4	million	
inhabitants.	The	region	is	characterized	by	good	access	to	medical	care	without	financial	
obstacles.	The	distance	to	a	hospital	has	always	been	less	than	30	kilometres.	The	area	does	
not	contain	university	or	specialized	cancer	hospitals.	There	are	six	pathology	laboratories,	
all	 participating	 in	 the	 nationwide	 PALGA	 network2,	 3,	 which	 also	 notifies	 the	 regional	
cancer	registries.	The	cancer	registry	receives	lists	of	newly	diagnosed	patients	on	a	regular	
base	from	the	pathology	departments.	In	addition,	the	medical	records	departments	of	
the	hospitals	provide	lists	of	outpatients	and	hospitalized	cancer	patients.	Following	this	
notification,	the	medical	records	of	newly	diagnosed	patients	(and	tumours)	are	collected,	
and	trained	registrars	from	the	cancer	registry	abstract	the	required	information.	Data	are	
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checked	for	duplicate	records.	Patients	who	live	in	the	catchment	area	of	the	ECR,	but	are	
diagnosed	in	hospitals	elsewhere	in	the	Netherlands,	are	regularly	retrieved	from	all	other	
Dutch	cancer	registries	since	1989.	Before	this	year	it	was	done	directly	through	retrievals	
at	all	the	cancer	centres.
Staging
Staging	of	breast	cancer	is	categorised	according	to	the	TNM-classification	developed	and	
maintained	by	the	International	Union	Against	Cancer	(UICC)4.	The	TNM	classification	is	
based	on:	1)	the	size	of	the	tumour	(T),	2)	whether	or	not	the	tumour	has	spread	to	the	
lymph	nodes	in	the	armpits	(N),	and	3)	whether	the	tumour	has	metastasized	(M).
Histological classification 
Breast	tumours	were	classified	based	on	site	(topography)	and	morphology	(histology),	
according	 to	 the	 WHO	 International	 Classification	 of	 Diseases	 for	 Oncology	 (ICD-O)5.	
Histologic	 tumour	 grade	 was	 recorded	 as:	 well	 differentiated	 (low	 grade),	 moderately	
differentiated	(intermediate	grade),	or	poorly	differentiated	(high	grade).	
Receptor status
Breast	cancer	cells	may	or	may	not	have	three	important	receptors:	Oestrogen	Receptor	
(ER),	Progesterone	Receptor	(PR),	and	Human	Epidermal	growth	factor	Receptor	2	(Her2/
neu;	also	known	as	ErbB-2).	Since	1984,	ER	and	PR	status	have	been	recorded	by	the	ECR	
on	each	woman	diagnosed	with	breast	carcinoma	which	was	determined	by	means	of	
immunohistochemistry.	The	result	of	hormone	receptor	status	was	recorded	as	‘positive’,	
‘weakly	positive’	 and	‘negative’.	 In	 this	 thesis,	 tumours	coded	as	‘weakly	positive’	 in	 the	
pathology	reports	were	also	classified	in	the	‘positive’	group.	For	hormone	receptor	status	
one	combined	variable	was	created	with	the	following	subgroups:	ER+	and/or	PR+;	ER-	
and	PR-;	unknown.
Since	2005,	Her2/neu	status	was	recorded	in	the	ECR	on	a	routine	basis.	Her2-positivity	was	
recorded	using	a	widely	recommended	testing	algorithm6,	7.	An	 immunohistochemistry	
(IHC)	 score	3+	was	considered	positive.	When	 IHC	was	 inconclusive	 (2+),	 an	additional	
fluorescent	in	situ	hybridization	(FISH)	test	was	indicated.	IHC	score	3+	or	a	positive	FISH	
test	was	considered	indicative	for	Her2/neu	overexpression.	
Initial treatment
Initial	treatment	(i.e.	treatment	given	or	planned	within	the	first	six	months	after	diagnosis)	
was	recorded	in	the	ECR,	including	radiotherapy	(yes/no),	chemotherapy	(yes/no),	endocrine	
treatment	(yes/no)	and	surgery.	Details	on	the	type	of	surgical	procedure	were	recorded	as	well,	
such	as	breast	conserving	surgery	or	mastectomy	with	or	without	axillary	dissection.	Moreover,	
the	 sequence	 of	 breast-cancer	 treatment	 was	 registered	 to	 define	whether	 breast-cancer	
treatment	had	been	tumour-removing	surgery	followed	by	chemotherapy	and/or	radiation	
therapy,	or	whether	chemotherapy	was	started	before	surgery	(neoadjuvant	chemotherapy).	
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Co-morbidity
Since	1993,	the	registry	also	records	co-morbidity	according	to	a	slightly	adaptation	of	the	
list	of	serious	diseases	drawn	up	by	Charlson	and	colleagues.8
Table 1. Classification of co-morbidity, modified version of the list of Charlson et al.8 
Co-morbidities
Chronic obstructive pulmonary disease (COPD)
Cardiovascular disease: myocardial infarction, cardiac insufficiency, angina pectoris, coronary artery bypass graft 
(CABG)
Peripheral arterial disease: intermittent claudication, abdominal aneurysm, surgical intervention
Cerebrovascular diseases (cerebrovascular accident, hemiplegia)
Other malignancies (except basal cell carcinoma)
Hypertension
Diabetes mellitus
Other:
  Autoimmune diseases: sarcoidosis, Wegener’s disease, systemic lupus erythematosis (SLE)
  Rheumatoid arthritis
  Kidney diseases: glomerulonephritis, pyelonethritis
  Gastrointestinal: stomach ulcer and resection, colitis
  Liver diseases: cirrhosis, hepatitis
  Dementia
  Chronic infections
In	 short,	 the	 following	 important	 conditions	 were	 recorded	 (Table	 1):	 chronic	
obstructive	 pulmonary	 diseases	 (COPD),	 cardiovascular	 and	 cerebrovascular	 diseases,	
other	malignancies	 (excluding	basal	 cell	 carcinoma	of	 the	 skin),	 and	diabetes	mellitus.	
Furthermore,	 hypertension,	 connective	 tissue	 diseases,	 rheumatoid	 arthritis,	 kidney,	
bowel,	and	liver	diseases,	dementia,	tuberculosis,	and	other	chronic	infections	were	also	
recorded.9,	10
Socio-economic status
An	indicator	of	socio-economic	status	developed	by	Statistics	Netherlands	was	used.11	At	
the	six-position	level	of	postal	code,	data	on	household	income	and	the	economical	value	
of	the	house	are	available	from	fiscal	data	from	the	year	2000.	Within	each	postal	code	there	
are	about	17	households,	so	this	aggregate	measure	counts	for	a	very	small	geographic	
area,	which	enhances	the	reliability.	Furthermore,	the	use	of	routinely	collected	income	
tax	data	(no	questionnaires	or	interviews)	gives	reliable	estimates	of	household	income.	
Socio-economic	status	was	categorized	according	to	quintiles	ranging	from	1	(low)	to	5	
(high),	with	a	separate	class	for	postal	codes	with	a	care	providing	institution	(such	as	a	
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nursing	home).	This	measure	is	assumed	to	be	valid	ten	years	before	and	after	the	set	year	
(2000).	Socio-economic	differences	based	on	neighbourhood	data	have	proven	to	be	a	
fairly	good	reflection	of	socio-economic	differences	at	an	individual	level.12	
PHARMO Record Linkage System
The	 PHARMO	 Record	 Linkage	 System	 (PHARMO	 RLS)13	 is	 a	 population-based	 patient-
centric	data	tracking	system	which	started	in	1986	including	high	quality	and	complete	
information	of	approximately	3	million	inhabitants	of	65	municipal	areas	in	the	Netherlands.	
The	central	patient	database	is	linked	to	more	than	ten	databases	using	different	record	
linkage	algorithms.14-17	Databases	relevant	for	observational	cancer	research	include	virtual	
complete	 longitudinal	 data	 obtained	 from	 hospital	 discharge	 records	 (Dutch	 National	
Medical	Registration:	LMR),	community	pharmacies	(out-patient),	and	a	growing	number	
of	in-hospital	pharmacies	(in-patient),	clinical	laboratories	and	general	practitioners	(these	
last	three	databases	are	available	for	a	sub-cohort	of	the	patients	included	in	the	PHARMO	
RLS).	 The	 out-	 and	 in-patient	 pharmacy,	 clinical	 laboratory	 and	 general	 practitioner	
database	are	managed	by	PHARMO	and	directly	accessible,	while	permission	is	needed	to	
use	the	data	from	the	Dutch	National	Medical	Registration.	Moreover,	external	databases	
are	linked	on	a	patient	level	to	the	PHARMO	central	patient	database	and	can	be	used	on	
a	project	basis	(after	permission	from	the	database	holders),	such	as	the	Dutch	National	
Pathology	Registry	(PALGA)2,	3	and	the	Perinatal	Register18.	Patient-centric	information	from	
the	databases	can	be	enriched	via	direct	access	to	the	patient	or	caregivers.	A	schematic	
overview	of	the	PHARMO	RLS	and	the	created	research	database	is	presented	in	Figure	3.	
The	PHARMO	RLS	includes	a	dynamic	cohort	of	patients.	Turnover	occurs	when	patients	
move	 in	 and	 out	 of	 the	 PHARMO	RLS	 catchment	 area.	The	 records	 of	‘transferred	 out’	
patients	 remain	 in	 the	 database	 and	 are	 available	 for	 retrospective	 studies	 with	 the	
appropriate	time	periods.	Patients	can	be	followed	over	a	long	period	of	time,	until:	the	
patient	moves	out	of	the	PHARMO	RLS	catchment	area;	death;	end	of	data	collection	of	
one	of	the	databases	used	in	a	specific	research	study;	or	end	of	study	period	of	a	specific	
research	study.	
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Figure 2. Schematic overview of the PHARMO RLS
Hospital discharge records: Dutch National Medical Register (LMR) 
The	Dutch	National	Medical	Register	 (LMR)19	 is	 a	national	database	of	 the	Netherlands	
(more	than	16	million	inhabitants)	and	linked	to	the	community	pharmacy	database,	this	
database	covers	an	area	of	approximately	3	million	inhabitants.	It	comprises	all	hospital	
admissions,	i.e.,	admissions	for	more	than	24	hours	and	admissions	for	less	than	24	hours	
for	which	a	bed	 is	 required.	These	records	 include	detailed	 information	concerning	the	
primary	 (mandatory)	 and	 secondary	 (optional)	 discharge	 diagnoses,	 procedures	 and	
dates	 of	 hospital	 admission	 and	 discharge.	 All	 diagnoses	 are	 coded	 according	 to	 the	
International	Classification	of	Diseases,	9th	edition	(ICD-9-CM)	20.
Drug dispensing data: via community pharmacies (out-patient)
The	community	pharmacy	database	is	a	nationally	representative	database	which	was	started	
in	1986	and	includes	dispensing	information	from	community	pharmacies	in	the	Netherlands.	
The	database	includes	all	general	practitioner	or	specialist	prescribed	and	pharmacy	dispensed	
healthcare	products	on	the	Dutch	market.	The	database	covers	an	area	of	approximately	3	
million	 inhabitants	and	a	 total	of	 approximately	4	million	patient	 lives	are	 included	 in	 the	
database.	 Of	 each	 dispensed	 drug,	 the	 Anatomical	 Therapeutic	 Chemical	 (ATC)	 code21,	
dispensing	date,	prescriber,	prescribed	dosage	regimen,	dispensed	quantity	are	available.	The	
duration	of	use	of	each	dispensing	is	defined	by	dividing	the	number	of	units	dispensed	by	
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the	number	of	units	to	be	used	per	day,	as	defined	in	the	pharmacies.	The	costs	of	drugs	are	
estimated	from	a	third	payer	perspective	and	represent	reimbursement	costs	per	dispensing	
record	including	VAT.	All	drug	dispensing	data	in	the	pharmacy	database	are	encoded	according	
to	standards	based	upon	the	Z-Index	drug	database22.	It	is	possible	to	identify	and	classify	drug	
use	followed	over	time,	both	on	the	basis	of	national	and	international	classification	schemes	
and	on	the	basis	of	a	drug’s	individual	active	ingredients	and	administration	forms.	
Drug dispensing data: via in-hospital pharmacies (in-patient)
The	 in-hospital	 pharmacy	 database	 comprises	 hospital	 pharmacy	 data	 collected	 in	
a	 growing	 number	 of	 general	 hospitals	 in	 the	 Netherlands	 (currently	 a	 subset	 of	 15	
hospitals).	 The	 database	 covers	 an	 area	 of	 approximately	 1	 million	 inhabitants	 and	 a	
total	of	approximately	2	million	patient	lives	are	included	in	the	database.	This	database	
includes	data	on	in-patients’	medication	orders	(type	of	drug,	dose,	time	of	administration	
and	duration	of	 use).	 Chemotherapy	data	 in	 the	 in-hospital	 pharmacy	database	 is	 not	
complete	 for	 all	 the	 included	 hospital	 pharmacies,	 as	 not	 all	 hospitals	 have	 data	 on	
administered	 chemotherapies	 electronically	 available.	 For	 complete	 registration	 of	 the	
supplied	chemotherapies	in	this	database,	currently	additional	non-electronic	data	from	
the	hospital	pharmacies	is	collected	and	added	to	this	in-hospital	database.
Clinical laboratory data
The	clinical	laboratory	database	includes	tests	taken	(e.g.,	blood	tests)	and	results	for	all	of	
these	tests	derived	through	a	total	of	9	clinical	laboratories	in	the	Netherlands.	The	database	
covers	an	area	of	approximately	1	million	inhabitants	and	a	total	of	almost	2	million	patient	
lives	are	 included	 in	 the	database.	The	clinical	 laboratories	are	completely	computerized	
and	use	auto-analysers	for	testing,	thereby	including	all	test	results	in	a	central	database.	
Test	 results	are	checked	against	 threshold	values	and	controlled	by	clinical	chemists	and	
those	 requesting	 the	data,	before	storing	 into	 the	database.	Errors	are	corrected	and	 re-
analyses	can	be	run	on	the	same	(blood	tissue	or	other)	sample.	Erroneous	test	results	are	
overwritten	by	new	re-analyses.	The	laboratory	data	are	of	superior	quality	as	everything	is	
recorded	independently	of	the	test	result	or	physician.	The	tests	are	requested	by	general	
practitioners	and/or	 specialists.	 Laboratory	 function	 tests	 (e.g.	 lung	 tests)	are	 structurally	
collected	by	only	 one	of	 the	nine	 laboratories	 in	 this	 database	 and	 include	mostly	 only	
general	practitioner	requested	functional	laboratory	tests.	
General practitioner data
The	general	practitioner	database	is	a	longitudinal	observational	database	that	contains	
data	 from	 computer-based	 patient	 records	 of	 general	 practitioners	 (GPs)	 throughout	
the	 Netherlands.	 GPs	 receive	 completely	 control	 usage	 of	 their	 data,	 through	 the	
Steering	 Committee	 and	 are	 permitted	 to	withdraw	 data	 for	 specific	 research	 studies.	
Collaborating	 practices	 are	 located	 throughout	 the	Netherlands	 and	 the	 collaborating	
GPs	are	comparable	to	other	GPs	in	the	country	based	on	age	and	gender.	The	general	
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practitioner	database	covers	an	area	of	almost	1	million	 inhabitants	 including	almost	2	
million	patient	lives.	Detailed	clinical	information	and	prescription	drugs	data	are	captured	
in	 this	 database,	 including	 among	 other	 things,	 demographic	 data	 (age,	 sex,	 patient	
identification,	 GP	 registration	 information),	 diagnoses,	 physician-linked	 indications	 for	
therapy,	co-morbidity,	drug	prescriptions,	 laboratory	values	(e.g.	potassium,	creatinine),	
doctor	in	attendance,	referrals	to	specialists,	and	a	‘medical	chart’	containing	free-text	as	
noted	by	the	general	practitioner.	Diagnoses	and	symptoms	are	recorded	based	on	the	
International	Classification	of	Primary	Care	(ICPC)	–	which	can	be	mapped	to	 ICD-9-CM	
codes,	but	diagnoses	and	complaints	can	also	be	entered	as	free	text.23	Prescription	data	
such	 as	 product	 name,	 quantity	 dispensed,	 dosage	 regimens,	 strength	 and	 indication	
are	entered	 into	the	computer.	Prescriptions	 include	medications	prescribed	by	the	GP	
(please	note	that	specialist	prescriptions	are	generally	not	included	in	the	GP	data).	
Other databases
Databases	that	can	be	linked	to	the	ECR	and/or	the	PHARMO	RLS	to	obtain	information	
relevant	for	(pharmaco)epidemiologic	studies	in	the	area	of	oncology	are	the	data	from	
the	Central	Bureau	of	Genealogy	and	the	Dutch	National	Pathology	Registry.
Survival
Either	 the	 ECR	 or	 the	 PHARMO	 RLS	 can	 be	 linked	 to	 data	 from	 the	 Central	 Bureau	 of	
Genealogy	(CBG)24,	or	 the	Dutch	municipal	personal	administrative	database	 (GBA)25	 to	
obtain	information	on	the	vital	status.	The	CBG	is	the	Dutch	information	and	documentation	
centre	for	genealogy,	family	history	and	related	sciences.	Data	are	national	and	collected	
since	October	1994	and	include	virtually	complete	coverage	of	all	deceased	Dutch	citizens.	
In	the	GBA	all	deceased	and	emigrated	persons	in	the	Netherlands	are	registered.
Pathology
The	Dutch	nationwide	network	and	registry	for	histo-	and	cytopathology	(Pathologisch	
Anatomisch	Landelijk	Geautomatiseerd	Archief;	PALGA)	contains	data	of	all	histological,	
cytological	 and	 autopsy	 examinations	 in	 the	 Netherlands.2,	 3	 PALGA	 has	 developed	 a	
system	of	online	central	archiving	for	use	in	direct	patient	care	and	research.	The	data	is	
generated	and	used	voluntarily	on	daily	basis	by	all	(65)	departments	in	the	Netherlands.	
This	registration	started	in	1975	and	reached	100%	participation	in	the	country	since	1990.	
It	also	serves	for	several	national	population-based	screening	examinations	and	forms	the	
main	database	source	for	the	Dutch	regional	cancer	registries,	as	described	above.	PALGA	
contains	 abstracts	 of	 the	 pathology	 reports;	 an	 abstract	 consists	 of	 encrypted	 patient	
identification;	a	summary	of	the	report;	diagnostic	terms	being	in	scope	with	SNOMED	
classification.	Currently,	about	42	million	abstracts	of	more	than	10	million	patients	have	
been	stored	and	each	year	more	than	2	million	abstracts	are	being	added
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L i n k a g e  c o n c e p t s
Overlap of ECR and PHARMO RLS
The	overlap	area	of	the	ECR	and	the	PHARMO	RLS	in	2008	is	presented	by	the	black	area	in	
Figure	1.	This	ECR-PHARMO	catchment	area	includes	approximately	1	million	inhabitants.	
Cancer	patients	living	in	this	catchment	area	were	eligible	for	linkage	and	patients	who	
were	not	a	member	of	the	catchment	population	of	both	registries	were	eliminated.	
Figure 1. The current area of the Eindhoven Cancer Registry (ECR) and overlap with the area of the PHARMO 
record linkage system (PHARMO RLS)
Record linkage concepts
Cancer	 patients	 registered	 in	 the	 ECR	 are	 identified	 by	 a	 unique	 patient	 identification	
number.	This	number	differs	from	the	patient	number	used	in	the	PHARMO	RLS.	Moreover,	
as	both	databases	only	contain	deidentified	information	(i.e.,	all	personal	identifiers	have	
been	removed	from	the	file),	no	unique	personal	identifiers	are	available.	As	a	result,	simple	
deterministic	linkage	using	a	patient	identifier	as	linkage	key	cannot	be	performed	and	
semi-deterministic	or	probabilistic	linkage	is	needed.	Semi-deterministic	and	probabilistic	
linkage	are	based	on	the	calculation	that	two	records	belong	to	the	same	patient	given	
a	set	of	on	itself	not	unique	patient	characteristics.	Semi-deterministic	linkage	has	a	very	
high	 specificity:	 the	number	of	 true	matches	among	 the	 linked	pairs	 is	high,	provided	
information	of	variables	is	sufficiently	high	and	error	rates	are	not	extreme;	while	it	has	
Area ECR
Overlap area ECR and PHARMO RLS
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a	 relatively	 low	 sensitivity	 as	many	 true	matches	may	not	be	 found	even	 if	 error	 rates	
per	 variable	 are	 low1.	 As	 semi-deterministic	 linkage	 will	 not	 allow	 any	 transcription	
flaws	or	records	with	missing	data,	probabilistic	linkage	is	preferred	in	our	situation.	The	
probabilistic	concept	assumes	that	errors	and	missings	will	always	be	present	in	the	record	
linkage	process.
Detailed	information	on	the	methodology	and	the	validation	of	the	used	record	linkage	
method	in	this	thesis	can	be	found	elsewhere1-8	as	well	as	the	used	terminology	(see	Table	
1	of	Blakely	and	Salmond7).	In	short,	probabilistic	linkage	includes	three	major	procedures:	
1)	blocking,	2)	matching	and	3)	linking.	Blocking	is	the	process	of	creating	pairs	of	patient	
records	based	on	variables	that	are	assumed	to	be	filled-out	correctly	and	do	not	change	
over	time,	such	as	gender	and	date	of	birth.	This	is	the	only	step	in	the	linkage	process	
that	does	not	allow	variables	to	include	transcription	flaws.	Blocking	results	in	improving	
matching	 efficiency	 (speeding	 up	 the	matching	process)	 as	 not	 all	 records	 of	 the	 ECR	
have	to	be	matched	to	each	record	of	the	PHARMO	RLS,	but	only	those	that	are	included	
in	a	 record	pair.	 Following	 the	blocking	 step,	matching	occurs,	which	 is	 the	process	of	
comparing	pairs	of	records	to	predict	whether	they	should	be	 linked.	There	are	several	
models	for	statistical	probabilistic	record	linkage	and	in	this	thesis	Bayesian	algorithms2	
are	used	which	are	also	used	for	the	linkage	of	the	PHARMO	hospital	discharge	records	
(LMR)	to	the	PHARMO	community	pharmacy	database3-6.	Multiple	variables,	such	as	first	
initial	and	zip	code	are	used	and	the	contribution	of	each	matching	variable	is	expressed	
in	a	 likelihood	ratio.	By	multiplication	of	 these	 likelihood	ratios	and	prior	 linkage	odds,	
the	odds	can	be	calculated	that	two	records	belong	to	the	same	patient	against	that	they	
belong	to	different	patients.	Finally,	linkage	is	performed	based	on	the	summarized	match	
odds	of	all	variables	and	a	threshold	value	above	which	comparison	pairs	are	categorized	
as	links	and	below	which	the	comparison	pairs	are	categorized	as	non-links.	The	optimal	
single	threshold	value	is	the	odds	at	which	misclassification	is	minimal	and	the	pair	with	
the	highest	weight	value	above	threshold	is	defined	as	positive	link	(same	patient)	and	all	
other	pairs	of	that	specific	block	are	defined	as	negative	links	(different	patients),	as	only	
one	file	record	can	logically	belong	to	the	same	patient.	A	special	situation	occurs	when	
more	than	two	records	yield	the	same,	highest	match	odds,	which	exceeds	the	threshold.	
In	this	situation	no	decision	can	be	reached	as	probably	both	records	actually	belong	to	
the	same	patient.	These	record	pairs	are	defined	as	unsolvable	pairs	and	need	to	be	solved	
manually.	
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Abstract
Background: 
Insight	 into	co-morbidity	and	treatment	effects	 is	pivotal	 to	 improve	quality	of	
care	for	cancer	patients.
Objectives: 
To	determine	whether	 the	 linkage	of	 the	Eindhoven	Cancer	Registry	 (ECR)	and	
the	PHARMO	Record	Linkage	System	(RLS)	was	technically	feasible	and	to	assess	
which	patient-centric	data	would	result	from	this.
Methods: 
The	 ECR	 records	 data	 on	 tumour	 stage	 and	 primary	 treatment	 of	 all	 newly	
diagnosed	 cancer	 patients	 in	 the	 southeastern	 Netherlands	 including	 co-
morbidity	 at	diagnosis,	whereas	 the	PHARMO	RLS	 includes	data	 from	multiple	
linked	observational	databases	such	as	data	on	drug	utilization	(for	both	in-	and	
out-patients,	 including	 chemotherapy),	 hospitalisations	 and	 clinical	 laboratory	
measurements.	All	patients	who	lived	or	had	been	living	in	the	overlapping	area	
served	 by	 the	 ECR	 and	 the	 PHARMO	 RLS	 during	 1998-2006	were	 selected	 for	
linkage	which	was	performed	with	probabilistic	medical	record	linkage.
Results: 
The	linkage	resulted	in	an	ECR-PHARMO	cohort	of	40,004	cancer	patients	with	a	
total	of	42,767	primary	tumours.	The	cancer	patients	in	the	linked	ECR-PHARMO	
cohort	were	representative	for	the	cancer	patients	included	in	the	total	ECR	during	
1998-2006.	Cancer	patients	 included	 in	 the	cohorts	had	a	mean	history	of	five	
years	and	a	mean	follow-up	ranging	from	two	to	more	than	four	years	(dependent	
on	the	survival	rate	of	the	specific	cancer	type).
Conclusions: 
Linkage	 of	 ECR	 and	 the	 PHARMO	 RLS	 creates	 the	 possibility	 to	 study	 patient-
centric	drug	utilization,	health	resources	utilization	and	their	costs,	in	addition	to	
the	effectiveness	and	safety	of	pharmaceuticals	in	routine	daily	practice	in	cancer	
patients.
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Introduction
In	Europe	 there	are	over	 two	million	 incident	patients	with	 cancer	every	year	 and	 it	 is	
expected	that	this	number	will	continue	to	rise1.	With	the	ageing	of	the	population	and	
the	 increasing	survival	of	cancer	patients	with	co-morbid	conditions,	cancer	 is	and	will	
become	an	increasingly	important	factor	in	the	global	burden	of	disease	in	the	decades	
to	come.	
A	growing	number	of	cancer	patients	are	treated	with	novel	treatment	combinations	and	
targeted	therapies	are	being	introduced	at	relatively	early	stages	of	disease	progression.	
While	 effectiveness	 and	 safety	 of	 these	 new	 therapies	 are	 thoroughly	 studied	 in	
randomized	clinical	trials,	little	data	are	available	on	these	parameters	in	a	daily	practice	
setting.	 Effectiveness	 of	 anti-cancer	 drugs	 may	 be	 different	 than	 expected	 as	 daily	
clinical	practice	differs	from	the	experimental	setting	with	respect	to	the	heterogeneity	
of	patients,	their	treatments	and	co-medication.	Moreover,	 important	safety	issues	may	
not	be	detectable	in	clinical	trials	since	the	frequency	of	many	adverse	events	is	low	and	
adverse	 effects	 of	 cancer	 therapies	may	occur	many	 years	 after	 drug	 administration.2-4	
Balancing	effectiveness	and	adverse	effects	is	therefore	a	major	challenge	in	the	treatment	
of	cancer	patients	and	monitoring	post	approval	drug	use	is	especially	important	for	anti-
cancer	drugs	that	receive	accelerated	FDA	and	EMEA	approval.	
Besides	monitoring	 the	effectiveness	and	safety	of	cancer	 treatments,	pharmaceuticals	
used	for	a	wide	variety	of	other	conditions	may	be	associated	with	increasing	or	decreasing	
risk	of	cancer,	 such	as	non-steroidal	anti-inflammatory	drugs	or	 lipid	 lowering	drugs5,	6.	
Data	to	confirm,	refute	or	elaborate	on	these	hypotheses	are	sparse.
To	shed	light	on	the	burden	of	cancer,	disease	management,	safety	aspects,	co-morbidity	
patterns	 and	 outcomes	 assessments,	 follow-up	 of	 patients	 before	 and	 after	 cancer	
diagnosis	 in	 routine	daily	practice	 is	pivotal.	For	 this,	 large	administrative	databases	or	
cancer	 registries	 are	 often	 used7.	 However,	 both	 type	 of	 data	 collections	 mostly	 lack	
detail;	 either	 with	 respect	 to	 the	 incidence	 and	 staging	 of	 cancer	 or	 with	 respect	 to	
(pharmaco)treatments,	morbidity	and	co-morbidity	during	follow-up8.	
We	therefore	explored	whether	the	linkage	of	a	regional	cancer	disease	register	(Eindhoven	
Cancer	Registration:	 ECR)	and	a	patient-centric	data	network	 including	multiple	 linked	
observational	databases	(PHARMO	Record	Linkage	System:	PHARMO	RLS9)	was	feasible,	
valid	 and	 detailed	 enough	 to	 fulfil	 the	 abovementioned	 information	 needed.	 In	 this	
manuscript	 we	 describe	 the	 results	 of	 this	 linkage	 as	 well	 as	 the	 patient-centric	 data	
on	drug	 treatment	 (out-patient	 and	 in-patient),	 hospitalisations	 and	 clinical	 laboratory	
measurements	that	become	available	during	follow-up	before	and	after	cancer	diagnosis	
for	the	cancer	patients	present	in	these	linked	databases.
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Methods
Data sources
The	 Eindhoven	 Cancer	 Registry	 (ECR)	 is	 a	 population-based	 registry	 (covering	
a	 demographic	 region	 with	 2.4	 million	 inhabitants)	 which	 is	 maintained	 by	 the	
Comprehensive	 Cancer	 Centre	 South	 and	 collates	 records	 on	 all	 newly	 diagnosed	
cancer	patients	 in	 the	southeastern	part	of	 the	Netherlands10,	11.	The	ECR	 is	notified	 for	
new	patients	with	cancer	by	six	pathology	departments,	ten	general	hospitals	and	two	
radiotherapy	 institutes.	Trained	 registry	personnel	 subsequently	actively	collect	on	site	
data	on	patient	characteristics,	diagnosis,	tumour	staging,	co-morbidity	at	diagnosis	and	
treatment	received	directly	after	diagnosis	(e.g.	chemotherapy	(yes/no),	radiation	therapy	
and	surgery).
The	 PHARMO	 RLS	 is	 a	 large,	 patient-centric	 data	 network	 including	 multiple	 linked	
observational	 databases	 designed	 for	 safety	 and	 outcomes	 research	 of	 drugs	 which	
collates	patient	 records	 in	48	geographic	defined	areas	 in	 the	Netherlands	 (covering	a	
demographic	 region	of	3	million	 inhabitants).	The	central	patient	database	 is	 linked	 to	
more	than	ten	databases	using	different	medical	record	linkage	algorithms.12-15	Databases	
relevant	 for	 observational	 cancer	 research	 include	 virtual	 complete	 longitudinal	 data	
obtained	 from	community	pharmacies	 (out-patient),	hospital	discharge	 records	 (Dutch	
National	Medical	Registration:	 LMR),	 a	mortality	 registration	and	a	growing	number	of	
clinical	laboratories,	in-hospital	pharmacies	(in-patient)	and	general	practitioners	(these	
last	three	databases	are	available	for	a	sub-cohort	of	the	patients	included	in	the	PHARMO	
RLS).	
Both	the	ECR	and	the	PHARMO	RLS	are	recognized	as	high	quality	sources	for	epidemiological	
research	that	collect	information	in	overlapping	regions	in	the	Netherlands	for	a	period	
of	at	least	10	years.
Medical record linkage 
The	 first	 step	 in	 combining	 the	 ECR	 and	 the	 PHARMO	 RLS	 was	 to	 identify	 in	 both	
databases	all	patients	who	lived	or	had	been	living	in	overlapping	zip	code	areas	and	were	
diagnosed	with	cancer	in	the	period	1998-2006.	This	overlapping	catchment	area	covered	
all	inhabitants	of	510	zip	codes	(approximately	1	million	inhabitants).	
Because	these	databases	only	contain	deidentified	information	(i.e.,	all	personal	identifiers	
have	been	removed	from	the	file),	no	unique	personal	identifiers	were	available	and	hence,	
the	 linkage	 of	 the	 ECR	 and	 the	 PHARMO	RLS	 had	 to	 be	 based	 on	probabilistic	 record	
linkage	technology.16-18	This	technology	is	also	used	for	the	linkage	of	several	databases	in	
the	PHARMO	RLS	and	involves	three	major	steps:	1)	blocking,	2)	matching	and	3)	linking.	
1)	In	the	blocking	step17,	for	each	patient	in	the	ECR,	data	on	patients	from	the	PHARMO	
RLS	with	similar	gender	and	date	of	birth	were	grouped	into	record	pairs.	An	example	of	
the	approach	would	be	as	follows:	If	there	were	2	patients	with	similar	gender	and	date	
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of	birth	in	the	ECR	and	there	were	3	patients	in	the	PHARMO	RLS,	then	the	blocking	step	
would	result	in	6	(2x3)	record	pairs.	
2)	 In	 the	matching	 step17,	 for	 each	 record	 pair	 the	 probability	 (match	 odds)	 that	 both	
records	of	the	ECR	and	the	PHARMO	RLS	belong	to	the	same	patient	was	calculated	using	
Bayesian	algorithms19.	Multiple	matching	variables	available	in	both	databases	were	used:	
first	initial,	first	letter	last	name,	soundex	code	of	last	name20,	first	four	characters	of	the	
patients’	most	 recent	zip	code	as	well	as	 singular	variables.	The	 latter	 represent	 logical	
relation	between	two	records,	i.e.	an	extra	weight	was	assigned	if	a	cancer	patient	from	
the	ECR	had	been	hospitalized	 for	 cancer	 as	notified	 in	 the	hospital	discharge	 records	
from	the	PHARMO	RLS.	
3)	Finally,	linkage	was	performed	based	on	the	summarized	match	odds	of	all	variables,	the	
weight	value,	by	applying	a	threshold	weight	value16,	17.	The	record	pair	with	the	highest	
cumulative	weight	value	above	threshold	was	defined	as	positive	link	(same	patient)	and	
all	other	pairs	were	defined	as	negative	links	(different	patients),	as	only	one	record	could	
logically	belong	to	the	same	patient.	
Validation
The	 quality	 of	 the	medical	 record	 linkage	 process	was	 evaluated	 in	 a	 random	 sample	
in	which	 additional	person	 information	was	obtained	 from	 the	original	patient-centric	
data	 sources	of	 the	PHARMO	RLS	 (in	 this	case,	 community	pharmacies	participating	 in	
the	PHARMO	system)	and	the	ECR,	including	full	name	and	address	of	the	patients:	the	
“gold	standard”.	Record	pairs	where	manually	compared	after	being	blinded	with	respect	
to	outcome	of	the	above	described	linkage	process.	This	validation	was	approved	by	the	
privacy	committee	of	 the	PHARMO	 Institute	 for	Drug	Outcomes	Research	and	met	 the	
criteria	of	the	health	research	code	of	conduct.21	
The	 validation	 resulted	 in	 true	 and	 false	 record	 pairs	 and	 detailed	 information	 on	
the	methodology	and	 the	validation	of	 the	used	 record	 linkage	method	can	be	 found	
elsewhere12,	 13,	 16-19,	 22,	 23.	 A	 flowchart	 of	 the	 linkage	 of	 the	 ECR	 to	 the	 PHARMO	 RLS	 is	
presented	in	Figure	1.
Representativeness 
The	 linkage	 process	 resulted	 in	 a	 linked	 ECR-PHARMO	 cohort.	 Representativeness	 to	
the	total	ECR	population	was	evaluated	by	comparing	the	distribution	of	gender,	age	at	
tumour	diagnosis,	year	of	diagnosis	and	the	most	common	cancer	sites.	With	respect	to	
the	latter,	unlike	other	current	cancer	registries,	basal	cell	carcinoma	is	also	registered	in	
the	ECR.24	
Characteristics	 per	 tumour	 cohort	 were	 shown	 for	 the	 total	 ECR	 and	 the	 linked	 ECR-
PHARMO	cohort	for	the	four	most	common	types	of	cancer	(not	accounting	for	basal	cell	
carcinoma):	breast	cancer,	colorectal	cancer,	lung	cancer	and	prostate	cancer.
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Illustration of information for different cancer cohorts
An	illustration	of	the	information	gained	from	linkage	of	the	ECR	and	PHARMO	RLS	was	
presented	for	patients	included	in	the	breast	cancer,	colorectal	cancer,	 lung	cancer	and	
prostate	 cancer	 cohorts.	 For	 this,	 information	on	history	 (before	 cancer	diagnosis)	 and	
follow-up	(after	cancer	diagnosis)	was	determined	for	patients	included	in	the	total	linked	
ECR-PHARMO	 cohort	 and	 for	 patients	 included	 in	 a	 sub-cohort	with	 information	 from	
the	clinical	laboratory	database	available	(approximately	80%	of	the	patients	in	the	total	
linked	cohort).	History	was	defined	as	the	time	between	the	date	of	entering	the	PHARMO	
RLS	to	the	date	of	cancer	diagnosis	as	registered	in	the	ECR.	Follow-up	was	defined	as	the	
time	between	date	of	cancer	diagnosis	until	end	of	data-collection	in	the	PHARMO	RLS	
(i.e.	the	patient	moves	out	of	the	PHARMO	RLS	catchment	area),	death,	or	end	of	the	study	
period	(December	31st,	2007),	whichever	occurred	first.
Co-morbidities	at	diagnosis,	medication	use,	hospitalisation	and	laboratory	measurements	
during	the	one	year	before	cancer	diagnosis	were	determined	for	patients	with	at	least	
one	year	history	and	with	data	from	the	clinical	laboratory	database	available.	Treatments	
received,	 medication	 use,	 hospitalisations	 and	 laboratory	 measurements	 during	 the	
one	 year	 after	 cancer	 diagnosis	 were	 determined	 for	 patients	 with	 at	 least	 one	 year	
follow-up	and	with	data	from	the	clinical	laboratory	database	available.	Co-morbidity	at	
cancer	diagnosis	and	initial	therapy	were	extracted	from	the	ECR	and	information	on	co-
medication,	hospitalisations	and	clinical	laboratory	measurement	were	extracted	from	the	
PHARMO	RLS.	For	patients	who	received	chemotherapy,	data	on	the	type	of	cytostatics	
(defined	as	ATC	code	L01)	was	extracted	 from	both	 in-hospital	pharmacies	 (in-patient,	
e.g.	cytostatics	administered	intravenously)	and	community	pharmacies	(out-patient,	e.g.	
cytostatics	administered	orally)	for	a	sub-cohort	(approximately	45%	of	the	patients)	of	
the	PHARMO	RLS.	
Data	 were	 subsequently	 analysed	 using	 SAS	 programs	 that	 are	 organised	 within	 SAS	
Enterprise	Guide	version	4.0	 (SAS	 Institute	 Inc.,	Cary,	NC,	USA).	Data	management	was	
conducted	under	UNIX	using	SAS	version	9.1.	
Results 
Of	the	104,562	cancer	patients	registered	in	the	ECR	in	the	period	1998-2006,	57,612	(55%)	
patients	were	not	eligible	 for	 linkage	of	which	2,339	 (2%)	were	diagnosed	 in	hospitals	
elsewhere	 in	 the	 Netherlands	 and	 55,273	 (53%)	 were	 not	 living	 in	 the	 ECR-PHARMO	
catchment	area	(Figure	1).	
44
Myrthe van Herk-Sukel
C h a p t e r  2
2
Figure 1. Flowchart of the linkage process and cohort formation 
ECR: Eindhoven cancer registry; 1 Data obtained from ECR; 2 Data obtained from PHARMO RLS
Of	 the	 remaining	 46,950	 patients	 who	 were	 eligible	 for	 linkage,	 40,004	 (85%)	 cancer	
patients	were	finally	linked	and	included	in	the	ECR-PHARMO	cohort	with	a	total	of	42,767	
primary	tumours.
Table 1. Representativeness of the linked ECR-PHARMO cohort compared to the total ECR in the period 
 1998-2006 for patients diagnosed with a primary tumour
Total ECR
(N=111,186)
n (%)
Linked ECR-PHARMO 
cohort
(N=42,767)
n (%)
Difference
(% total ECR minus 
% linked cohort)
%
Gender
Male 57,443 (52) 22,239 (52) -0.3
Female 53,743 (48) 20,528 (48) 0.3
Age at tumour diagnosis 
≤ 35 3,659 (3) 1,197 (3) 0.5
Eindhoven
Cancer Registry
≈ 2.4 million inhabitants
Cancer patients in 1998-2006:
N=104,562
(Primary tumours: N=111,186)
Total linked 
ECR-PHARMO cohort
Linked
ECR-PHARMO
sub cohorts
ECR-PHARMO catchment area
≈ 1 million inhabitants
Cancer patients eligible for linkage in 1998-2006
N=46,950 (45%)
(Primary tumours of these patients: N=50,592)
Cancer patients registered in the linked ECR-PHARMO cohort in 1998-2006  N=40,004
-detailed tumour characteristics and initial treatment available¹
-drug dispensing data from community pharmacies available in history and follow-up²
-hospital discharge records available in history and follow-up²
Number of primary tumours of these patients  N=42,767
For approximately 80% of the patients 
data from the clinical laboratory database 
was available2
For approximately 45% of the patients data 
from the in-hospital pharmacy (in-patient, 
e.g. chemotherapy) database was available2
PHARMO
RLS
≈ 3 million inhabitants
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35 – 49 11,909 (11) 4,277 (10) 0.7
50 – 59 20,322 (18) 7,613 (18) 0.5
60 – 69 29,629 (27) 11,761 (28) -0.9
70 – 79 30,895 (28) 12,231 (29) -0.8
89 – 90 13,349 (12) 5,175 (12) -0.1
≥ 90 1,423 (1) 513 (1) 0.1
Year of diagnosis 
1998-2000 32,784 (30) 11,162 (26) 3.4
2001-2003 37,292 (34) 14,626 (34) -0.7
2004-2006 41,110 (37) 16,978 (40) -2.7
Cancer sites
Skin, Basal Cell Carcinoma 22,693 (20) 9,403 (22) -1.6
Breast 14,226 (13) 5,545 (13) -0.2
Colon and Rectum 12,158 (11) 4,804 (11) -0.3
Lung, Bronchus and Trachea 12,105 (11) 4,395 (10) 0.6
Prostate 9,740 (9) 3,835 (9) -0.2
Haematolymphopoetic 6,193 (6) 2,285 (5) 0.2
Skin, other 4,185 (4) 1,594 (4) 0.0
Skin, Melanoma 3,469 (3) 1,210 (3) 0.3
Primary Site Unknown 3,129 (3) 1,147 (3) 0.1
Urinary Bladder 2,849 (3) 1,030 (2) 0.2
Stomach 2,545 (2) 935 (2) 0.1
Not further specified 17,894 (16) 6,584 (15) 0.7
ECR: Eindhoven cancer registry 
Detailed	tumour	data	and	initial	treatment	data	was	extracted	from	the	ECR.	Drug	dispensing	
data	(from	community	pharmacies)	and	hospitalisation	data	was	extracted	from	the	PHARMO	
RLS	for	all	patients	included	in	this	linked	ECR-PHARMO	cohort.	Data	from	the	clinical	laboratory	
database	was	available	for	approximately	80%	of	the	cancer	patients	in	the	linked	ECR-PHARMO	
cohort	and	data	on	specific	type	of	cytostatics	administered	to	a	patient	in-hospital	was	available	
for	approximately	45%	of	the	cancer	patients	in	the	linked	ECR-PHARMO	cohort.
Validation	of	a	random	sample	of	the	linked	ECR-PHARMO	cohort	resulted	in	2,887	true	positive	
links,	42	 false	positive	 links,	51	 false	negative	 links	and	9,009	 true	negative	 links,	 yielding	a	
sensitivity	of	98.3%	(95%	confidence	interval	(CI):	97.7%	-	98.7%)	and	a	specificity	of	99.5%	(95%	
CI:	99.4%	-	99.7%).
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Table 2. Representativeness of breast, colorectal, lung and prostate cancer cohorts1 extracted from the total 
 ECR compared to the cohorts extracted from the linked ECR-PHARMO cohort in the period 1998-2006
Breast Colon and Rectum Lung, Bronchus and 
Trachea
Prostate
Character-
istics
Total 
ECR
(N=14, 226)
n (%)
Linked
ECR- 
PHARMO 
(N=5,545)
n (%)
Total ECR
(N=12, 105)
n (%)
Linked 
ECR- 
PHARMO 
(N=4,804)
n (%)
Total 
ECR
(N=12, 158)
n (%)
Linked 
ECR- 
PHARMO
(N=4,395)
n (%)
Total
ECR
(N=9,740)
n (%)
Linked 
ECR- 
PHARMO
(N=3,835)
n (%)
Gender
Male 99 (0.7) 34 (0.6) 6,419 (53) 2,584 (54) 8,720 (72) 3,176 (72) 9,740 (100) 3,835 (100)
Female 14,127 (99) 5,511 (99) 5,686 (47) 2,220 (46) 3,438 (28) 1,219 (28) NA NA
Age at tumour diagnosis 
≤ 35 418 (3) 139 (3) 75 (0.6) 25 (0.5) 40 (0.3) 13 (0.3) 1 (<0.1) 0 (-)
35 – 49 3,249 (23) 1,178 (21) 650 (5) 252 (5) 816 (7) 252 (6) 75 (0.8) 26 (0.7)
50 – 59 3,523 (25) 1,375 (25) 1,881 (16) 715 (15) 2,253 (19) 781 (18) 1,143 (12) 420 (11)
60 – 69 3,105 (22) 1,272 (23) 3,409 (28) 1,361 (28) 3,969 (33) 1,479 (34) 3,576 (37) 1,413 (37)
70 – 79 2,507 (18) 1,031 (19) 4,036 (33) 1,653 (34) 4,056 (33) 1,489 (34) 3,778 (39) 1,497 (39)
89 – 90 1,265 (9) 488 (9) 1,884 (16) 731 (15) 998 (8) 371 (8) 1,104 (11) 454 (12)
≥ 90 159 (1) 62 (1) 170 (1) 67 (1) 26 (0.2) 10 (0.2) 63 (0.6) 25 (0.7)
Tumour stage
I 5,710 (40) 2,310 (42) 2,279 (19) 931 (19) 2,062 (17) 768 (18) 240 (3) 108 (3)
II 6,137 (43) 2,366 (43) 3,776 (31) 1,476 (31) 679 (6) 268 (6) 6,185 (64) 2,432 (63)
III 1,426 (10) 556 (10) 2,945 (24) 1,244 (26) 3,775 (31) 1,389 (32) 1,397 (14) 509 (13)
IV 621 (4) 225 (4) 2,356 (20) 912 (19) 4,039 (33) 1,410 (32) 1,589 (16) 663 (17)
Other/unknown 332 (2) 88 (2) 749 (6) 241 (5) 1,603 (13) 560 (13) 329 (3) 123 (3)
ECR: Eindhoven cancer registry; 1 four most common types of cancer not accounting for basal cell carcinoma; NA: not applicable. 
The	cancer	patients	included	in	the	linked	ECR-PHARMO	cohort	were	representative	for	
the	cancer	patients	included	in	the	total	ECR	in	the	period	1998-2006	as	shown	in	Table	
1.	The	difference	in	percentage	between	these	two	cohorts	(%	total	ECR	minus	%	linked	
ECR-PHARMO	 cohort)	 showed	 that	 patients	who	were	 linked	 tended	 to	 be	 somewhat	
older,	were	diagnosed	 in	 the	more	 recent	 years	 (2004-2006)	 and	were	diagnosed	with	
the	more	common	types	of	tumours.	Gender,	age	and	tumour	stage	distribution	for	the	
patients	included	in	the	breast,	colorectal,	lung	and	prostate	cancer	cohorts	were	similar	
for	the	total	ECR	and	the	linked	ECR-PHARMO	cohorts	(Table	2).
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Table 3. History before and follow-up after cancer diagnosis of patients included in the linked ECR-PHARMO 
 cohorts and sub-cohort in the period 1998-2006
Characteristics Breast
(N=5,545)
Colon and 
Rectum
(N=4,804)
Lung, 
Bronchus 
and Trachea
(N=4,395)
Prostate
(N=3,835)
History (before cancer diagnosis)
Mean ± SD (years ) 4.9 ± 3.5 5.2 ± 3.6 5.1 ± 3.5 5.2 ± 3.5
Median (interquartile range, years) 4.6 (2.1-7.1) 4.9 (2.2-7.4) 4.9 (2.2-7.4) 4.9 (2.4-7.4)
Patients with ≥ 1 year history 1
in total linked cohort 4,687 (85%) 4,153 (86%) 3,776 (86%) 3,324 (87%)
and with information from the clinical labo-
ratory database available (sub-cohort) 2
3,691 (67%) 3,431 (71%) 3,006 (68%) 2,829 (74%)
Follow-up (after cancer diagnosis)
Mean ± SD (years ) 4.4 ± 2.6 3.4 ± 2.6 2.0 ± 2.2 3.9 ± 2.4
Median (interquartile range, years) 4.1 (2.3-6.3) 2.8 (1.3-5.2) 1.1 (0.5-2.6) 3.5 (1.9-5.6)
Patients with ≥ 1 year follow-up 3 
in total linked cohort 5,164 (93%) 3,910 (81%) 2,403 (55%) 3,541 (92%)
and with information from the clinical labo-
ratory database available (sub-cohort) 2
4,005 (72%) 3,187 (66%) 1,856 (42%) 2,954 (77%)
1 history was defined as time between the date of entering the PHARMO RLS to the date of cancer diagnosis; 2 infor-
mation from the clinical laboratory database was available for approximately 80% of the patients in the total linked 
cohort; 3 follow-up was defined as the time between date of cancer diagnosis until end of data-collection in the 
PHARMO RLS (i.e. the patient moves out of the PHARMO RLS catchment area), death, or end of the study period 
(December 31st, 2007), whichever occurred first.
Patients	diagnosed	with	the	four	most	common	types	of	cancer	included	in	the	linked	ECR-
PHARMO	cohort	were	followed	before	and	after	cancer	diagnosis	to	assess	patients’	baseline	
covariate	status	before	diagnosis	and	(adverse)	events	after	diagnosis	and	treatment.	History	
before	cancer	diagnosis	was	approximately	five	years	and	 similar	 for	all	 four	 cancer	 types,	
while	follow-up	after	cancer	diagnosis	was	dependent	on	patients’	survival	and	ranged	from	a	
mean	follow-up	of	two	years	for	lung	cancer	patients	to	more	than	four	years	for	breast	cancer	
patients	(Table	3).	
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Of	the	cancer	patients	included	in	the	four	major	linked	cancer	cohorts	who	were	registered	
one	year	or	more	in	the	PHARMO	RLS	before	cancer	diagnosis	and	with	data	from	the	clinical	
laboratory	 database	 available,	 co-morbidities	 at	 diagnosis	 and	medication,	 hospitalisation	
and	laboratory	measurements	in	the	one	year	before	cancer	diagnosis	are	presented	in	Table	
4.	 For	 the	most	 common	 co-morbidities:	 cardiovascular	 disease	 (including	 hypertension),	
diabetes	 and	 respiratory	 disease,	 the	 percentage	 of	 patients	with	 these	 co-morbidities	 at	
diagnosis	as	registered	in	the	ECR,	and	the	percentage	of	patients	using	medications	or	who	
had	been	hospitalized	for	these	co-morbidities	as	registered	in	the	PHARMO	RLS,	were	in	the	
same	range	per	type	of	co-morbidity.	Moreover,	to	give	an	impression	of	the	type	of	laboratory	
measurements	available,	the	percentage	of	patients	with	laboratory	measurements	related	to	
their	co-morbidities	in	the	year	before	cancer	diagnosis	are	presented.	
Of	the	cancer	patients	included	in	the	four	major	linked	cancer	cohorts	who	were	registered	
one	year	or	more	in	the	PHARMO	RLS	after	cancer	diagnosis	and	with	data	from	the	clinical	
laboratory	database	available,	 initial	 therapies,	other	 received	medications,	hospitalisations	
and	laboratory	measurements	are	presented	in	Table	5.	Type	of	cytostatics	administered	to	a	
patient	was	available	from	the	PHARMO	RLS	from	in-hospital	pharmacy	data	(in-patient)	and	
the	community	pharmacy	data	(out-patient),	for	41%	(N=465)	of	the	breast	cancer	patients	
to	 55%	 (N=363)	 of	 the	 lung	 cancer	 patients	 who	 received	 chemotherapy.	 In	 Table	 5	 an	
overview	of	the	most	common	types	of	cytostatics	(categories	of	cytostatics)	per	cancer	type	
are	shown,	not	taking	into	account	combinations	of	cytostatics	used	in	the	same	treatment	
regimen.	Next	 to	data	on	cancer	 treatment,	 the	percentage	of	patients	using	medications	
or	who	had	been	hospitalized	during	the	first	year	after	cancer	diagnosis	for	the	three	most	
common	co-morbidities	are	shown.	Moreover,	an	example	is	shown	of	the	type	of	laboratory	
measurements	patients	had	related	to	patients’	cancer	diagnosis	and	co-morbidities	during	
the	one	year	follow-up.	
Table 4. Co-morbidities at diagnosis and medication, hospitalisation and laboratory measurements 
 during the one year before diagnosis of patients with breast, colorectal, lung and prostate cancer, 
 extracted from the linked ECR-PHARMO sub-cohort in the period 1998-2006 1
Characteristics Breast
(N=3,691)
n (%)
Colon and 
Rectum
(N=3,431)
n (%)
Lung, 
Bronchus and 
Trachea
(N=3,006)
n (%)
Prostate
(N=2,829)
n (%)
Co-morbidity at diagnosis; Data obtained from ECR
Number of co-morbidities at diagnosis
None 1,781 (48) 1,028 (30) 709 (24) 936 (33)
1 867 (24) 1,012 (30) 949 (32) 870 (31)
≥ 2 635 (17) 1,090 (32) 1,152 (38) 752 (27)
Unknown 408 (11) 301 (9) 196 (7) 271 (10)
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Characteristics Breast
(N=3,691)
n (%)
Colon and 
Rectum
(N=3,431)
n (%)
Lung, 
Bronchus and 
Trachea
(N=3,006)
n (%)
Prostate
(N=2,829)
n (%)
Type of co-morbidities at diagnosis
Cardiovascular disease 1,030 (28) 1,513 (44) 1,333 (44) 1,220 (43)
Diabetes 294 (8) 404 (12) 328 (11) 251 (9)
Respiratory disease 202 (5) 351 (10) 794 (26) 289 (10)
Medication and/or hospitalisations during one year of history; Data obtained from PHARMO RLS
Cardiovascular disease 
Hospitalisations 108 (3) 230 (7) 223 (7) 164 (6)
Medications 1,586 (43) 1,967 (57) 1,663 (55) 1,628 (58)
Hospitalisation and/or medication2 1,606 (44) 1,990 (58) 1,691 (56) 1,645 (58)
Diabetes
Hospitalisations 5 (0.1) 8 (0.2) 6 (0.2) 6 (0.2)
Medications 273 (7) 365 (11) 273 (9) 245 (9)
Hospitalisation and/or medication2 274 (7) 367 (11) 276 (9) 248 (9)
Respiratory disease
Hospitalisations 21 (0.6) 54 (2) 165 (6) 49 (2)
Medications 374 (10) 479 (14) 1,026 (34) 424 (15)
Hospitalisation and/or medication2 382 (10) 500 (15) 1,080 (36) 442 (16)
Clinical laboratory measurements during one year of history; Data obtained from PHARMO RLS
Cardiovascular related measurements e.g.:
LDL cholesterol 688 (19) 940 (27) 899 (30) 938 (33)
HDL cholesterol 765 (21) 1,024 (30) 972 (32) 1,038 (37)
Diabetes related measurements e.g.:
HbA1c, blood glucose 421 (11) 560 (16) 451 (15) 440 (16)
ECR: Eindhoven cancer registry; SD: standard deviation; LDL: low density lipoprotein; HDL: high density lipoprotein; 
HbA1c: glycated haemoglobin; 1 patients with at least 1 year of history, defined as time between the date of enter-
ing the PHARMO RLS to the date of cancer diagnosis; 2 numbers do not add up as hospitalized patients mostly also 
have received medications
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Table 5. Received treatments, medications, hospitalisations and laboratory measurements during the 
  one year after diagnosis of patients diagnosed with breast, colorectal, lung and prostate cancer 
 extracted from the linked ECR-PHARMO sub-cohort in the period 1998-2006 1
Characteristics Breast
(N=4,005)
n (%)
Colon and 
Rectum
(N=3,187)
n (%)
Lung, 
Bronchus and 
Trachea
(N=1,856)
n (%)
Prostate
(N=2,954)
n (%)
Initial therapies; Data obtained from ECR
Received initial therapies
Surgery 3,828 (96) 2,973 (93) 569 (31) 462 (16)
Radiation therapy 2,767 (69) 822 (26) 757 (41) 1,242 (42)
Hormonal therapy 1,635 (41) 0 (-) 0 (-) 1,383 (47)
Chemotherapy 1,127 (28) 902 (28) 656 (35) 15 (0.5)
Of those who received chemotherapy, type of cytostatics received during one year of follow-up;  
Data obtained from PHARMO RLS for a sub-cohort 2,3
(N=465) (N=411) (N=363) (N=7) 4
Pyrimidine analogues 304 (65) 387 (94) 151 (42) -
Platinum compounds 0 (-) 174 (42) 271 (75) -
Cyclophosphamide 425 (91) 4 (1) 70 (19) -
Anthracyclines 359 (77) 0 (-) 67 (18) -
Etoposide 0 (-) 0 (-) 136 (37) -
Methotrexate 78 (17) 0 (-) 0 (-) -
Monoclonal antibodies 31 (7) 33 (8) 0 (-) -
Taxanes 44 (9) 0 (-) 36 (10) -
Irinotecan 0 (-) 58 (14) 0 (-) -
Vinca alkaloids 0 (-) 0 (-) 18 (5) -
Medication and/or hospitalisations during one year of follow-up; Data obtained from PHARMO RLS
Cardiovascular disease 
Hospitalisations 132 (3) 185 (6) 136 (7) 198 (7)
Medications 1,821 (45) 1,896 (59) 1,122 (60) 1,824 (62)
Hospitalisation and/or medication 5 1,842 (46) 1,922 (60) 1,136 (61) 1,843 (62)
Diabetes
Hospitalisations 6 (0.1) 4 (0.1) 3 (0.2) 1 (<0.1)
Medications 317 (8) 340 (11) 175 (9) 285 (10)
Hospitalisation and/or medication 5 319 (8) 340 (11) 175 (9) 285 (10)
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Characteristics Breast
(N=4,005)
n (%)
Colon and 
Rectum
(N=3,187)
n (%)
Lung, 
Bronchus and 
Trachea
(N=1,856)
n (%)
Prostate
(N=2,954)
n (%)
Respiratory disease
Hospitalisations 42 (1) 52 (2) 197 (11) 58 (2)
Medications 405 (10) 409 (13) 779 (42) 460 (16)
Hospitalisation and/or medication 5 434 (11) 430 (13) 857 (46) 478 (16)
Clinical laboratory measurements during one year of follow-up; Data obtained from PHARMO RLS
Tumour markers, e.g.
PSA NA 392 (12) 212 (11) 2,528 (86)
CEA 476 (12) 1,862 (58) 92 (5) 82 (3)
CA 15.3 412 (10) 15 (0.5) 10 (0.5) NA
Blood level/count, e.g.
Haemoglobin 3,502 (87) 2,986 (94) 1,631 (88) 2,161 (73)
Leukocytes 2,807 (70) 2,804 (88) 1,578 (85) 1,665 (56)
Thrombocytes 2,307 (58) 2,449 (77) 1,451 (78) 1,053 (36)
Liver enzymes, e.g.
ALT 2,512 (63) 2,538 (80) 1,450 (78) 1,172 (40)
AST 2,102 (52) 2,334 (73) 1,368 (74) 909 (31)
ALP 1,545 (39) 1,798 (56) 1,066 (57) 924 (31)
GGT 1,811 (45) 2,014 (63) 1,074 (58) 734 (25)
LDH 684 (17) 717 (22) 409 (22) 181 (6)
ECR: Eindhoven cancer registry; SD: standard deviation; NA: not applicable; PSA: prostate specific antigen; CEA: 
carcinoembryonic antigen; CA: carcinogen antigen; ALT: alanine aminotransferase; AST: aspartate aminotransferase; 
ALP: alkaline phosphatase; GGT: gamma glutamyl transpeptidase; LDH: lactate dehydrogenase; 1 patients with at 
least one year of follow-up, defined as the time between date of cancer diagnosis until end of data-collection 
in the PHARMO RLS (i.e. the patient moves out of the PHARMO RLS catchment area), death, or end of the study 
period (December 31st, 2007), whichever occurred first; 2 for a sub-cohort of approximately 45% of the patients, 
both in-hospital pharmacy (e.g. cytostatics administered intravenously) and community pharmacy (e.g. cytostatics 
administered orally) data available; 3 numbers do not add up as patients may have received multiple cytostatics, 
pyrimidine analogues included: fluorouracil, gemcitabine and capecitabine; platinum compounds included: oxali-
platin (colorectal cancer) and cisplatin (lung cancer); anthracyclines included: doxorubicin and epirubicin; mono-
clonal antibodies included: trastuzumab (breast cancer) bevacizumab (colorectal cancer) and cetuximab (colorectal 
cancer); taxanes included: docetaxel and paclitaxel; 4 not further specified, due to low numbers; 5 numbers do not 
add up as hospitalized patients mostly also have received medications
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Discussion
In	this	study,	the	ECR	and	the	PHARMO	RLS	were	linked	creating	a	novel	ECR-PHARMO	
population-based	and	patient-centric	cohort	 that	provides	an	excellent	opportunity	 to	
gain	real-life	insights	into	drug	utilization	(for	both	in-	and	out-patients),	health	resources	
utilization	and	their	costs.	Moreover,	the	effectiveness	and	safety	of	pharmaceuticals	 in	
cancer	 patients	 outside	 the	 clinical	 trial	 setting	 can	 be	 assessed	 using	 hospitalisation	
data	and	clinical	 laboratory	measurements.	This	 linkage	also	enables	 research	 to	study	
cancer	as	an	adverse	event	of	a	wide	range	of	pharmaceuticals.	By	widely	communicating	
study	 results	 and	 providing	 feedback	 to	 clinicians	 on	 therapeutic	 choices	 made	 and	
subsequent	outcomes,	research	performed	with	the	ECR-PHARMO	cohort	can	lead	to	a	
better	understanding	of	burden	of	cancer	and	offer	potential	for	improvements	in	disease	
management	in	the	field.
Of	the	46,950	patients	that	were	eligible	for	linkage,	85%	could	be	accurately	linked	with	
an	 overall	 specificity	 of	 99.5%	 and	 a	 sensitivity	 of	 98.3%.	The	 quality	 of	 the	 linkage	 is	
comparable	to	linkage	based	on	a	unique	patient	identifier.	The	15%	eligible	ECR	cancer	
patients	that	were	not	linked	can	be	explained	by	overestimation	of	the	number	of	eligible	
cancer	patients	as	it	is	extremely	difficult	to	define	the	exact	overlapping	catchment	area	
of	the	ECR	and	the	PHARMO	RLS:	eligible	ECR	patients	might	not	turn	up	in	the	PHARMO	
RLS	when	1)	they	migrate	out	of	the	catchment	area,	2)	are	institutionalized	or	3)	fill	their	
prescriptions	in	pharmacies	outside	the	catchment	area	of	the	PHARMO	RLS	while	they	
are	living	inside	the	defined	catchment	area.	Next	to	eligibility,	patients	might	be	lost	in	
the	blocking	step	of	the	 linkage	as	the	blocking	variables	date	of	birth	and	gender	are	
subject	to	recording	errors,	which	will	directly	lead	to	a	non-link.	This	is	not	the	case	with	
the	variables	used	in	the	probabilistic	matching	step,	however,	in	this	step	it	is	inevitable	
that	there	is	some	degree	of	uncertainty	by	which	true	links	might	have	been	missed.
Currently,	cancer	patients	 included	 in	the	cohorts	had	a	mean	history	of	five	years	and	
a	mean	follow-up	ranging	from	two	to	more	than	four	years	(dependent	on	the	survival	
rate	of	the	specific	cancer	type)	to	study	utilization-related	outcomes,	such	as	medication,	
clinical	 laboratory	 measurements	 and	 (re)hospitalisation	 for	 complications	 following	
cancer	 diagnosis	 and	 treatment.	 This	 follow-up	 period	 will	 increase	 for	 the	 cancer	
survivors	as	both	the	ECR	and	the	PHARMO	RLS	are	prospective	data	collection	systems.	
The	longitudinal	and	patient-centric	nature	of	these	data	is	a	major	benefit,	because	they	
allow	for	evaluation	of	health	care	utilization	both	before	and	after	cancer	diagnosis,	as	
well	as	enable	evaluation	of	long-term	outcomes	often	missed	in	clinical	trials.	
The	 ECR	 and	 the	 PHARMO	 RLS	 currently	 collect	 data	 of	 more	 than	 2	 and	 3	 million	
inhabitants,	 respectively.	 However,	 only	 45%	 of	 the	 catchment	 areas	 (approximately	 1	
million	inhabitants)	overlap.	The	size	of	the	linked	ECR-PHARMO	cohort	can	be	doubled	
in	the	future	by	either	expanding	the	PHARMO	RLS	in	the	ECR	region	or	by	linkage	of	the	
PHARMO	RLS	to	other	cancer	registries	in	the	Netherlands.	
At	 the	 time	 of	 this	 study,	 recruitment	 of	 all	 clinical	 laboratories	 in	 the	 ECR-PHARMO	
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region	was	not	yet	completed,	resulting	in	clinical	laboratory	findings	for	around	80%	of	
all	patients.	Moreover,	mid	2009,	 the	 recruitment	process	of	 in-hospital	pharmacy	data	
(including	intravenous	chemotherapy	data)	was	still	going	on.	Availability	of	cytostatics	
data	was	dependent	on	when	and	in	which	hospital	the	patient	was	treated	and	whether	
there	 was	 access	 to	 data	 from	 the	 in-hospital	 pharmacy	 in	 that	 specific	 time	 period.	
Recruitment	of	in-hospital	pharmacies	supplying	the	hospitals	in	the	ECR-PHARMO	region	
to	obtain	information	on	specific	type	of	cytostatics	administered	intravenously	was	for	
about	 45%	 complete	 in	 the	 study	 period	 1998-2006.	 In	 this	manuscript,	 a	 description	
of	 the	 data	 becoming	 available	 after	 linkage	 of	 two	 existing	 databases,	 and	 the	most	
common	categories	of	cytostatics	per	cancer	type	were	shown.	For	a	specific	study	using	
these	data,	one	could	present	the	various	cancer	treatments	by	tumour	stage	or	stratify	
treatment	regimens	in	first,	second	and	third	line	therapy	as	was	performed	in	a	previous	
study	in	breast	cancer	patients25.	
The	availability	 to	select	a	cancer-free	control	group	using	data	 from	the	PHARMO	RLS	
enables	 comparative	 studies	 between	 cancer	 patients	 and	 their	 cancer-free	 controls	
that	would	not	be	possible	if	there	were	only	data	on	cancer	patients.	For	example,	the	
controls	can	be	used	to	compare	the	rate	of	adverse	events	in	cancer	patients	following	
cancer	treatment	with	the	rate	of	similar	adverse	events	found	in	the	general	population	
as	identified	from	the	controls.	These	comparisons	are	of	major	importance	as	they	allow	
quantification	of	the	occurrence	of	adverse	effects	and	accompanying	risk	factors.	
Finally,	 additional	 information	 on	 quality	 of	 life	measurements,	 information	 on	 health	
beliefs	or	health	behaviours,	psychological	measurements,	detailed	patient	characteristics,	
tumour	biomarkers,	disease	progression	and	diagnostics	not	standard	collected	via	the	
ECR	or	the	PHARMO	RLS	can	be	collected	additionally	via	medical	files	or	questionnaires	
by	going	back	to	the	original	data	sources	or	the	patient.
In	conclusion,	the	results	of	our	study	show	that	the	linkage	of	data	from	the	ECR	and	the	
PHARMO	RLS	 is	 feasible	and	accurate;	 yielding	a	new	database	 that	 facilitates	broader	
research	 possibilities.	 The	 size	 of	 the	 cohort	 is	 still	 relatively	 limited	 and	 expansion	 is	
needed	to	facilitate	the	study	of	more	rare	cancers.	However,	it	offers	a	unique	opportunity	
for	 detailed	pharmacoepidemiologic	 cancer-related	 treatment	 and	outcomes	 research,	
eventually	allowing	improvement	in	future	patient	care.
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Abstract
Background: 
Adjuvant	systemic	treatment for	early	stage	breast	cancer	patients	is	focused	on	
cure	and	the	prevention	of	relapse.	
Objectives: 
This	study	evaluated	trends	in	adjuvant	systemic	treatment	among	breast	cancer	
patients	and	analysed	the	factors	on	which	treatment	choice	was	based.
Methods: 
Patients	 diagnosed	with	 early	 stage	 breast	 cancer	 in	 1990-2006	were	 selected	
from	the	registry	of	the	Eindhoven	Cancer	Registry	(n=8,261).	The	probability	of	
receiving	therapy	was	determined	per	characteristic	for	the	periods	1990-1997,	
1998-2001	and	2002-2006,	separately.
Results: 
The	use	of	adjuvant	systemic	treatment	increased	from	37%	in	1990-1997	to	53%	
in	2002-2006.	In	1990-1997,	the	probability	of	receiving	chemotherapy	was	mainly	
determined	by	age	and	nodal	status,	while	from	1998	onwards,	tumour	size,	grade	
and	hormone	receptor	status	were	also	associated.	The	use	of	hormonal	therapy	
was	 mainly	 determined	 by	 receptor	 status,	 in	 addition	 to	 age,	 nodal	 status,	
tumour	size	and	grade.	Marked	differences	were	observed	between	hospitals	in	
the	adoption	of	adjuvant	systemic	treatment	for	node-negative	patients.	
Conclusions: 
The	use	of	adjuvant	systemic	treatment	for	breast	cancer	increased	significantly	
in	the	period	1990-2006.	In	1990-1997,	treatment	choice	was	mainly	determined	
by	 age	 and	 nodal	 status,	 while	 from	 1998	 onwards,	 hormone	 receptor	 status,	
tumour	size	and	grade	were	also	considered.	Overall,	the	likelihood	of	receiving	
chemotherapy	remained	strongly	dependent	of	age.
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Introduction
As	the	majority	of	breast	cancers	are	diagnosed	at	an	early	stage,1	treatment	is	focused	
on	cure	and	 the	prevention	of	 relapse.	Adjuvant	chemotherapy	and	hormonal	 therapy	
have	proven	 to	be	effective	 in	preventing	or	delaying	 relapses	 and	 increasing	 survival	
in	 patients	 with	 early	 stage	 breast	 cancer.2-4	 Therefore,	 these	 therapies	 have	 become	
part	of	the	treatment	plan	of	many	of	these	patients.	Based	on	results	from	clinical	trials	
and	reviews,	the	guidelines	for	adjuvant	systemic	treatment	have	evolved	over	time	and	
strategies	have	become	more	tumour	and	patient	specific	than	ever	before.5,	6	
Rising	 trends	 in	 the	 actual	 use	of	 chemotherapy	 and	hormonal	 therapy	 among	breast	
cancer	patients	have	been	observed	in	the	USA,	regardless	of	lymph	node	and	oestrogen	
receptor	status.7,	8		Women	with	node-positive	tumours	and	younger	women	were	more	
likely	 to	 receive	 chemotherapy	 than	 women	 with	 node-negative	 tumours	 and	 older	
women.7,	8	Adjuvant	systemic	treatment	for	older	women	usually	consisted	of	hormonal	
therapy	 alone	 and	 was	 given	 irrespective	 of	 the	 oestrogen	 receptor	 status	 of	 their	
tumours.7	
Previous	studies	on	factors	influencing	the	choice	of	adjuvant	systemic	treatment	in	clinical	
practice	found	that	increasing	age	decreased	the	likelihood	of	receiving	chemotherapy8-
10,	that	patients	with	a	large	tumour,	positive	lymph	node	status	and	negative	hormone	
receptor	 status	were	more	 likely	 to	 receive	chemotherapy8,	9,	11	 and	 that	women	with	a	
positive	hormone	receptor	status	more	often	received	hormonal	therapy10,	11.	
This	 study	was	undertaken	 to	 assess	 the	extent	 to	which	adjuvant	 systemic	 treatment	
patterns	among	women	with	early	stage	breast	cancer	have	changed	from	1990	through	
2006	 in	 the	 southeastern	 part	 of	 the	 Netherlands.	 Special	 attention	 was	 paid	 to	 the	
independent	factors	that	played	a	role	in	the	choice	of	treatment	during	three	different	
time	periods	in	which	major	changes	in	the	guidelines	occurred.		
Methods
The	Eindhoven	Cancer	Registry	 (ECR)	 is	a	population-based	registry,	maintained	by	the	
Comprehensive	 Cancer	 Centre	 South	 (CCCS),	 and	 records	 data	 on	 all	 patients	 newly	
diagnosed	with	 cancer	 in	 the	 southeastern	part	 of	 the	Netherlands,	 an	 area	with	now	
2.4	 million	 inhabitants	 (about	 15%	 of	 the	 Dutch	 population).	 This	 population-based	
registry	 is	 notified	 by	 six	 pathology	 departments,	 ten	 community	 hospitals	 and	 two	
radiotherapy	 institutes.	 Registration	 takes	 place	 around	 six	 months	 after	 diagnosis.	
Trained	registry	personnel	actively	collect	data	on	diagnosis,	staging	and	treatment	from	
the	medical	 records	 after	 notification	 by	 pathologists	 and	medical	 registration	 offices.	
The	infrastructure	of,	and	good	access	to,	Dutch	health	care	facilities,	together	with	the	
notification	procedures	used,	have	made	it	possible	to	establish	cancer	registries	with	a	
completeness	exceeding	95%.12
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All	patients	diagnosed	with	a	breast	tumour,	defined	as	C50.0–C50.6	according	to	 ICD-
O-3,	in	the	period	1990–2006	were	selected	from	the	ECR.	Only	patients	diagnosed	with	
early	stage	breast	cancer	(stage	I-IIIa)	according	to	the	International	Union	Against	Cancer	
(UICC)	TNM	Classification	of	Malignant	Tumours13	were	included	in	the	study	cohort.
Due	to	major	changes	in	the	Dutch	guidelines	for	adjuvant	systemic	treatment	in	breast	
cancer	in	1998	and	2002,14,	15	characteristics	of	the	patients	included	in	the	study	cohort	
were	 shown	 for	 the	periods	1990–1997,	1998–2001	and	2002–2006,	 separately.	Age	at	
diagnosis	was	classified	 into	five	groups:	≤	35,	36-49,	50-59,	60-69	and	≥	70	years.	The	
following	tumour	characteristics	were	recorded:	tumour	size	(≤1.0	cm,	1.1-2.0	cm,	2.1-5.0	
cm	and	>	5.0	cm),	lymph	node	status	(positive	or	negative),	histologic	tumour	grade	(well	
differentiated	(low	grade),	moderately	differentiated	(intermediate	grade)	and	poorly	or	
undifferentiated	 (high	grade))	 and	 oestrogen	 receptor	 (ER)	 and	progesterone	 receptor	
(PR)	 status	 (positive	 or	 negative).	 Moreover,	 the	 following	 treatments	 that	 patients	
received	after	diagnosis	were	defined:	 chemotherapy	 (yes/no),	hormonal	 therapy	 (yes/
no),	radiation	therapy	(yes/no),	breast	surgery	(breast-conserving	surgery	or	mastectomy)	
and	combinations	of	the	aforementioned	therapies.	Serious	co-morbidity	was	recorded	
according	to	a	slightly	modified	version	of	the	Charlson	classification16	with	classification	
based	on	the	number	of	co-morbidities	at	time	of	diagnosis	(none,	1,	≥	2).	An	indicator	of	
socio-economic	status	was	provided	at	aggregated	level	for	each	postal	code	as	described	
before.17	Socio-economic	status	was	categorized	in	high,	intermediate	and	low	and	postal	
codes	of	care-providing	institutions,	such	as	nursing	homes,	were	assigned	to	a	separate	
category.	Hospital	of	treatment	was	coded	1	to	7,	including	in	this	study	only	patients	that	
were	treated	at	the	seven	largest	hospitals	in	the	ECR	area.		
Analyses
Patient	and	tumour	characteristics	are	displayed	according	to	period	of	diagnosis.	Trends	in	the	
distribution	of	the	characteristics	across	the	three	periods	(1990–1997,	1998–2001	and	2002–
2006)	were	evaluated	by	p-value	for	linear	trend	computed	by	univariate	logistic	regression	
analyses,	 by	 categorizing	 the	 diagnostic	 periods	 and	 characteristics	 as	 ordinal	 variables.	
Distribution	of	the	adjuvant	systemic	treatment	(chemotherapy	only,	hormonal	therapy	only,	
both	chemotherapy	and	hormonal	therapy,	or	any	adjuvant	systemic	treatment)	are	shown	
according	to	lymph	node	status,	age	and	year	of	diagnosis.	In	these	figures,	age	at	diagnosis	
was	classified	into	four	groups:	≤	35,	36-49,	50-69	and	≥	70	years	based	on	the	Dutch	breast	
cancer	treatment	guidelines.14	The	probability	of	receiving	chemotherapy	or	hormonal	therapy	
was	determined	per	tumour	and	patient	characteristic	and	presented	by	period	of	diagnosis.	
Since	 the	 parameter	 under	 study	 (receiving	 adjuvant	 systemic	 treatment)	was	 not	 a	 rare	
event,	odds	ratios	are	not	good	approximations	of	probability	ratios	(risk	ratios	or	prevalence	
ratios),	as	these	overestimate	the	probability.18	Probability	ratios	were	therefore	computed	
by	SAS	Proc	Genmod	using	a	modified	Poisson	regression	approach.	The	following	variables,	
which	are	considered	to	likely	affect	the	use	of	adjuvant	systemic	treatment	in	breast	cancer	
patients,	were	included	in	the	model:	age,	tumour	size,	lymph	node	status,	histologic	tumour	
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grade,	hormone	receptor	status,	non-systemic	cancer	therapies,	number	of	co-morbidities,	
socio-economic	status	and	hospital	of	treatment.	Difference	in	the	probability	of	receiving	
adjuvant	systemic	treatment	within	a	characteristic	was	assessed	by	the	chi-square	test	using	
Proc	Genmod,	while	adjusting	for	the	other	characteristics.	Variation	in	administration	of	any	
adjuvant	 systemic	 treatment	 in	 the	 seven	hospitals	was	determined	over	 time.	Results	 in	
the	Tables	are	presented	by	period	of	diagnosis	(1990-1997,	1998-2001	and	2002-2006)	and	
in	the	Figures	by	year	of	diagnosis.	For	all	analyses	the	SAS/STAT®	statistical	software	(SAS	
system	8.2,	SAS	Institute,	Cary,	NC)	was	used.
Results
Table	1	lists	the	patient	and	tumour	characteristics	of	the	8,261	women	with	early	stage	
breast	cancer	included	in	the	study,	according	to	period	of	diagnosis.	The	use	of	adjuvant	
systemic	treatment,	irrespective	of	the	type,	increased	from	37%	in	1990-1997	to	51%	in	
1998-2001	and	53%	in	2002-2006	(p	for	trend	<	0.0001).	The	mean	age	at	diagnosis	was	
similar	for	all	three	periods	(58,	59,	and	58	years,	respectively).	Size	of	the	breast	tumours	
at	diagnosis	decreased	significantly	over	time	(p	for	trend	<	0.0001).	When	not	taking	into	
account	 the	 large	proportion	of	patients	with	an	unknown	histologic	 tumour	grade	or	
hormone	 receptor	 status,	 the	proportion	of	patients	with	 a	well-differentiated	 tumour	
increased	from	14%	in	1990-1997	to	32%	in	2002-2006,	while	the	percentage	of	women	
with	ER-	and/or	PR-positive	tumours	was	stable	over	time,	with	85%	in	1990-1997	and	84%	
in	2002-2006.	The	percentage	of	women	with	breast-conserving	 surgery	and	 radiation	
therapy	 increased,	while	 the	percentage	of	women	with	mastectomy,	with	 or	without	
radiation	therapy,	decreased	(p	for	trend	<	0.0001).	Breast	cancer	therapy	combinations	
including	systemic	therapy	increased	significantly	over	time	(p	for	trend	<	0.0001).	
Table 1. Distribution of patient and tumour characteristics of women with early stage breast cancer, 
 according to period of diagnosis 
Period of diagnosis
1990-1997
(N=3,281)
%
1998-2001
(N=2,034)
%
2002-2006
(N=2,946) 
%
p-value for 
linear trendCharacteristics
Age 0.960
≤ 35 years 4 3 3
36-49 years 25 24 26
50-59 years 25 25 27
60-69 years 25 23 22
≥ 70 years 21 26 22
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Period of diagnosis
1990-1997
(N=3,281)
%
1998-2001
(N=2,034)
%
2002-2006
(N=2,946) 
%
p-value for 
linear trendCharacteristics
Tumour size <.0001
≤1.0 cm 15 21 19
1.1-2.0 cm 42 43 44
2.1-5.0 cm 40 33 34
> 5.0 cm 3 3 3
Lymph node status 0.434
Positive 37 39 38
Negative 59 58 58
Unknown 4 3 4
Histologic tumour grade <.0001
Well 5 14 26
Moderate 15 24 36
Poor 15 20 20
Unknown 65 42 18
Hormone receptor status <.0001
ER+ and/or PR+ 60 67 80
ER- and PR- 11 12 16
Unknown 29 21 4
Non-systemic cancer therapies <.0001
BCS alone 2 4 3
BCS and RT 51 57 62
Mastectomy alone 29 26 22
Mastectomy and RT 16 12 10
Other/none/unknown 3 2 3
Therapy <.0001
S 23 16 10
S+RT 40 33 36
S+RT+ST 28 36 36
S+ST 8 14 15
ST 1 1 2
Other/none/unknown 0 0 1
66
Myrthe van Herk-Sukel
3
C h a p t e r  3
Period of diagnosis
1990-1997
(N=3,281)
%
1998-2001
(N=2,034)
%
2002-2006
(N=2,946) 
%
p-value for 
linear trendCharacteristics
Number of co-morbidities <.0001
None 48 61 56
1 15 22 21
≥ 2 5 10 12
Unknown 33 7 11
Socio-economic status 0.038
High 30 29 31
Intermediate 38 40 41
Low 28 26 23
Institutionalized (nursing homes) 4 4 4
Unknown 0 0 2
Hospital of treatment 0.805
1 14 15 14
2 12 11 11
3 17 18 15
4 6 5 7
5 15 16 18
6 13 13 13
7 23 22 22
ER: Oestrogen receptor; PR: Progesterone receptor; BCS: Breast-conserving surgery; RT: Radiation therapy; S: surgery; 
ST: systemic therapy 
Figure	 1a-1d	 and	 2a-2d	 present	 the	 time	 trends	 in	 adjuvant	 systemic	 treatment	 by	 age	
category	and	year	of	diagnosis	for	women	with	early	stage	breast	cancer	with	positive	nodes	
(Figure	1)	or	negative	nodes	(Figure	2),	excluding	298	patients	of	whom	information	on	lymph	
node	status	was	not	available.	Among	patients	≤35,	36-49	and	50-69	years	with	node-positive	
breast	cancer,	the	percentage	receiving	both	hormonal	therapy	and	chemotherapy	increased	
over	time,	being	47%,	67%	and	37%,	respectively	in	2006.	Of	the	patients	of	70	years	and	older,	
less	than	2%	received	chemotherapy.	For	node-negative	patients,	the	percentage	receiving	
any	adjuvant	systemic	treatment	increased	for	all	age	groups	from	1996	onwards	and	seemed	
to	stabilize	around	2000	for	patients	50	years	and	older	with	approximately	23%	usage,	and	
around	2002	for	patients	younger	than	50	years	with	approximately	44	%	usage	for	patients	
36-49	years	and	approximately	83%	usage	for	patients	≤35	years.	None	of	the	node-negative	
patients	aged	≥	70	years	received	chemotherapy	in	the	period	1990-2006.	
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Figure 1a-1d. Proportion of women with early stage node-positive breast cancer receiving adjuvant systemic 
 treatment, by age and year of diagnosis 
Chemotherapy, Hormonal therapy and Both are mutually exclusive, Any adjuvant systemic treatment is the sum of 
the three aforementioned; Age categories are based on the Dutch breast cancer treatment guidelines14. 
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Figure 2a-2d. Proportion of women with early stage node-negative breast cancer receiving adjuvant systemic 
 treatment, by age and year of diagnosis 
Chemotherapy, Hormonal therapy and Both are mutually exclusive, Any adjuvant systemic treatment is the sum of 
the three aforementioned; Age categories are based on the Dutch breast cancer treatment guidelines14. 
The	independent	predictors	of	the	probability	of	receiving	chemotherapy	changed	over	
time,	as	presented	in	Table	2.	
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Table 2. Probability of receiving adjuvant chemotherapy* for women diagnosed with early stage 
 breast cancer by tumour and patient characteristics, according to period of diagnosis 
 1990-1997 1998-2001 2002-2006
Characteristics PRadj (95% CI) PRadj (95% CI) PRadj (95% CI)
Age  
≤ 35 years 1 -1 1 -1 1 -1
36-49 years 0.92 (0.81-1.1) 1.2 (0.95-1.5) 0.94 (0.82-1.1)
50-59 years 0.24 (0.19-0.31) 0.68 (0.53-0.86) 0.66 (0.57-0.76)
≥ 60 years** 0.01 (0.00-0.02) 0.13 (0.09-0.19) 0.14 (0.11-0.18)
Tumour size 
≤ 1.0 cm 1 - 1 -2 1 -1
1.1 – 2.0 cm 1.2 (0.89-1.6) 1.5 (1.1-1.9) 1.8 (1.4-2.1)
2.1 -5.0 cm 1.2 (0.88-1.6) 1.7 (1.3-2.2) 2.2 (1.8-2.6)
> 5.0 cm 1.2 (0.86-1.7) 2.1 (1.5-2.9) 2.3 (1.8-3.0)
Lymph node status 
Negative 1 -1 1 -1 1 -1
Positive 26 (17-40) 3.6 (3.0-4.3) 2.3 (2.1-2.6)
Histologic tumour grade 
Well 1 - 1 -1 1 -1
Moderate 1.1 (0.76-1.6) 1.3 (0.97-1.7) 1.4 (1.2-1.7)
Poor 1.3 (0.98-2.0) 1.7 (1.3-2.3) 2.2 (1.8-2.5)
Unknown 1.2 (0.88-1.7) 1.3 (0.96-1.7) 1.6 (1.3-1.9)
Hormone receptor status 
ER+ and/or PR+ 1 - 1 -1 1 -1
ER- and PR- 1.2 (0.99-1.4) 2.1 (1.8-2.4) 1.6 (1.4-1.7)
Unknown 1.1 (0.96-1.2) 0.61 (0.48-0.77) 0.82 (0.57-1.2)
PRadj: Probability Ratio, adjusted for age, tumour size, lymph node status, histologic tumour grade, hormone receptor 
status, non-systemic cancer therapies, number of co-morbidities, socio-economic status and hospital of treatment; 95% 
CI: 95% Confidence interval; ER: Oestrogen receptor;  PR: Progesterone receptor; * Chemotherapy alone, or in combination 
with hormonal therapy; ** Patients aged 60-69 years and ≥ 70 years have been grouped together due to low number 
of patients older than 70 years receiving chemotherapy; Due to low numbers, patients with tumour size ‘unknown’, and 
lymph node status ‘unknown’ were deleted from the analysis (N=3);  1p<0.0001, 2p=0.0001-0.001: Statistically significant 
difference in the probability of receiving chemotherapy within the categories of that specific characteristic 
Decrease	in	the	use	of	chemotherapy	with	advancing	age	was	seen	in	1990-1997	as	well	as	in	
1998-2001	and	2002-2006.	In	the	period	1990-1997,	positive	lymph	node	status	and	younger	
age	were	 the	 only	 significant	 predictors	 for	 the	 use	 of	 chemotherapy.	 From	 1998	 onwards,	
increasing	tumour	size,	poor	tumour	differentiation	and	negative	hormone	receptor	status	were	
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additional	factors	that	were	positively	associated	with	the	probability	of	receiving	chemotherapy,	
taking	into	account	non-systemic	cancer	therapies	(breast-conserving	surgery,	mastectomy	and	
radiation	therapy),	number	of	co-morbidities,	socio-economic	status	and	hospital	of	treatment.	
Table 3. Probability of receiving adjuvant hormonal therapy* for women diagnosed with early stage 
 breast cancer by tumour and patient characteristics, according to period of diagnosis 
 1990-1997 1998-2001 2002-2006
Characteristics PRadj (95% CI) PRadj (95% CI) PRadj (95% CI)
Age 
≤ 35 years 1 -1 1 -1 1 -2
36-49 years 1.2 (0.53-2.6) 1.5 (0.82-2.6) 0.90 (0.73-1.1)
60-69 years 6.7 (3.2-14) 2.7 (1.5-4.7) 0.92 (0.75-1.1)
50-59 years 8.1 (3.8-17) 3.3 (1.9-5.8) 1.0 (0.83-1.3)
≥ 70 years 9.3 (4.4-20) 3.3 (1.9-5.9) 1.1 (0.88-1.3)
Tumour size
≤ 1.0 cm 1 - 1 -1 1 -1
1.1 – 2.0 cm 1.2 (1.0-1.4) 1.5 (1.2-1.8) 1.7 (1.4-2.1)
2.1 -5.0 cm 1.2 (0.99-1.4) 1.5 (1.3-1.9) 2.3 (1.9-2.7)
> 5.0 cm 1.2 (0.99-1.5) 1.9 (1.4-2.4) 2.2 (1.7-2.7)
Lymph node status
Negative 1 -1 1 -1 1 -1
Positive 35 (25-49) 3.7 (3.2-4.3) 2.9 (2.6-3.2)
Unknown 18 (12-27) 2.3 (1.7-3.1) 2.5 (2.0-3.2)
Histologic tumour grade
Well 1 - 1 -1 1 -1
Moderate 1.1 (0.94-1.3) 1.3 (1.1-1.5) 1.3 (1.1-1.4)
Poor 1.1 (0.95-1.3) 1.6 (1.3-1.9) 1.7 (1.5-1.9)
Unknown 1.1 (0.94-1.3) 1.2 (1.0-1.4) 1.2 (1.0-1.4)
Hormone receptor status
ER+ and/or PR+ 1 -2 1 -1 1 -1
ER- and PR- 0.84 (0.74-0.96) 0.2 (0.14-0.30) 0.06 (0.04-0.10)
Unknown 0.94 (0.86-1.0) 0.6 (0.47-0.63) 0.45 (0.33-0.61)
PRadj: Probability Ratio, adjusted for age, tumour size, lymph node status, histologic tumour grade, hormone recep-
tor status, non-systemic cancer therapies, number of co-morbidities, socio-economic status and hospital of treat-
ment; 95% CI: 95% Confidence interval; ER: Oestrogen receptor;  PR: Progesterone receptor; * Hormonal therapy 
alone, or in combination with chemotherapy; Due to low numbers, patients with tumour size 'unknown'  were 
deleted from the analysis (N=2); 1p<.0001, 2p=0.01-0.05: Statistically significant difference in the probability of receiv-
ing hormonal therapy within the categories of that specific characteristic
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Univariate	analyses	showed	that	in	all	three	periods,	patients	with	co-morbidity	compared	
to	patients	without	co-morbidity	and	patients	with	a	low	socio-economic	status,	or	who	
were	 institutionalized	 at	 time	 of	 diagnosis,	 compared	 to	 patients	 with	 a	 high	 socio-
economic	status,	were	less	likely	to	receive	chemotherapy.	Moreover,	univariate	analyses	
showed	a	difference	in	the	administration	of	chemotherapy	between	the	seven	hospitals.	
However,	 these	 differences	 were	 no	 longer	 significant	 after	 adjustment	 for	 potential	
confounders	in	the	multivariate	analyses.
Results	of	 the	multivariate	analyses	of	 the	characteristics	 that	 influence	the	probability	
to	receive	hormonal	 therapy	are	shown	 in	Table	3.	The	use	of	hormonal	 therapy	 in	the	
period	1990-1997	was	determined	by	the	presence	of	positive	lymph	nodes,	increasing	
age	and	positive	hormone	receptor	status.	In	the	period	1998-2001,	additional	predictors	
of	 the	 probability	 to	 receive	 hormonal	 therapy	were	 increasing	 tumour	 size	 and	 poor	
differentiation	of	the	tumour.	In	2002-2006	age	had	become	a	less	important	factor	in	the	
choice	of	hormonal	therapy	use	compared	to	the	two	other	periods	and	a	positive	hormone	
receptor	 status	became	the	most	 important	 factor	determining	hormonal	 therapy	use.	
Non-systemic	 cancer	 therapies,	 the	 number	 of	 co-morbidities,	 socio-economic	 status	
and	hospital	of	treatment	were	also	included	in	the	multivariate	model	but	showed	no	
significant	relation	with	the	use	of	hormonal	therapy.
Figure 3. Proportion of women with early stage node-negative breast cancer receiving adjuvant systemic 
 treatment (chemotherapy and/or hormonal therapy), by hospital of treatment and year of diagnosis 
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There	were	no	 large	differences	observed	between	 the	hospitals	 in	 the	administration	
of	any	adjuvant	systemic	treatment	for	early	stage	node-positive	breast	cancer	patients	
in	 the	period	1990-2006.	For	node-negative	breast	cancer	patients,	marked	differences	
were	 seen	 between	 the	 seven	 hospitals	 of	 treatment	 (see	 Figure	 3).	 Node-negative	
breast	cancer	patients	treated	 in	hospitals	which	were	early	adopters	of	 the	guidelines	
(hospital	1,	3	and	6)	were	more	likely	to	receive	any	adjuvant	systemic	therapy	compared	
with	patients	treated	in	hospital	7,	which	was	a	late	adopter	of	the	treatment	guidelines.	
This	was	seen	in	period	1998-2001	as	well	as	 in	period	2002-2006,	after	adjustment	for	
potential	confounders	(PR	2.5;	95%	CI	1.7-3.6	and	PR	1.5;	95%	CI	1.3-1.9,	respectively).
Discussion
The	 use	 of	 adjuvant	 systemic	 treatment	 for	 patients	 with	 early	 stage	 breast	 cancer	
increased	significantly	over	time,	from	37%	in	the	period	1990-1997,	to	53%	in	2002-2006.	
This	increase	differed	according	to	patients’	age	and	tumour	characteristics.	In	the	earlier	
years	(1990-1997)	age	and	lymph	node	status	were	the	most	important	determinants	in	
the	choice	of	adjuvant	systemic	treatment,	while	from	1998	onwards	the	decision	became	
increasingly	 dependent	 on	 the	 hormone	 receptor	 status,	 tumour	 size	 and	 histologic	
tumour	 grade,	 which	 is	 in	 accordance	 with	 the	 incorporation	 of	 these	 factors	 in	 the	
treatment	guidelines.14	While	several	studies	have	demonstrated	the	impact	of	guidelines	
on	the	use	of	adjuvant	systemic	treatment	in	clinical	practice,7,	8,	19-22	this	study	is	the	first	
to	 quantify	 relative	 effect	 estimates	 by	 calculating	 adjusted	 probability	 ratios	 in	 three	
subsequent	time-periods,	characterised	by	major	changes	in	treatment	guidelines.
During	the	whole	study	period,	age	remained	the	most	important	factor	in	the	decision	
whether	or	not	a	patient	should	receive	chemotherapy.	Like	in	previous	published	studies,	
the	use	of	chemotherapy,	alone	or	in	combination	with	hormonal	therapy,	decreased	with	
increasing	age.3,	7-9,	20,	21,	23-26	The	 fact	 that	older	women	are	 less	 likely	 to	be	treated	with	
adjuvant	chemotherapy	may	be	explained	by	many	factors,	including	co-morbidities	and	
lack	of	evidence	for	the	benefit	of	chemotherapy	for	women	aged	70	years	and	older.3,	7,	8,	
10,	20,	21,	23,	27,	28	
The	use	hormonal	therapy,	however,	was	much	less	dependent	of	age:	in	the	period	2002-
2006	age	was	no	longer	a	significant	predictor	of	the	use	of	hormonal	therapy,	which	is	in	
accordance	with	the	findings	of	other	studies.25,	29	Over	the	years,	the	hormone	receptor	
status	became	the	most	important	factor	to	determine	whether	or	not	a	patient	should	
receive	therapy.	This	is	in	line	with	the	guidelines,	recommending	only	hormonal	therapy	
for	 patients	with	 a	 breast	 tumour	with	 a	 positive	 hormone	 receptor	 status	 from	 1998	
onwards.14	
Next	 to	 the	 patient	 and	 tumour	 characteristics	 shown	 in	 Table	 2	 and	 3,	 which	 are	
incorporated	in	the	current	guidelines,	several	other	factors	that	may	influence	the	choice	
of	adjuvant	systemic	treatment	in	clinical	practice,	such	as	co-morbidity,	socio-economic	
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status	and	hospital	of	treatment,	have	been	taken	into	account	in	this	study.	In	our	study,	
co-morbidity	 was	 no	 longer	 associated	 with	 the	 use	 of	 adjuvant	 systemic	 treatment	
after	adjusting	for	potential	confounders,	while	previous	studies	found	a	small,	 though	
significant,	decrease	in	the	likelihood	of	receiving	chemotherapy	when	co-morbidity	was	
present.3,	8,	9	For	node-negative	breast	cancer	patients,	this	study	found	marked	differences	
in	the	use	of	adjuvant	systemic	treatment	between	the	seven	community	hospitals	in	the	
southeastern	part	of	 the	Netherlands.	The	observed	pattern	 illustrates	 that	 there	have	
been	early	and	late	adopters	of	the	treatment	guidelines,	despite	the	coordinating	role	
of	the	CCCS	in	the	diffusion	of	the	guidelines	in	this	area.	Whether	this	variation	is	due	
to	the	physicians	based	in	these	hospitals	or	other	hospital	characteristics	could	not	be	
determined	from	the	data	used	in	this	study.	
HER2/neu	 is	 a	 tumour	marker	 that	 plays	 a	 role	 in	 predicting	 the	 response	 to	 specific	
adjuvant	systemic	treatments	for	women	with	breast	cancer.30	No	trend	could	be	evaluated	
for	this	tumour	characteristic	as	HER2/neu	status	was	not	available	 in	the	registry	 in	all	
three	time	periods	(1990-1997,	1998–2001	and	2002–2006).	In	the	near	future,	HER2/neu	
overexpression	should	be	included	in	studies	analysing	factors	associated	with	the	use	of	
adjuvant	systemic	treatment	for	patients	with	early	stage	breast	cancer,	as	more	clinicians	
will	be	considering	it	when	deciding	which	adjuvant	systemic	treatment	options	should	
be	offered	to	their	patients.	
In	conclusion,	trends	in	adjuvant	systemic	treatment	over	a	 large	period	of	time	(1990-
2006)	showed	that	treatment	with	hormonal	therapy	and	chemotherapy	increased	over	
time,	especially	for	patients	with	node-negative	breast	cancer.	In	the	earlier	years	(1990-
1997)	the	probability	of	receiving	adjuvant	systemic	treatment	was	mainly	determined	by	
age	and	lymph	node	status,	while	from	1998	onwards,	hormone	receptor	status,	tumour	
size	 and	 histologic	 tumour	 grade	were	 also	 taken	 into	 account	 when	 deciding	 if	 and	
which	systemic	therapy	options	should	be	offered	to	a	patient.	Patient’s	age	remained	an	
important	factor	when	deciding	on	the	use	of	chemotherapy	and,	as	is	reflected	by	the	
marginal	use	in	patients	≥70	years,	most	clinicians	do	not	consider	it	to	be	an	effective	
treatment	option	for	their	elderly	patients.	Moreover,	hospital	variation	showed	that	there	
were	early	and	late	adopters	of	the	treatment	guidelines	in	clinical	practice,	despite	the	
coordinating	role	of	the	CCCS	in	the	diffusion	of	the	guidelines	in	southeastern	part	of	the	
Netherlands.
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Abstract 
Background: 
There	 is	 little	 information	available	on	 the	patterns	of	chemotherapy	 regimens	
used	in	breast	cancer	patients	in	daily	practice.	
Objectives: 
To	 determine	 trends	 in	 type	 of	 chemotherapy	 regimens	 administered	 to	 early	
stage	or	metastatic	breast	cancer	patients.
Methods:
Breast	 cancer	 patients	 in	 the	 period	 2000-2008	 who	 received	 chemotherapy	
were	selected	from	the	Eindhoven	Cancer	Registry,	 including	data	on	all	newly	
diagnosed	cancer	patients	in	the	southeastern	Netherlands.	Those	included	were	
linked	to	the	PHARMO	Record	Linkage	System,	including	data	on,	among	other	
things,	in-	and	outpatient	drug	use.	First	and	subsequent	chemotherapy	regimens	
were	classified	based	on	the	received	combinations.	Trends	in	the	distribution	of	
adjuvant	 chemotherapy	 regimens	 (for	 early	 stage	breast	 cancer)	 and	palliative	
chemotherapy	 regimens	 (for	 metastatic	 breast	 cancer)	 were	 determined	 and	
stratified	by	Her2/neu	status	when	possible.
Results: 
In	 this	 study,	 422	 patients	 diagnosed	 with	 early	 stage	 breast	 cancer	 received	
adjuvant	chemotherapy.	The	use	of	CMF	(cyclophosphamide,	methotrexate	and	5-
fluorouracil)	decreased	from	90%	in	2000	to	almost	none	since	2005.	Administration	
of	anthracyclines	(without	taxanes)	increased	from	4%	in	2000	to	94%	in	2005,	but	
decreased	to	60%	in	2008,	being	replaced	by	both	trastuzumab	and	taxanes	(with	
or	without	anthracyclines).	Among	the	82	breast	cancer	patients	who	 received	
palliative	chemotherapy	at	diagnosis	or	after	breast	cancer	 recurrence,	 the	use	
of	 CMF	 and	 anthracyclines	 (without	 taxanes)	 decreased	 (0%	and	15%	 in	 2008,	
respectively),	while	the	use	of	taxanes	(with	or	without	anthracyclines)	increased	
(26%	 in	 2008).	 Trastuzumab	 was	 used	 as	 palliative	 chemotherapy	 from	 2003	
onwards,	with	22%	of	the	metastatic	breast	cancer	patients	receiving	trastuzumab	
containing	regimens	in	2008,	and	bevacizumab	was	administered	since	2007	with	
19%	of	the	patients	receiving	bevacizumab	containing	regimens	in	2008.		
Conclusions: 
Major	changes	have	taken	place	in	the	chemotherapeutic	treatment	of	patients	
with	 early	 and	 recurrent	 breast	 cancer.	These	 changes	 reflect	 the	 key	 findings	
from	large	clinical	trials,	as	incorporated	in	the	Dutch	guidelines.
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Introduction
Treatment	 of	 breast	 cancer	 with	 chemotherapeutic	 agents	 is	 a	 rapidly	 evolving	 field	
which	 includes	 both	 the	 conventional	 agents	 that	 interfere	with	 rapidly	 dividing	 cells	
as	well	as	the	targeted	therapies	that	interfere	with	specific	targeted	molecules	needed	
for	 carcinogenesis	 and	 tumour	 growth1.	 Adjuvant	 chemotherapy	 is	 administered	 to	
early	stage	breast	cancer	patients	after	 local-regional	 treatment	 to	 improve	survival	by	
eliminating	residual	micrometastatic	disease2.	Neoadjuvant	(preoperative)	chemotherapy	
is	 increasingly	applied	 in	 the	 last	decade	among	patients	with	 locally	advanced	breast	
cancer.	Potential	benefits	are	a	greater	 likelihood	of	breast	conserving	surgery	and	the	
ability	 to	predict	 the	effectiveness	of	chemotherapy	by	evaluating	 the	 response	of	 the	
primary	 tumour3.	 Palliative	 chemotherapy	 is	 administered	 to	 patients	 with	metastatic	
breast	 cancer	 (at	 diagnosis	 or	 after	 distant	 breast	 cancer	 recurrence)	 to	 delay	 tumour	
progression	and	provide	relief	of	symptoms4.	
In	 the	 last	 quarter	 of	 the	 previous	 century,	 treatment	 for	 early	 stage	 breast	 cancer	
included	 a	 combination	 of	 cyclophosphamide,	 methotrexate	 and	 5-fluorouracil	 (CMF)	
which	 demonstrated	 a	 reduced	 risk	 of	 breast	 cancer	 recurrence	 and	 death	 in	women	
with	 operable	 node-positive	 breast	 cancer5.	 In	 the	 eighties,	 anthracycline-containing	
combinations	were	tested	 in	the	adjuvant	setting,	 followed	by	taxanes	 in	the	nineties2.	
Overall,	 the	 taxane	 containing	 combinations	 are	 superior	 to	 anthracycline	 containing	
combinations	 which	 perform	 better	 than	 CMF.	 However,	 this	 superior	 effectiveness	
is	 often	 associated	 with	 more	 toxicity2,	 6-8.	 Finally,	 in	 2005,	 trastuzumab	 entered	 the	
adjuvant	setting,	after	it	had	shown	to	be	significantly	improving	disease	free	and	overall	
survival	 in	 breast	 cancer	 patients	whose	 tumours	 over-express	Her2/neu9.	 Next	 to	 the	
chemotherapeutics	 approved	 for	 the	 treatment	 of	 early	 stage	 breast	 cancer,	 there	 are	
the	agents	such	as	capecitabine,	vinorelbine	and	gemcitabine,	or	targeted	therapies	such	
as	bevacizumab	and	lapatinib,	that	have	been	approved	for	the	treatment	of	metastatic	
breast	cancer4.	
Guidelines	are	provided	 to	assist	 clinicians	 to	determine	which	 type	of	 single	agent	or	
multidrug	chemotherapy	to	use10-12.	Little	information	is	available	in	literature	on	the	exact	
types	of	chemotherapeutics	administered	in	daily	practice,	especially	in	the	more	recent	
years13-15.	Investigating	recent	trends	will	help	predict	future	developments	and	is	useful	
for	 clinicians	 and	policy	makers	 to	understand	 the	 speed	 in	which	new	guidelines	 are	
adopted.	Therefore,	we	determined	the	types	and	trend	of	use	of	chemotherapy	regimens	
administered	to	patients	with	early	stage	or	metastatic	breast	cancer.	
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Methods
Data Sources
Data	were	obtained	from	the	Eindhoven	Cancer	Registry	(ECR)	linked	on	a	patient-level	to	
the	PHARMO	Record	Linkage	System	(PHARMO	RLS)	covering	an	overlapping	demographic	
region	in	the	southeastern	part	of	the	Netherlands	of	approximately	one	million	inhabitants.	
The	construct	and	validity	of	the	ECR-PHARMO	cohort	are	described	elsewhere.16	The	ECR	
is	a	population-based	registry	which	is	maintained	by	the	Comprehensive	Cancer	Centre	
South	and	collates	 records	on	all	newly	diagnosed	cancer	patients	 in	 the	southeastern	
part	of	the	Netherlands.	Trained	registry	personnel	actively	collect	on	site	data	on	patient	
characteristics	(e.g.	co-morbidity	at	diagnosis),	diagnosis,	tumour	staging,	and	treatment	
received	directly	after	diagnosis	(e.g.	chemotherapy	(yes/no),	radiation	therapy	and	type	
of	surgery).
The	 PHARMO	 RLS	 is	 a	 large	 patient-centric	 data	 network	 including	 multiple	 linked	
observational	databases	designed	for	safety	and	outcomes	research	of	drugs.	Databases	
relevant	 for	 this	 study	 include	 complete	 longitudinal	 data	 obtained	 from	 hospital	
discharge	records	(Dutch	Hospital	Data:	LMR),	community	pharmacies	(out-patient)	and	
in-hospital	pharmacies	(in-patient).	Data	on	type	of	chemotherapy	were	obtained	from	
the	community	and	 in-hospital	pharmacy	databases	based	on	Anatomical	Therapeutic	
Chemical	(ATC)	code	L01.	Data	on	oral	agents	were	mainly	obtained	from	the	community	
pharmacies,	while	data	on	intravenously	administered	agents	were	extracted	from	the	in-
hospital	pharmacies.	As	every	hospital	has	its	own	way	of	documenting	the	administered	
type	of	chemotherapeutic	agent,	regimen	and	dosing, extracting	of	the	electronic	and	non-
electronic	data	was	difficult	and	therefore,	data	were	only	available	for	a	subpopulation	of	
the	ECR-PHARMO	cohort.	
Study population
The	 source	 population	 included	 all	 women	 registered	 in	 the	 ECR-PHARMO	 cohort	
diagnosed	with	breast	cancer	in	the	period	January	1,	2000	to	December	31,	2008.	From	
this	source	population	 it	was	determined	whether	they	received	chemotherapy.	Of	the	
patients	who	received	chemotherapy,	data	on	specific	types	of	chemotherapeutic	agents	
administered	 was	 available	 for	 a	 sub-cohort.	 Patients	 included	 in	 this	 study	 cohort	
were	 followed	 from	 breast	 cancer	 diagnosis	 onwards	 and	 were	 censored	 at	 time	 of	
hospitalisation	 for	cancer	other	 than	breast	cancer	 (ICD-9-CM	codes	140-230	excl.	174,	
196,	197,	198	or	199),	death,	loss	to	follow-up	in	the	PHARMO	RLS,	or	end	of	study	period	
(December	31,	2008),	whichever	occurred	first.	
Dutch guidelines of chemotherapy treatment for breast cancer
Up	 to	 2005,	 the	 advised	 adjuvant	 chemotherapy	 regimens	were	CMF	or	 anthracycline	
based	regimens11,	12.	From	2005	onwards,	anthracycline	based	regimens	alone	or	followed	
by	taxanes	were	advised	to	Her2/neu	negative	patients	and	anthracyclines	followed	by	
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taxanes	with	trastuzumab	for	patients	with	Her2/neu	overexpression10.	For	neoadjuvant	
therapy,	 the	 same	 regimens	 as	 for	 adjuvant	 chemotherapy	 were	 recommended10.	 For	
palliative	 chemotherapy,	 guidelines	 were	 less	 specific,	 with	 trastuzumab	 containing	
chemotherapies	 being	 recommended	 for	 patients	 with	 Her2/neu	 overexpression	 and	
otherwise	CMF,	anthracycline	or	taxanes	based	chemotherapy	regimens11,	12.	From	2007	
onwards,	 bevacizumab	 was	 recommended	 in	 combination	 with	 paclitaxel	 in	 patients	
with	metastatic	breast	cancer	without	Her2/neu	overexpression	who	did	not	respond	to	
anthracycline	based	regimens17.	
Chemotherapy regimens
Administered	chemotherapies	after	breast	cancer	diagnosis	were	classified	in	regimens	
of	use	based	on	the	received	chemotherapy	combinations	and	sequences.	The	regimens	
of	 chemotherapy	 used	 were	 classified	 as	 CMF,	 anthracycline	 based	 regimens	 (FEC:	 5-
fluorourcil,	epirubicin,	cyclophosphamide;	AC:	doxorubicin,	cyclophosphamide;	and	FAC:	
5-fluourouracil,	doxorubicin,	cyclophosphamide),	taxane	based	regimens	(TAC:	docetaxel,	
doxorubicin,	 cyclophosphamide;	 taxane	 as	 single	 agent	 or	 taxane	with	 anthracycline),	
trastuzumab	containing	regimens,	bevacizumab	containing	regimens	and	other	(single	
agents	e.g.	 cyclophosphamide,	 capecitabine	and	vinorelbine).	Adjuvant	 chemotherapy	
regimens	were	defined	as	chemotherapy	regimens	received	by	early	stage	breast	cancer	
patients	 (stage	 I-III)	 after	 diagnosis	 up	 to	 an	 interruption	 between	 two	 chemotherapy	
regimens	of	more	than	90	days.	Of	these	patients	it	was	determined	whether	they	received	
neoadjuvant	chemotherapy,	defined	as	chemotherapy	received	before	surgery.	Palliative	
chemotherapy	regimens	were	defined	as	regimens	received	by	breast	cancer	patients	who	
had	metastatic	disease	at	diagnosis	(stage	IV),	or	regimens	received	after	an	interruption	
of	more	than	90	days	by	patients	who	had	early	stage	breast	cancer	at	diagnosis	assuming	
that	these	patients	restarted	chemotherapy	due	to	a	distant	recurrence.
Her2/neu status
From	2005	onwards,	Her2/neu	overexpression	has	been	recorded	 in	 the	ECR.	However,	
Her2/neu	 status	 of	 a	 breast	 tumour	 could	 not	 always	 be	 established.	 Moreover,	 for	
patients	diagnosed	with	breast	cancer	before	2005,	Her2/neu	status	was	not	registered	
and	therefore	unknown.	Patients	were	defined	as	having	a	breast	tumour	with	Her2/neu	
overexpression	 if	 the	Her2/neu	status	was	 registered	positive	or	 if	 the	Her2/neu	status	
was	unknown,	but	the	patient	received	trastuzumab	(presumably	with	a	positive	Her2/
neu	status).	The	remainder	of	the	patients	was	classified	in	the	group	of	Her2/neu	status	
negative	or	unknown.
Analyses
The	representativeness	of	 the	breast	cancer	patients	 for	whom	detailed	chemotherapy	
data	 was	 available	 (the	 study	 cohort)	 was	 determined	 by	 comparing	 characteristics	
of	 these	women	with	 patients	who	 did	 receive	 chemotherapy	 but	 for	whom	detailed	
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chemotherapy	data	was	not	available,	by	using	the	Chi-square	test.	Chi-square	trend	test	
was	used	 to	 assess	 the	 changes	 in	 characteristics	 over	 time.	Trends	 in	 the	distribution	
of	 adjuvant	 and	 palliative	 chemotherapy	 regimens	 are	 shown	 according	 to	 year	 of	
administration	 of	 the	 regimens,	 including	 CMF,	 anthracyclines,	 taxanes,	 trastuzumab,	
bevacizumab	and	other	cytostatics.	The	types	of	chemotherapy	regimens	(single	agent	
or	multidrug)	administered	as	adjuvant	or	palliative	chemotherapy	were	defined	by	Her2/
neu	status.	Moreover,	for	adjuvant	therapy,	the	proportion	of	patients	receiving	a	specific	
chemotherapy	 combination	were	 determined	 across	 four	 periods	 of	 time	 (2000-2002,	
2003-2004,	2005-2006	and	2007–2008)	and	stratified	by	Her2/neu	status,	with	those	for	
Her2/neu	overexpression	presented	from	2005	onwards	as	from	that	year	on	it	had	been	
recorded	in	the	ECR.	Data	were	analysed	using	SAS	programs	that	are	organised	within	
SAS	Enterprise	Guide	version	4.1	(SAS	Institute	Inc.,	Cary,	NC,	USA).	Data	management	was	
conducted	under	UNIX	using	SAS	version	9.1.		
Results
There	were	6,050	female	breast	cancer	patients	included	in	the	linked	ECR-PHARMO	cohort	
during	2000-2008,	of	whom	1,847	(30.5%)	received	chemotherapy.	For	453	(25%)	of	those	
patients,	data	on	specific	types	of	chemotherapeutic	agents	administered	was	available	
during	follow-up.	These	patients	did	not	differ	significantly	with	respect	to	age,	tumour	
stage	and	other	therapies	received	compared	to	those	without	detailed	chemotherapy	
data	available	 (Table	1).	The	period	of	diagnosis,	however,	was	different	between	both	
groups:	 detailed	 data	 on	 chemotherapy	 regimen	 was	 more	 likely	 to	 be	 available	 for	
patients	diagnosed	with	breast	cancer	in	the	more	recent	years	(>	2003).	There	were	no	
substantial	changes	over	time	in	the	distribution	of	age,	tumour	stage,	received	surgery,	
radiotherapy	or	endocrine	therapy	(p	for	trend	>	0.1).		
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Table 1. Characteristics of breast cancer patients treated with chemotherapy in the first year after diagnosis, 
 by detailed data on regimen type available (yes/no)
Patients treated with chemotherapy 
 
 
 
Characteristics at 
diagnosis
Patient with no 
detailed chemotherapy 
data1 available  
N=1,394  
n (%)
Patients with detailed 
chemotherapy data1 
available  
N=453  
n (%)
 
 
 
 
p-value
Age 0.863
< 35 years 89 (6.4) 24 (5.3)
35-49 years 601 (43.1) 197 (43.5)
50-59 years 472 (33.9) 151 (33.3)
60-69 years 201 (14.4) 72 (15.9)
≥ 70 years 31 (2.2) 9 (2.0)
Period of diagnosis <.0001
2000-2002 423 (30.3) 87 (19.2)
2003-2004 309 (22.2) 113 (24.9)
2005-2006 308 (22.1) 137 (30.2)
2007-2008 354 (25.4) 116 (25.6)
Tumour stage 0.233
I 219 (15.7) 62 (13.7)
II 824 (59.1) 256 (56.5)
III 277 (19.9) 104 (23.0)
IV 55 (3.9) 26 (5.7)
unknown 19 (1.4) 5 (1.1)
Therapy other than chemotherapy
Surgery (yes) 1,352 (97.0) 434 (95.8) 0.222
Radiotherapy (yes) 1,046 (75.0) 339 (74.8) 0.932
Endocrine therapy (yes) 747 (53.6) 249 (55.0) 0.609
 1Data on specific type of single agent or multidrug chemotherapy 
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Of	the	453	breast	cancer	patients	included	in	the	study	cohort,	422	were	diagnosed	with	
breast	cancer	stage	I-III	and	received	adjuvant	chemotherapy	after	diagnosis.	Of	those,	9%	
received	 chemotherapy	as	 a	neoadjuvant	 treatment.	This	percentage	 increased	during	
the	study	period,	with	none	of	the	patients	receiving	neoadjuvant	chemotherapy	in	the	
year	2000	and	16%	in	2008.	The	distribution	of	the	types	of	neoadjuvant	chemotherapy	
administered	was	 similar	 to	 the	 distribution	 of	 all	 adjuvant	 chemotherapies,	 therefore	
results	are	presented	together	with	adjuvant	administered	chemotherapies.	
Figure 1. Trend in the distribution of breast cancer chemotherapy regimens in the southeastern Netherlands 
 by a) adjuvant chemotherapy regimens and b) palliative chemotherapy regimens 
CMF: cyclophosphamide, methotrexate, 5-fluorouracil
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Table 2. Adjuvant and palliative chemotherapy regimens for the treatment of breast cancer in the period 
 2000-2008, by Her2/neu status
Adjuvant 
chemotherapy
Palliative 
chemotherapy
Her2/neu 
positive
 
N=58
Her2/neu 
negative or 
unknown 
N=364
Her2/neu 
positive
 
N=24
Her2/neu 
negative or 
unknown 
N=58
Type of chemotherapy regimen n % n % n % N %
CMF 1 1.7 56 15.4 1 1.7
Anthracycline based regimens 11 19.0 278 76.4 16 27.6
FEC alone 8 13.8 234 64.3 9 15.5
AC alone 3 5.2 37 10.2 1 1.7
FAC alone 6 1.6 1 1.7
Anthracycline followed by another cytostatic (regimen)1 1 0.3 5 8.6
Taxane based regimens 1 1.7 29 8.0 1 4.2 25 43.1
TAC alone 1 1.7 15 4.1
Docetaxel alone 2 0.5 7 12.1
Paclitaxel alone 3 5.2
Anthracycline and taxane 11 3.0 10 17.2
Taxane followed by another cytostatic (regimen)1 1 0.3 1 4.2 5 8.6
Trastuzumab containing regimens 43 74.1 22 91.7
Trastuzumab alone 9 37.5
Anthracycline2 followed by trastuzumab 10 17.2 4 16.7
Anthracycline2 followed by taxane with trastuzumab 23 39.7
Taxane3 followed by / in combination with trastuzumab 10 17.2 9 37.5
Bevacizumab containing regimens 1 4.2 6 10.3
Other cytostatics4 2 3.4 1 0.3   10 17.2
CMF: cyclophosphamide, methotrexate, 5-fluorouracil; FEC: 5-fluorouracil, epirubicin, cyclophosphamide; AC: doxo-
rubicin, cyclophosphamide; FAC: 5-fluorouracil, doxorubicin, cyclophosphamide; TAC: docetaxel, doxorubicin, cy-
clophosphamide; 1another cytostatic (regimen) e.g. CMF, capecitabine or vinorelbine; 2Antracycline= anthracycline 
based regimens (FEC, AC, FAC) or single agent (e.g. doxorubicin); 3Taxane= taxane based regimens (TAC) or single 
agents (e.g. docetaxel, paclitaxel); 4cytostatic monotherapy e.g. cyclophosphamide, capecitabine, vinorelbine.
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In	our	study	cohort	there	were	26	patients	with	breast	cancer	stage	IV	at	diagnosis	and	of	
the	breast	cancer	patients	diagnosed	with	stage	I-III,	56	patients	restarted	chemotherapy	
after	 three	 months.	 The	 types	 of	 chemotherapy	 regimens	 received	 by	 both	 groups	
were	 similar,	 although	 patients	 restarting	 chemotherapy	 received	 slightly	 more	 often	
an	anthracycline	plus	taxane	 instead	of	an	anthracycline	alone.	Results	were	presented	
together,	resulting	in	82	patients	receiving	palliative	chemotherapy.	
The	use	of	CMF	as	adjuvant	chemotherapy	decreased	from	90%	in	2000	to	almost	none	
from	2005	onwards	(Figure	1a).	The	use	of	anthracycline	without	taxanes	increased	from	
4%	in	2000	to	94%	in	2005	and	decreased	from	2005	onwards	to	60%	in	2008.	Both	the	
use	of	 trastuzumab	 containing	 regimens	 and	 taxane	based	 regimens	 (with	or	without	
anthracyclines)	increased	from	2005	onwards	to	24%	and	16%	respectively	in	2008.	For	
palliative	administered	 regimens,	 trends	 in	 treatment	were	 less	 straightforward	 (Figure	
1b).	The	use	of	CMF	and	anthracycline	based	 regimens	decreased	over	 time,	while	 the	
use	of	 taxane	based	 regimens	 increased.	Trastuzumab	containing	 regimens	were	used	
as	palliative	 chemotherapy	 from	2003	onwards	and	bevacizumab	was	administered	as	
palliative	treatment	from	2007	onwards.	
Of	the	422	patients	receiving	adjuvant	chemotherapy	in	the	total	study	period,	58	patients	
(14%)	 were	 diagnosed	 with	 Her2/neu	 overexpression	 (Table	 2).	 The	majority	 of	 these	
patients	(74%)	received	trastuzumab	after	anthracycline	treatment	and/or	in	combination	
with	 a	 taxane	 (paclitaxel	 or	 docetaxel).	 Patients	who	were	diagnosed	with	 a	Her2/neu	
negative	 tumour	 or	 unknown	 Her2/neu	 status,	 mainly	 received	 FEC	 (64%).	 Of	 the	 82	
patients	receiving	palliative	chemotherapy,	24	patients	(29%)	were	diagnosed	with	Her2/
neu	overexpression.	Almost	all	of	these	patients	(92%)	received	trastuzumab	containing	
regimens.	Patients	who	were	diagnosed	with	a	Her2/neu	negative	tumour	or	unknown	
Her2/neu	 status	 mainly	 received	 taxane	 based	 regimens	 (43%).	 Additional	 analyses	
showed	that	of	the	21	patients	diagnosed	with	Her2/neu	overexpression	that	were	not	
yet	 treated	with	 trastuzumab	 in	 the	 adjuvant	 setting,	 86%	did	 receive	 trastuzumab	 in	
the	palliative	 setting.	Of	 the	Her2/neu	negative	patients	 treated	with	 an	 anthracycline	
based	regimen	in	the	adjuvant	setting	and	who	had	a	distant	recurrence	during	follow-up	
(N=30),	the	majority	(73%)	restarted	chemotherapy	with	a	taxane	based	regimen.
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Figure 2. Proportion of patients receiving a specific type of adjuvant chemotherapy regimen over four periods 
 of time by a) Her2/neu negative or unknown and b) Her2/neu positive.
CMF: cyclophosphamide, methotrexate, 5-fluorouracil; FEC: 5-fluorouracil, epirubicin, cyclophosphamide; AC: doxo-
rubicin, cyclophosphamide. The distribution of adjuvant chemotherapy regimens administered to patients with 
Her2neu overexpression is presented from the period 2005-2006 onwards as Her2/neu status was registered from 
2005 onwards. 
For	 the	 adjuvant	 administered	 chemotherapies,	 the	 proportion	 of	 patients	 receiving	
a	 specific	 chemotherapy	 combination	over	 time	was	 stratified	by	Her2/neu	 status.	 For	
patients	diagnosed	with	a	Her2/neu	negative	tumour	or	unknown	Her2/neu	status	(Figure	
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2a),	the	choice	of	CMF	as	adjuvant	treatment	decreased	over	time	(from	49%	in	2000-2002	
to	none	in	the	period	2007-2008)	and	the	use	of	FEC	changed	from	31%	in	2000-2002	to	
90%	 in	2005-2006	and	76%	 in	2007-2008.	Almost	half	of	 the	patients	 (47%)	diagnosed	
with	Her2/neu	overexpression	in	the	period	2005-2006,	did	not	receive	a	chemotherapy	
regimen	 containing	 trastuzumab	 (Figure	 2b).	 Of	 these,	 80%	 were	 treated	 in	 2005.	 In	
contrast,	 in	the	period	2007-2008	all	patients	diagnosed	with	Her2/neu	overexpression	
received	 a	 trastuzumab	 containing	 regimen	 of	 which	 the	 majority	 (58%)	 received	 an	
anthracycline	based	regimen	followed	by	a	taxane	with	trastuzumab.
Discussion
The	type	of	chemotherapeutics	administered	in	daily	practice	to	patients	with	early	stage	
and	 metastatic	 breast	 cancer	 has	 changed	 markedly	 in	 the	 period	 2000-2008.	 While	
patients	in	the	adjuvant	setting	were	in	general	treated	according	to	the	guidelines,	there	
was	a	larger	variation	in	the	palliative	setting.	
In	the	year	2000	the	majority	of	the	early	stage	breast	cancer	patients	received	CMF	(90%),	
while	in	2005	almost	all	patients	received	anthracycline	based	regimens	without	taxanes	
(94%).	These	utilization	patterns	reflect	the	changes	in	the	Dutch	guidelines	which	were	
based	on	the	studies	presented	in	the	meta-analyses	of	the	Early	Breast	Cancer	Trialists’	
Collaborative	Group	 in	2005,	concluding	a	superiority	of	anthracycline	based	regimens	
over	CMF18.	From	2005	onwards,	the	use	of	taxane	based	regimens	(including	regimens	
with	anthracycline	plus	taxane)	increased.	This	also	reflects	the	revised	guidelines	which	
were	 based	 on	 the	 results	 of	 multiple	 trials	 supporting	 the	 use	 of	 taxane-containing	
regimens	over	non-taxane-containing	regimens19.	The	presented	increase	of	trastuzumab	
containing	 regimens	 among	 early	 stage	 breast	 cancer	 patients	 since	 2005	 is	 also	 in	
accordance	with	 the	 Dutch	 guidelines.	 These	were	 based	 on	 trials	 showing	 improved	
disease-free	 and	 overall	 survival	 among	women	with	 Her2/neu	 positive	 breast	 cancer	
after	 treatment	 with	 trastuzumab20,	 21.	 For	 neoadjuvant	 chemotherapy,	 choice	 of	 type	
of	 treatment	 is	 based	 on	 the	 same	 criteria	 as	 for	 adjuvant	 therapy	 (Her2/neu	 status,	
nodal	status,	age	and	performance	status)22.	In	our	study,	the	distribution	of	the	types	of	
neoadjuvant	chemotherapy	administered	was	similar	to	the	distribution	of	all	the	agents	
used	in	the	adjuvant	setting.	
Although	various	population-based	studies	presented	the	overall	pattern	of	chemotherapy	
among	 breast	 cancer	 patients	 over	 time13-15,	 23-26,	 only	 three	 also	 showed	 data	 on	 the	
specific	types	of	chemotherapy13-15,	however,	not	beyond	the	year	2004.	The	trends	in	the	
use	of	CMF,	anthracycline	and	taxane	based	regimens	seen	in	these	studies	are	continued	
in	our	study	period.	The	study	of	Harlan	et al.13	and	Giordano	et al.15	presented	results	from	
the	SEER	(Surveillance,	Epidemiology	and	End	Results)	registry	over	the	period	1987-1995	
and	1991-1999,	respectively.	These	studies	already	showed	a	decrease	in	the	use	of	CMF	
and	an	 increase	of	anthracycline-based	chemotherapies	 (CAF	and	AC)	and	taxanes13,	15.	
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A	study	of	Shen	et al.14	at	the	M.D.	Anderson	Cancer	Centre	also	showed	that	the	use	of	
anthracycline	plus	taxane	chemotherapy	already	increased	from	1997	onwards	(17%	in	
1997	to	81%	in	2004)	and	that	the	use	of	anthracyclines	without	taxanes	had	dropped	
among	lymph	node	positive	breast	cancer	patients	(from	76%	in	1997	to	20%	in	2000)14.	
The	more	rapid	changes	seen	in	the	study	of	Shen	et al.14	compared	to	our	study	might	
be	due	to	the	fact	that	20%	of	the	patients	were	treated	within	clinical	trials,	while	in	our	
study	no	data	of	academic	hospitals	are	included.	
From	 2005	 onwards,	 Her2/neu	 status	 had	 a	 major	 influence	 on	 the	 type	 of	 adjuvant	
chemotherapy	 prescribed	 and	 therefore	 information	 on	 Her2/neu	 overexpression	 has	
been	recorded	in	the	ECR	from	this	year	onwards.	Of	the	patients	diagnosed	with	Her2/
neu	overexpression	who	did	not	receive	a	cytostatic	regimen	containing	trastuzumab	in	
the	adjuvant	setting	in	the	period	2005-2006,	80%	were	treated	in	2005.	These	patients	
were	 probably	 already	 treated	 before	 the	 implementation	 of	 the	 new	 guidelines	 in	
september	2005,	advising	trastzumab	to	early	stage	breast	cancer	patients	with	Her2/neu	
overexpression10.	All	other	Her2/neu	positive	patients	diagnosed	in	2006,	2007,	2008	were	
treated	with	 trastuzumab,	 except	 for	 two	patients	 diagnosed	 in	 2006.	Not	 all	 patients	
diagnosed	 with	 Her2/neu	 overexpression	 are	 acceptible	 candidates	 for	 trastuzumab	
because	of	the	possible	cardiotoxicity	of	trastuzumab.27	Of	the	patients	diagnosed	with	
Her2/neu	 overexpression	who	were	 not	 yet	 treated	with	 trastuzumab	 in	 the	 adjuvant	
setting	and	were	diagnosed	with	recurrent	breast	cancer	(N=21),	the	majority	(86%)	did	
receive	trastuzumab	in	the	palliative	setting.
In	 our	 study	 we	 assumed	 that	 restart	 of	 chemotherapy	 after	 90	 days	 indicated	 a	 distant	
recurrence	as	secondary	adjuvant	chemotherapy	for	the	treatment	of	a	local	recurrence	is	not	
recommended22.	Results	on	the	use	of	chemotherapy	of	patients	with	metastases	at	diagnosis	
or	during	follow-up	were	presented	together,	as	these	patients	are	expected	to	be	treated	in	
a	similar	way.	Patients	with	a	distant	recurrence	received	slightly	more	often	an	anthracycline	
plus	taxane	instead	of	an	anthracycline	alone,	probably	because	they	already	had	received	
anthracyclines	in	the	adjuvant	setting.	The	lack	of	widely	accepted	patient-specific	treatment	
guidelines	 for	 metastatic	 breast	 cancer	 is	 the	 result	 of	 the	 high	 variability	 in	 individual	
presentation.	Therefore,	 clinicians	must	 determine	which	 therapeutic	 intervention	 is	most	
appropriate	for	each	patient,	based	on	the	patient	and	tumour	characteristics,	the	number	
and	 sites	 of	 metastases,	 vital	 organ	 involvement,	 previous	 treatments	 and	 the	 previous	
disease-free	survival	interval.4,	22	While	it	seems	unlikely	that	any	single	agent	or	combination	
regimen	will	emerge	as	superior	in	the	near	future,	progress	in	chemotherapeutic	treatment	
of	metastatic	breast	cancer	is	made28	and	our	study	did	present	trends	in	chemotherapy	use.	
The	use	of	CMF	decreased	from	around	50%	in	the	period	2000-2003	to	no	use	in	2008	and	
new	treatments	that	were	approved	for	the	treatment	of	metastatic	breast	cancer,	such	as	
bevacizumab,	entered	the	palliative	setting.
Data	on	specific	type	of	single	agent	or	multidrug	chemotherapy	were	available	for	only	
25%	of	the	breast	cancer	patients	included	in	the	ECR-PHARMO	cohort.	With	expansion	
of	 the	 in-hospital	pharmacy	database	 in	 the	near	 future,	 studies	on	 in-hospital	 variety	
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and	presenting	 the	 various	 chemotherapy	 regimens	by	 for	 example	nodal	 status,	 age,	
performance	status	and	socio-economic	status	will	be	possible.	Next	to	treatment	pattern	
studies	also	outcome	studies	will	be	possible,	which	is	important	as	with	a	growing	pool	
of	active	drugs	for	the	treatment	of	breast	cancer,	their	long-term	toxicity	profiles	come	
into	focus	when	considerations	turn	to	cure	and	preservation	of	quality	of	life.	
The	results	from	our	study	suggest	that	key	findings	in	chemotherapeutic	treatment	for	
breast	cancer	patients	from	large	clinical	trials	over	the	last	decade	were	incorporated	in	
the	Dutch	guidelines,	which	resulted	in	substantial	changes	in	patient	care	practices	 in	
community	hospitals	in	the	southeastern	Netherlands.	
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Abstract 
Background: 
Observational	 studies	on	 long-term	endocrine	 treatment	among	breast	 cancer	
patients	have	presented	discontinuation	rates	on	tamoxifen,	but	lack	information	
on	the	continuance	of	any	endocrine	treatment	(both	tamoxifen	and	aromatase	
inhibitors	(AI))	within	the	same	cohort.	
Objectives: 
To	 determine	 switching	 rates	 from	 tamoxifen	 to	 AIs,	 discontinuation	 rates	 of	
tamoxifen	only,	discontinuation	rates	of	any	endocrine	treatment	and	determinants	
of	first	treatment	switch	and	treatment	discontinuation.
Methods: 
Patients	with	early	 stage	breast	cancer	 (stage	 I-IIIa)	 starting	on	 tamoxifen	were	
selected	from	the	linked	Eindhoven	Cancer	Registry-PHARMO	RLS	cohort	in	the	
period	 1998	 to	 2006.	 Continuous	 use	 (allowing	 a	 60	 days	 gap	between	 refills)	
of	 tamoxifen	only	and	any	endocrine	 treatment	were	determined	after	various	
follow-up	periods:	1,2,3,4	and	5	years.	Time	to	first	switch	from	tamoxifen	to	an	AI	
was	assessed.	Cox	regression	was	used	to	identify	determinants	of	first	treatment	
switch,	 discontinuation	 of	 tamoxifen	 and	 discontinuation	 of	 any	 endocrine	
treatment.
Results: 
A	 total	 of	 1,451	 new	 early	 stage	 breast	 cancer	 patients	 started	 on	 tamoxifen.	
Of	those,	380	had	a	treatment	switch	to	an	AI	during	follow-up.	Of	the	patients	
followed	 for	 five	 years,	 40%	 continuously	 used	 tamoxifen,	 which	was	 49%	 for	
any	 endocrine	 treatment.	 Older	 age	 (older	 than	 70	 versus	 50-69	 years)	 was	
independently	associated	with	 increased	discontinuation	of	tamoxifen	and	any	
endocrine	 therapy.	Patients	with	 two	or	more	concomitant	diseases	 (versus	no	
co-morbidity)	showed	an	increased	likelihood	to	stop	any	endocrine	treatment	or	
switch	treatment	from	tamoxifen	to	an	AI.	
Conclusions: 
Up	to	half	of	the	breast	cancer	patients	starting	tamoxifen	continued	five	years	
of	endocrine	 treatment.	 Identification	of	patients	at	 risk	of	discontinuation	will	
assist	 in	 the	 development	 of	 interventions	 to	 improve	 treatment	 continuation	
comparable	to	that	of	patients	included	in	clinical	trials.
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Introduction
Adjuvant	 endocrine	 treatment	 in	 women	 with	 early	 stage	 breast	 cancer	 significantly	
prolongs	disease	free	and	overall	survival	time1,	2.	For	nearly	20	years	the	anti-oestrogen	
tamoxifen	 was	 the	 standard	 endocrine	 adjuvant	 treatment	 used	 for	 postmenopausal	
women	with	hormone	 receptor-positive	early	 stage	breast	 cancer1.	 In	 the	 late	nineties	
of	the	previous	century,	aromatase	inhibitors	(AIs)	became	available	for	the	treatment	of	
postmenopausal	women	with	hormone	receptor-positive	advanced	breast	cancer.	Since	
about	five	years	AIs	also	have	been	approved	for	the	adjuvant	treatment	of	women	with	
hormone	receptor	positive,	early	stage	breast	cancer2.	
Discontinuation	 with	 endocrine	 therapy	 among	 early	 stage	 breast	 cancer	 patients	 in	
daily	practice	has	become	a	widespread	concern.	While	breast	cancer	patients	are	likely	
to	be	highly	motivated	to	continue	endocrine	treatment3,	many	studies	using	pharmacy,	
medical	 and	 health	 insurance	 records	 have	 reported	 high	 rates	 of	 discontinuation	 of	
tamoxifen	ranging	from	35%	to	51%	in	study	periods	of	3.5	to	5	years4-6.
The	 question	 remains	 whether	 these	 patients	 actually	 stop	 endocrine	 treatment	 or	
whether	 they	switch	 from	tamoxifen	to	an	aromatase	 inhibitor.	Recently,	a	study	using	
health	 insurance	 records,	 reported	 rates	 of	 treatment	 discontinuation	 of	 all	 types	 of	
endocrine	treatment	together	(tamoxifen,	anastrozole,	letrozole	or	exemestane):	20%	of	
the	women	discontinued	endocrine	treatment	after	one	year	of	follow-up7.	Moreover,	one	
recent	chart	review	reported	next	to	treatment	discontinuation,	results	on	switching	from	
first-line	endocrine	therapy8.	However,	to	our	knowledge	there	are	no	published	studies	
with	five	years	of	follow-up	in	which	discontinuation	rates	on	both	tamoxifen	only	and	
any	endocrine	treatment	have	been	studied.	
Among	early	stage	breast	cancer	patients	we	determined	the	following	during	the	first	five	
years	after	start	of	tamoxifen:	switching	rates	from	tamoxifen	to	AIs,	discontinuation	rates	
of	 tamoxifen	only,	discontinuation	 rates	of	 any	endocrine	 treatment	and	determinants	
of	first	treatment	switch	and	treatment	discontinuation.	For	a	sub-cohort	of	patients,	the	
date	of	first	breast	cancer	recurrence	was	studied	in	relation	to	the	date	of	discontinuation	
of	tamoxifen	or	switch	from	tamoxifen	to	an	AI.	
Methods
Data Source
Data	were	obtained	from	the	Eindhoven	Cancer	Registry	(ECR)	linked	on	a	patient-level	
to	the	PHARMO	Record	Linkage	System	(PHARMO	RLS)	covering	a	demographic	region	
in	the	southeastern	part	of	the	Netherlands	of	approximately	one	million	inhabitants.	The	
construct,	validity	and	contents	of	the	PHARMO-ECR	cohort	are	described	elsewhere.9
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Study population
The	source	population	included	all	women	registered	in	the	PHARMO-ECR	cohort	in	the	
period	1998–2006	diagnosed	with	early	stage	breast	cancer	(stage	I-IIIa).	Of	these,	it	was	
determined	whether	they	started	endocrine	treatment	(cohort	entry	date)	in	the	first	year	
after	 diagnosis.	 Patients	were	 followed	 from	 the	 cohort	 entry	 date	 onwards	 and	were	
censored	at	time	of	hospitalisation	for	cancer	other	than	breast	cancer	(ICD-9-CM	codes	
140-230	excl.	174,	196,	197,	198	or	199),	death,	loss	to	follow-up	in	the	PHARMO	RLS,	or	
end	of	study	period	(December	31,	2007),	whichever	occurred	first.	
Endocrine treatment of early stage breast cancer
In	our	study	period,	five	years	of	tamoxifen	only,	five	years	of	AIs	(anastrozole,	letrozole	
and	exemestane)	or	sequential	therapy	of	2-3	years	of	tamoxifen	followed	by	3-2	years	of	
AIs	were	advised	in	the	Dutch	guidelines.	Treatment	choice	was	dependent	on	the	patient	
characteristics	such	as	menopausal	status	and	tumour	characteristics	such	as	Her2/neu	
status.	 Patients	 intolerant	of	one	 type	of	 endocrine	 therapy	were	 advised	five	 years	of	
treatment	with	the	other.10,	11	As	starting	on	AI	was	advised	in	the	guidelines	from	2004	
onwards,	patients	starting	on	AI	were	excluded	from	further	analyses	as	they	did	not	have	
five	years	of	follow-up	time.
Treatment discontinuation and switching
Treatment	 continuation	 is	 defined	 as	 the	 percentage	 of	 patients	 who	 used	 the	 drug	
during	a	 specific	period	of	 time	without	 failure	 to	continue	 renewals.12,	13	 In	 this	 study,	
treatment	continuation	was	assessed	using	episodes	of	endocrine	treatment	based	on	the	
method	published	by	Catalan	and	LeLorier.14	To	assemble	endocrine	treatment	episodes,	
the	duration	of	use	of	each	dispensing	was	calculated	by	dividing	the	number	of	units	
dispensed	by	the	number	of	units	to	be	used	per	day,	as	defined	in	the	pharmacies.	In	case	
of	an	interruption	between	two	dispensings,	the	episode	was	considered	uninterrupted	
if	the	duration	of	this	gap	was	less	than	the	permissible	gap	of	60	days6.	We	additionally	
performed	sensitivity	analyses	allowing	a	gap	of	90	days7	and	180	days4,	5.	The	treatment	
episode	was	measured	as	 the	time	span	between	the	start	of	 the	first	dispensing	until	
the	end	of	the	final	dispensing.	The	 latter	was	set	at	half	the	duration	of	time	after	the	
last	date	that	the	drug	was	dispensed,	with	the	assumption	that	patients	stopped	their	
medication	somewhere	in	time	after	filling	their	last	prescription.	Treatment	continuation	
with	 tamoxifen	was	defined	as	 the	number	of	days	 from	start	of	 therapy	 (cohort	entry	
date)	 to	 the	 date	 of	 first	 failure	 to	 continue	 renewals	 of	 tamoxifen	 (end	 date	 of	 the	
first	 treatment	episode)	or	 the	 start	date	of	 an	AI	 (switch),	whichever	occurred	first.	 In	
addition,	we	assessed	treatment	continuation	with	any	endocrine	therapy	 (irrespective	
of	type	of	treatment;	tamoxifen	or	AIs),	i.e.	the	number	of	days	of	continuous	use	of	any	
endocrine	 therapy	 from	cohort	entry	date	onwards.	Treatment	episodes	of	 continuous	
use	of	tamoxifen	(initial	treatment)	and	any	endocrine	therapy	were	defined	up	to	5	years,	
following	the	guidelines.10,	11	
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Determinants of treatment discontinuation
The	 following	 potential	 determinants	 of	 discontinuation	 of	 tamoxifen,	 first	 treatment	
switch	and	discontinuation	of	any	endocrine	treatment	were	considered,	based	on	available	
information	 in	 the	 PHARMO-ECR	 cohort,	 clinical	 knowledge	 and	 recently	 published	
studies4,	6,	15-17:	age,	hormone	receptor	status,	tumour	size,	lymph	node	status,	histologic	
tumour	grade,	treatments	other	than	endocrine	treatment	(surgery,	chemotherapy	and	
radiation	therapy),		co-morbidity	at	diagnosis	according	to	a	slightly	modified	version	of	
the	Charlson	classification18,	drug	treatment	in	the	year	before	cohort	entry,	the	number	
of	different	drug	classes	used	(anatomical	classes	ATC	level	1,	excluding	use	of	endocrine	
treatment)	and	socio-economic	status.	
Breast cancer recurrence
Since	 1989,	 the	 Eindhoven	 Cancer	 Registry	 has	 recorded	 follow-up	 information	 for	 a	
sub-cohort	of	breast	cancer	patients	diagnosed	in	the	eastern	part	of	the	region.	Follow-
up	 information	 included	 the	date	 and	 site	 of	 local,	 regional	 and	distant	 recurrence.	 In	
contrast	 to	 the	 actively	 performed	 data	 collection	 on	 diagnosis	 and	 treatment	 of	 the	
primary	tumour,	this	follow-up	information	is	a	passive	registration.	Histologic	or	cytologic	
confirmed	breast	 cancer	 recurrences	 are	 provided	 by	 the	 pathology	 departments	 and	
assumed	to	be	complete.	However,	information	on	breast	cancer	recurrences	without	a	
cytologic	or	histologic	confirmation	had	to	be	provided	by	surgeons,	radiotherapists	and	
oncologist	and	was	not	actively	collected.		This	means	that	there	was	an	unknown	amount	
of	 underreporting.	 No	 breast	 cancer	 recurrence	 can	mean	 that	 a	 woman	 was	 indeed	
disease	free	or	that	the	data	is	missing.	For	the	patients	included	in	our	study	population,	
date	of	the	first	reported	breast	cancer	recurrence	was	defined	when	recorded	before	loss	
to	follow-up	in	the	PHARMO	RLS,	or	end	of	study	period	(December	31,	2007).	
Analyses
Baseline	and	treatment	characteristics	of	early	stage	breast	cancer	patients	who	did	not	
switch	(tamoxifen	use	only)	and	patients	who	switched	to	an	AI	were	compared	using	the	
Chi-square	 test.	 Survival	 functions	describing	 the	proportion	of	 continuous	drug	users	
over	time	for	a)	tamoxifen	use	only	or	b)	any	endocrine	treatment,	were	computed	using	
Kaplan-Meier	survival	analyses	with	treatment	discontinuation	or	–in	case	of	tamoxifen	
use	only-	 switch	 to	 an	AI,	 considered	as	 elimination	and	 censoring	patients	who	were	
considered	 lost	 to	 follow-up.	 Rates	 of	 endocrine	 treatment	 discontinuation	 were	
determined	at	1,2,3,4	and	5	years	after	start	tamoxifen	treatment.	Cox	proportional	hazards	
regression	models	were	used	 to	 identify	 independent	determinants	of	discontinuation	
of	tamoxifen,	switch	to	an	AI	or	discontinuation	of		any	endocrine	treatment	within	five	
years	after	 start	of	 treatment	 (cohort	entry	date).	Adjusted	hazard	 ratios	 (HR)	and	95%	
confidence	intervals	(CI)	are	presented	for	independent	variables,	with	variables	associated	
with	treatment	change	(discontinuance	or	switch)	in	the	univariate	analyses	included	in	
the	multivariate	analyses.	Statistical	significance	was	defined	at	an	alpha	level	of	0.05.	For	
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a	sub-cohort	of	patients	with	data	on	breast	cancer	 recurrence,	 the	date	of	first	breast	
cancer	recurrence	was	set	out	against	the	date	of	first	treatment	change:	either	stop	with	
endocrine	 (tamoxifen)	 treatment	or	switch	 to	an	AI	and	the	 linear	correlation	between	
these	dates	was	determined	using	the	Pearson	correlation	test.	Data	were	analysed	using	
SAS	programs	that	are	organised	within	SAS	Enterprise	Guide	version	4.1	(SAS	Institute	
Inc.,	Cary,	NC,	USA).	Data	management	was	conducted	under	UNIX	using	SAS	version	9.1.	
Results
The	 PHARMO-ECR	 cohort	 included	 4,917	 women	 diagnosed	 with	 early	 stage	 breast	
cancer	in	the	period	1998-2006	of	whom	1,725	(35%)	started	endocrine	treatment	in	the	
first	year	after	diagnosis	 (Figure	1).	The	median	duration	 (interquartile	 range)	between	
diagnosis	 and	 start	 of	 endocrine	 treatment	was	 2	 (1-5)	months.	Of	 the	 1,725	patients,	
1,451	(84%)	started	on	tamoxifen	and	274	(16%)	started	treatment	with	an	AI.	There	were	
no	patients	who	started	on	the	anti-oestrogen	fulvestrant	or	the	AI	aminoglutethimide	
in	the	first	year	after	diagnosis.	The	1,451	patients	starting	on	tamoxifen	were	included	in	
the	study	cohort.	They	had	a	mean	follow-up	of	4.1±2.4	years	in	the	PHARMO	RLS.	Patients	
were	censored	at	time	of	hospitalisation	for	cancer	other	than	breast	cancer	(7%),	death	
(15%),	loss	to	follow-up	in	the	PHARMO	RLS	(17%),	or	end	of	study	period	at	December	
31,	2007	(61%).
Figure 1. Flowchart patient selection.
Exemestane Anastrozole Letrozole
N=154 (8.9%) N=89 (5.2%) N=31 (1.8%)
Study cohort
Anastrozole Letrozole
N=113 (30%) N=64 (17%)
Exemestane
N=203 (53%)
Switch to an aromatase inhibitor N=380 (26%)No switch after 
N=1,071 (74%)
tamoxifen
Exclude late stage breast cancer patients                      N=604 (11%)
Breast cancer patients selected from the linked ECR-PHARMO cohort in 1998-2006        N=5,545
Exclude males                                                                      N=34 (1%)
No endocrine treatment in the 
first year after diagnosis
Endocrine treatment in the first year after diagnosis 
Women with early stage breast cancer                                                                               N=4,917 (89%)
Tamoxifen
N=1,451 (84%)
N=3,192 (65%) N=1,725 (35%)
Aromatase inihibitors N=274 (16%)Antiestrogen
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Of	the	patients	who	started	on	tamoxifen,	380	(26%)	switched	to	an	AI	during	follow-up	
(Table	1).	Patients	who	switched	to	an	AI	were	younger	than	patients	who	used	tamoxifen	
only;	mean	age	(±SD)	of	57	(±12)	years	versus	62	(±15)	years	(p<.0001).	They	started	treatment	
in	the	more	recent	years,	had	received	more	often	surgery,	chemotherapy	and	radiotherapy,	
had	used	more	different	classes	of	drugs	in	the	year	after	starting	on	tamoxifen	and	had	a	
higher	socio-economic	status.	When	not	taking	into	account	the	proportion	of	patients	with	
an	unknown	 lymph	node	status,	 there	was	no	difference	 in	 lymph	node	status	between	
patients	who	only	used	tamoxifen	and	patients	who	switched	to	an	AI.	
Table 1. Characteristics at diagnosis of early stage breast cancer patients, by type of endocrine treatment 
Tamoxifen only 
and no switch
Tamoxifen 
and switch to 
Aromatase inhibitor
Characteristics at diagnosis (N=1,071)
%
(N=380)
%
p-value
Age <.0001
≤ 35 years 2 2
36-49 years 21 26
50-59 years 21 31
60-69 years 21 23
≥ 70 years 35 18
Period of diagnosis <.0001
1998-2001 46 26
2002-2003 20 39
2004-2006 34 35
Hormone receptor status 0.187
ER+ and/or PR+ 76 81
ER- and PR- 2 1
Unknown 22 18
Tumour size 0.503
≤1.0 cm 9 7
1.1-2.0 cm 39 40
2.1-5.0 cm 46 47
> 5.0 cm 5 6
Lymph node status 0.001
Positive 29 27
Negative 66 72
Unknown 6 1
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Tamoxifen only 
and no switch
Tamoxifen 
and switch to 
Aromatase inhibitor
Characteristics at diagnosis (N=1,071)
%
(N=380)
%
p-value
Histologic tumour grade 0.133
Well 15 15
Moderate 32 32
Poor 21 26
Unknown 32 27
Therapies other than endocrine
Surgery (yes) 96 99 0.004
Chemotherapy (yes) 31 46 <.0001
Radiotherapy (yes) 65 74 0.002
Number of co-morbidities at diagnosis 0.522
None 82 82
1 4 4
≥ 2 4 3
Unknown 10 11
Most frequent co-morbidities at diagnosis 
Lung disease 4 5 0.670
Cardiovascular disease (incl. hypertension) 26 20 0.094
Diabetes 8 6 0.372
Number of different drug classes used in 
the year after start tamoxifen
<.0001
0-1 class 8 1
2-3 classes 12 15
4-5 classes 24 32
≥ 6 classes 24 26
Unknown1 31 27
Socio-economic status 0.030
High 28 34
Intermediate 39 39
Low 26 23
Institutionalized (nursing homes) 6 2
Unknown 1 1  
ER: Oestrogen receptor; PR: Progesterone receptor; 1 Not able to define number of drug classes used in the year after 
cohort entry as patients were not registered for 1 year or more in the PHARMO RLS after cohort entry. 
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The	percentage	of	continuous	users	of	tamoxifen	only	(N=1,071)	at	1,	2,	3,	4	and	5	years	
was	83%,	70%,	55%,	50%	and	40%,	respectively	(Figure	2a).	Sensitivity	analyses	showed	
that	 allowing	 a	 gap	of	 90	or	 180	days	 instead	of	 60	days	 increased	 the	percentage	of	
continuous	users	of	tamoxifen	at	5	years;	50%	and	56%,	respectively.	Of	the	380	patients	
who	switched	to	an	AI,	the	largest	decrease	in	continuance	of	tamoxifen	(switch	to	an	AI)	
was	shown	in	the	period	from	2	to	3	years:	from	55%	to	25%.	The	mean	duration	(±	SD)	of	
tamoxifen	use	until	switch	was	1.9	±	1.2	years	until	switch	to	anastrozole,	2.0	±	1.3	years	
until	switch	to	exemestane	and	2.1	±	1.4	years	until	switch	to	letrozole.
Figure 2 a-b. Proportion of early stage breast cancer patients who start tamoxifen therapy: a) continue 
 tamoxifen over a 5-year follow-up period until first treatment change: stop with tamoxifen 
 treatment (N=1,071) or switch to an aromatase inhibitor (N=380) b) continue any endocrine 
 treatment (irrespective of type of endocrine treatment) over a 5-year follow-up period (N=1,451).
The	percentage	of	continuous	users	of	any	endocrine	treatment	at	1,	2,	3,	4	and	5	years	
was	87%,	78%,	69%,	63%	and	49%,	respectively	(Figure	2b).		Allowing	a	gap	of	90	or	180	
days	instead	of	60	days	showed	an	increase	of	the	percentage	of	continuous	users	of	any	
endocrine	treatment	at	5	years;	59%	and	66%,	respectively.	
0.0
0.2
0.4
0.6
0.8
1.0
0 1 2 3 4 5
Duration of treatment in years
stop with tamoxifen
switch to aromatase inhibitor
Pr
op
or
tio
n 
of
 c
on
tin
uo
us
 ta
m
ox
ife
n 
us
er
s
un
til
 s
to
p 
or
 s
w
itc
h 
to
 a
n 
ar
om
at
as
e 
in
hi
bi
to
r
0.0
0.2
0.4
0.6
0.8
1.0
0 1 2 3 4 5
Duration of treatment in years
Pr
op
or
tio
n 
of
 c
on
tin
uo
us
 d
ru
g 
us
er
s 
un
til
st
op
 a
ny
 e
nd
oc
rin
e 
tr
ea
tm
en
t
a)
b)
0.0
0.2
0.4
0.6
0.8
1.0
0 1 2 3 4 5
Duration of treatment in years
stop with tamoxifen
switch to aromatase inhibitor
Pr
op
or
tio
n 
of
 c
on
tin
uo
us
 ta
m
ox
ife
n 
us
er
s
un
til
 s
to
p 
or
 s
w
itc
h 
to
 a
n 
ar
om
at
as
e 
in
hi
bi
to
r
Myrthe van Herk-Sukel
105
Medication use among women with breast cancer in the Netherlands
5
E n d o c r i n e  t r e a t m e n t 
Table 2. Determinants of discontinuation of tamoxifen due to stop of endocrine treatment or switch to 
 an aromatase inhibitor and stop with any endocrine therapy within five years after start
Early stage breast cancer patients who start tamoxifen therapy
Stop with tamoxifen 
treatment 
(N=1,071)
Switch to an aromatase 
inhibitor 
(N=380)
Total, stop with any 
endocrine treatment 
(N=1,451) 
Characteristics HR 
Adjusted1 
95% CI HR 
Adjusted1
95% CI HR 
Adjusted1
95% CI
Age at diagnosis
≤ 49 years 0.83 (0.65-1.05) 0.77 (0.46-1.30) 0.77 (0.60-1.01)
50-69 years 0.74 (0.61-0.90) 0.83 (0.53-1.28) 0.71 (0.59-0.85)
≥ 70 years 1  - 1  - 1  -
Tumour size 
≤1.0 cm 1  -   1  -
1.1-2.0 cm 0.98 (0.72-1.34)   0.96 (0.72-1.27)
2.1-5.0 cm 1.12 (0.82-1.53)   1.05 (0.79-1.39)
> 5.0 cm 1.45 (0.93-2.26)   1.28 (0.86-1.91)
Number of co-morbidities at diagnosis 
None 1  - 1  - 1  -
1 0.87 (0.55-1.39) 2.08 (1.01-4.31) 1.03 (0.70-1.53)
≥ 2 1.30 (0.88-1.92) 4.56 (1.96-10.6) 1.58 (1.10-2.25)
Unknown 0.83 (0.61-1.12) 1.44 (0.88-2.35) 0.93 (0.72-1.20)
Number of different drug classes used in the year after start tamoxifen
0-1 class 1  - 1  - 1  -
2-3 classes 0.82 (0.62-1.07) 1.04 (0.58-1.85) 0.82 (0.64-1.05)
4-5 classes 0.89 (0.68-1.17) 1.42 (0.79-2.53) 0.96 (0.75-1.23)
≥ 6 classes 1.15 (0.89-1.49) 1.68 (0.95-2.98) 1.21 (0.96-1.54)
Socio-economic status 
High     1  -
Intermediate     1.00 (0.83-1.21)
Low     1.11 (0.91-1.37)
Institutionalized or 
unknown
    1.08 (0.76-1.54)
HR: hazard ratio; 1Adjusted for variables potentially associated with discontinuance in the crude analyses (p < 0.05).
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Multivariate	analyses	in	Table	2	show	that	patients	who	did	not	continue	tamoxifen	were	
less	likely	to	be	aged	50-69	years	(versus	≥70	years;	hazard	ratio	(HR)=0.74;	95%CI:	0.61-
0.90).	This	was	also	seen	for	discontinuation	of	any	endocrine	therapy	(50-69	years	versus	
≥70	 years;	 HR=0.71;	 95%CI:	 0.59-0.85).	 Moreover,	 multivariate	 analyses	 showed	 that	
patients	who	did	not	continue	any	endocrine	therapy	were	more	likely	to	have	2	or	more	
concomitant	diseases	 (versus	no	co-morbidity;	HR=1.58;	95%CI:	1.10-2.25).	Multivariate	
analyses	of	switch	from	tamoxifen	to	an	AI	showed	that	women	with	one	or	multiple	co-
morbidities	were	more	likely	to	switch	from	tamoxifen	to	an	AI	than	patients	without	co-
morbidities	at	diagnosis:	HR=2.08	(95%CI:	1.01-4.31)	for	patients	with	one	co-morbidity	
and	HR=4.56	(95%CI:	1.96-10.6)	for	patients	with	two	or	more	co-morbidities.
Of	the	1,451	patients	starting	on	tamoxifen,	98	patients	were	known	to	have	developed	a	
breast	cancer	recurrence	during	follow-up.	For	these	patients,	the	date	of	first	treatment	
change	(either	stop	or	switch)	was	set	out	against	the	date	of	first	breast	cancer	recurrence	
(Figure	3a	and	3b).	The	average	 time	 (±	SD)	 from	cohort	entry	until	 first	breast	 cancer	
recurrence	was	2.8	(±1.8)	years.	Of	the	56	women	with	a	breast	cancer	recurrence	who	
stopped	with	endocrine	treatment	(N=21	with	a	local/regional	recurrence	and	N=35	with	
a	distant	recurrence),	the	date	of	stop	and	date	of	recurrence	were	significantly	correlated	
(r=0.74,	p<.0001).	Of	the	42	women	with	a	breast	cancer	recurrence	who	switched	from	
tamoxifen	 to	 an	AI	 during	 follow-up	 (N=12	with	 a	 local/regional	 recurrence	 and	N=30	
with	 a	 distant	 recurrence),	 the	date	 of	 switch	 and	date	 of	 recurrence	were	 even	more	
significantly	correlated	(r=0.93,	p<.0001).
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Figure 3 a-b. Of the patients of whom a breast cancer recurrence was reported during follow-up (N=98) the 
 date of first treatment change was set out against the date of first breast cancer recurrence. 
 With treatment change defined as a) stop with endocrine (tamoxifen) treatment (N=56) or b) 
 switch to an aromatase inhibitor (N=42).
Discussion
This	 observational	 study	 showed	 that	 in	 daily	 practice	 40%	 to	 56%	 of	 patients	 with	
early	stage	breast	cancer	continuously	used	tamoxifen	over	a	five	year	follow-up	period,	
allowing	a	permissible	gap	of	60	to	180	days,	respectively.	When	evaluating	the	use	of	all	
types	of	endocrine	treatment	together	(tamoxifen,	anastrozole,	letrozole	or	exemestane)	
and	allowing	patients	to	switch	endocrine	treatment	multiple	times,	 the	percentage	of	
patients	continuously	using	any	endocrine	 treatment	over	a	five	year	 follow-up	period	
was	still	only	49%	to	66%.	Increasing	the	permissible	gap	from	60	to	180	days	indicates	
that	around	15%	of	the	patients	restart	treatment	during	five	years	of	follow-up.
To	date,	multiple	clinical	trials	have	demonstrated	that	five	year	use	of	adjuvant	endocrine	
treatment	 among	 patients	 with	 hormone	 receptor	 positive,	 early	 stage	 breast	 cancer	
improves	 disease-free	 and	 overall	 survival1,	 19,	 20.	 However,	 high	 discontinuation	 rates	
as	 reported	 in	 this	observational	 study,	 lower	 the	benefit	 found	 in	 clinical	 trials.	These	
high	discontinuation	rates	were	also	 found	 in	previous	studies	on	tamoxifen	use	using	
pharmacy,	medical	and	 insurance	records,4-6	especially	when	the	same	permissible	gap	
and	study	follow-up	period	were	taken	into	account.	
In	this	study,	older	age	(older	than	70	versus	50-69	years)	was	independently	associated	
with	increased	discontinuation	of	tamoxifen.	Other	studies	also	found	that	extremes	of	
age	 (under	 45	 and	over	 75)	were	 associated	with	 tamoxifen	discontinuation	 and	non-
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adherence.4,	6,	15-17		For	any	endocrine	therapy,	having	two	or	more	concomitant	diseases	
versus	no	co-morbidity	was,	next	to	older	age,	also	associated	with	an	increased	likelihood	
to	discontinue	any	endocrine	therapy.	Owusu	et al.6	 found	that	an	 increase	 in	Charlson	
co-morbidity	index	at	3	years	from	diagnosis	was	related	with	an	increased	likelihood	to	
discontinue	tamoxifen	treatment,	suggesting	that	patients	discontinue	treatment	due	to	
other	life	threatening	diseases.	
Previous	 studies	 using	 self-report	 questionnaires	 or	 telephone	 interviews	 on	 non-
adherence	or	discontinuation	of	tamoxifen	have	reported	that	reasons	for	discontinuation	
vary,	ranging	from	treatment	related	side	effects,	simply	forgetting	to	take	the	medication,	
to	lack	of	confidence	in	prescribed	endocrine	treatment.3,	15,	16,	21-25	Psychological	factors,	
particularly	depression	and	anxiety	also	seem	to	contribute	to	treatment	discontinuation.	
However,	in	our	study	we	did	not	find	an	increased	likelihood	to	discontinue	endocrine	
treatment	 among	women	who	 received	 antidepressants	 in	 the	 year	 before	 tamoxifen	
initiation	(10%	of	the	women	included	in	the	study	cohort).	
The	observational	study	of	McCowan	et al.5	showed	that	decreased	duration	of	tamoxifen	
use	 in	daily	practice	 increased	the	risk	of	all	cause	mortality.	However,	 the	 influence	of	
breast	cancer	recurrence	on	the	decision	to	stop	with	tamoxifen	could	not	be	established,	
as	the	authors	commented	this	to	be	difficult	to	ascertain	within	a	community	setting.5	
In	our	study	data	on	breast	cancer	recurrence	were	only	available	for	a	sub-cohort,	due	
to	 the	 fact	 that	 no	 active	 follow-up	 had	 taken	 place	 of	 the	 patients	 documented	 by	
the	Eindhoven	Cancer	Registry.	Nevertheless,	presenting	the	date	of	first	breast	cancer	
recurrence	and	date	of	stop	with	tamoxifen	treatment	showed	that	most	patients	with	
a	breast	cancer	recurrence	stopped	tamoxifen	treatment.	Future	observational	database	
studies	should	report	whether	they	have	information	on	breast	cancer	recurrence	and/or	
exclude	these	patients	from	further	analyses,	as	has	been	done	in	previous	interview	and	
questionnaire	studies21,	23.
Of	the	patients	who	switched	treatment	from	tamoxifen	to	an	AI,	most	switched	after	2	
to	3	years	of	tamoxifen	use.	This	is	in	accordance	with	the	guidelines	advising	switching	
of	treatment	in	this	period	and	this	is	also	reported	in	a	recent	performed	retrospective	
chart	review8.	Switching	to	an	AI	within	2	years	after	starting	on	tamoxifen	could	be	due	
to	intolerability	to	tamoxifen	and	switching	within	2	years	or	after	3	years	of	tamoxifen	
treatment	could	be	due	to,	among	other	things,	a	breast	cancer	recurrence.	In	our	study,	
patients	having	one	or	more	 concomitant	diseases	 versus	no	 co-morbidity	were	more	
likely	to	switch	from	tamoxifen	to	an	AI.	Moreover,	we	found	a	strong	correlation	between	
date	 of	 breast	 cancer	 recurrence	 and	 date	 of	 switch.	 Schwartzberg	 and	 colleagues8	
performed	 exploratory	 telephone	 interviews	 to	 determine	 reasons	 for	 switching	 and	
nearly	all	patients	cited	doctor	recommendation	or	side	effects	as	a	reason	for	switching.	
In	 this	 study	we	were	only	 able	 to	 report	discontinuation	 rates	of	patients	 starting	on	
tamoxifen	as	at	the	moment	of	the	study,	patients	starting	on	AIs	had	too	short	follow-
up	time	to	be	able	 to	 report	five	year	discontinuation	rates.	While	several	studies	have	
reported	treatment	discontinuation	rates	of	patients	starting	with	AIs	after	one	year	of	
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follow-up7,	26,	27,	 long-term	observational	 studies	are	needed	 in	 the	 future	 to	determine	
treatment	continuation	and	switching	patterns	during	five	years	of	follow-up	of	patients	
starting	on	AIs.
This	study	reports	results	of	observational	data,	however,	some	of	the	patients	included	
in	 our	 study	 cohort	 might	 be	 included	 in	 a	 post-marketing	 multinational	 trial28.	 As	 a	
result,	continuous	use	of	endocrine	treatment	among	these	patients	might	be	increased	
compared	to	the	rates	found	in	daily	practice.	However,	in	this	study	we	still	found	high	
overall	discontinuation	rates	of	endocrine	treatment.
From	 the	 results	 of	 this	 study	 we	 conclude	 that	 up	 to	 half	 of	 the	 women	 to	 whom	
adjuvant	 tamoxifen	 treatment	was	prescribed	stop	 taking	 tamoxifen	before	 the	end	of	
the	recommended	treatment	period	of	five	years.	Even	after	 increasing	the	permissible	
gap	and	allowing	multiple	switching	 to	other	endocrine	 therapies,	 the	 rate	of	patients	
who	discontinue	endocrine	treatment	remained	high.	These	high	discontinuation	rates	
lower	the	benefit	of	adjuvant	endocrine	treatment	among	women	with	hormone	receptor	
positive,	early	 stage	breast	cancer	on	disease-free	and	overall	 survival	 found	 in	clinical	
trials.	Identification	of	patients	at	risk	of	discontinuation	of	endocrine	treatment,	either	or	
not	intentionally,	may	help	to	improve	treatment	continuation.	
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Abstract
Background: 
Cardiotoxicity	is	a	well-known	side	effect	of	several	chemotherapeutics	and	may	
be	the	dose-limiting	factor	in	chemotherapy.	
Objectives: 
To	assess	 the	 incidence	of	 cardiovascular	events	among	breast	 cancer	patients	
after	chemotherapy.	
Methods: 
Women	≥	18	years	with	a	breast	 tumour	who	received	chemotherapy	 in	1992-
2003	were	selected	from	the	PHARMO	RLS.	Chemotherapy	with	anthracyclines,	
a	 combination	 of	 anthracyclines	 and	 taxanes,	 or	 second	 line	 treatment	 with	
trastuzumab	was	classified	as	cardiotoxic.	Cardiovascular	events	were	determined	
based	on	drug	use	and	hospital	admissions.	Incidence	rates	of	cardiovascular	events	
and	hazard	ratios	(HR)	for	the	cardiotoxic	versus	non-cardiotoxic	chemotherapy	
group	were	assessed	during	the	first	year	and	total	follow-up.
Results: 
Of	 648	 patients	 with	 breast	 cancer	 included	 in	 the	 study	 cohort,	 353	 (54%)	
received	cardiotoxic	chemotherapy.	At	baseline,	patients	who	received	cardiotoxic	
chemotherapy	compared	with	patients	receiving	non-cardiotoxic	chemotherapy,	
received	 less	anticoagulants/haemostatics	 (5%	versus	11%;	p	=	0.012)	and	had	
been	less	often	hospitalized	for	cardiovascular	disease	(1%	versus	5%;	p	=	0.007)	
two	years	before	the	cohort	entry	date.
After	one	year	follow-up,	the	incidence	rate	of	cardiovascular	events	was	69/1,000	
py	for	patients	with	cardiotoxic	chemotherapy	and	98/1,000	person	years	(py)	for	
patients	with	 non-cardiotoxic	 chemotherapy,	which	 did	 not	 differ	 significantly	
(HR	 0.74	 95%CI:	 0.39,	 1.41).	 After	 total	 follow-up,	 this	 was	 81/1,000	 py	 for	
patients	 with	 cardiotoxic	 and	 92/1,000	 py	 for	 patients	 with	 non-cardiotoxic	
chemotherapy	(HR	0.81,	95%CI:	0.54,	1.20).
Conclusions: 
This	 study	 showed	 similar	 cardiovascular	 incidence	 rates	 during	 follow-up	 for	
breast	cancer	patients	treated	with	cardiotoxic	and	non-cardiotoxic	chemotherapy.	
Specialists	seemed	to	take	pre-existing	cardiovascular	diseases	into	account	when	
treating	the	breast	cancer	patient.	
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Introduction
Breast	cancer	is	the	most	common	cancer	in	women	and	every	year	over	300,000	women	in	
Europe	are	diagnosed	with	the	disease.1	The	type	of	treatment	such	as	endocrine	therapy,	
radiation	 therapy	 or	 chemotherapy,	 depends	 on	 the	 individual	 patient	 and	 tumour	
characteristics.	Therefore,	balancing	effectiveness	and	adverse	effect	is	a	major	challenge	
in	the	treatment	of	breast	cancer	patients.2	Cardiotoxicity	is	a	well-known	adverse	effect	of	
several	cytotoxic	chemotherapy	agents,	notably	the	anthracyclines	but	also	newer	drugs	
such	as	trastuzumab	in	second	line	treatment.3-9	It	includes	a	wide	range	of	cardiac	effects	
from	small	 changes	 in	blood	pressure	and	arrhythmias	 to	 serious	cardiomyopathy	and	
may	lead	to	long	term	cardiovascular	morbidity.4-6,	8	
Incidences	of	cardiovascular	events	found	in	earlier	studies	are	in	the	range	of	0.5%	to	20%	
depending	on,	among	other	things,	dose	of	cardiotoxic	drug,	rate	of	administration	of	the	
cytotoxic	chemotherapy	agent	and	definition	of	cardiovascular	event.4,	6,	7,	9-11		Interactions	
between	drugs	such	as	taxanes	and	anthracyclines	are	likely	to	increase	cardiotoxicity.3	
Other	risk	factors	associated	with	cardiotoxicity	 include	baseline	characteristics	such	as	
age	and	a	history	of	pre-existing	cardiovascular	disorders.4,	6	
With	the	ageing	of	the	population	and	the	increasing	survival	of	breast	cancer	patients	
with	 co-morbid	 conditions,	 cardiotoxicity	 of	 chemotherapy	 becomes	 increasingly	
important. Limited	 information	 is	 available	 on	 the	 background	 rates	 of	 cardiovascular	
disorders	before	and	after	chemotherapy	among	breast	cancer	patients	in	current	clinical	
practice.	The	objective	of	the	present	study	was	therefore,	to	investigate	the	incidence	of	
cardiovascular	events	in	patients	treated	with	chemotherapy	in	daily	clinical	practice	and	
place	 this	 in	 the	perspective	of	pre-existing	cardiovascular	 risk	 factors	and	 the	specific	
chemotherapeutic	agent	used.
Methods
Data sources
This	study	was	conducted	with	data	from	the	PHARMO	Record	Linkage	System	(PHARMO	
RLS)	which	includes	data	from	community	and	hospital	pharmacies	and	hospital	discharge	
records	for	more	than	two	million	individuals	in	defined	areas	in	the	Netherlands.	Data	from	
community	pharmacies	include	information	on	the	dispensed	drug,	the	type	of	prescriber,	
the	dispensing	date,	the	amount	dispensed,	the	prescribed	dose	regimens,	and	the	legend	
duration	of	use	 (prescription	 length).	All	drugs	are	coded	according	 to	 the	Anatomical	
Therapeutic	Chemical	(ATC)	Classification.	The	hospital	discharge	records	include	detailed	
information	on	admissions	for	more	than	24	hrs	and	admissions	for	less	than	24	hours	for	
which	a	bed	is	required,	concerning	the	primary	and	secondary	diagnoses,	procedures,	
and	 dates	 of	 hospital	 admission	 and	 discharge.	 All	 diagnoses	 are	 coded	 according	 to	
the	International	Classification	of	Diseases,	9th	Revision,	Clinical	Modification	(ICD-9-CM).	
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Data	from	hospital	pharmacies	contain	per	patient,	complete	information	of	in-hospital	
drug	use,	related	to	diagnoses	and	procedures.	Because	not	all	hospitals	that	participated	
in	this	study	had	electronically	data	available	on	chemotherapies,	additional	electronic	
and	non-electronic	data	were	obtained	from	the	hospitals	and	added	to	the	in-hospital	
pharmacy	database.	
Data	 on	 staging	 of	 cancer	was	 obtained	 from	 the	 in-hospital	 files	 and	 the	 Eindhoven	
Cancer	Registry	(ECR).	This	registry	records	data	of	all	malignant	neoplasms	in	an	area	of	
2.3	million	inhabitants	in	the	south	of	the	Netherlands.	Information	is	available	on	date	of	
incidence,	histology,	topography,	invasiveness,	grade,	stage	and	basis	of	diagnosis.	
	
Study population
From	the	PHARMO	RLS,	incident	patients	with	breast	cancer	were	identified	and	defined	
as	women	aged	18	years	or	older	who	had	been	hospitalized	 for	breast	cancer	 (ICD-9-
CM	coding	174	and	198.81)	from	January	1992-December	2003.	Patients	were	included	
if	 they	had	been	treated	with	chemotherapy	 (ATC	code:	L01)	 in	 the	period	of	 less	 than	
two	months	before	diagnosis	or	within	six	months	after	diagnosis.	This	period	around	the	
date	of	diagnosis	was	chosen	because	of	the	observed	lag	time	between	diagnosis	and	
actual	registration	in	the	hospital	files	and	the	observed	lag	time	between	diagnosis	and	
start	of	treatment	after	diagnosis.	The	date	of	the	first	chemotherapy	during	this	period	
was	defined	as	the	cohort	entry	date.	To	ensure	a	reasonable	time	period	to	assess	the	
patients’	baseline	status,	we	included	patients	only	if	they	had	a	history	of	registration	in	
PHARMO	RLS	for	at	least	two	years	prior	to	the	cohort	entry	date.	Patients	were	followed	
from	baseline	until	end	of	registration	in	PHARMO	RLS	(death	or	loss	to	follow-up),	or	end	
of	study	period	(31	December	2003),	whichever	came	first.
Of	 the	patients	 included,	 age,	 year	 of	 start	 of	 chemotherapy	 and	breast	 tumour	 stage	
at	diagnosis,	were	determined	at	cohort	entry	date.	Breast	tumour	staging	was	defined	
as	 specified	by	 the	American	 Joint	 Committee	 on	Cancer	 (AJCC)	TNM	Classification	 of	
Malignant	Tumours.12,	13	
Breast cancer therapy
At	cohort	entry	date,	chemotherapy	was	classified	in	cardiotoxic	treatment	that	included	
treatment	with	anthracyclines,	a	combination	of	anthracyclines	and	taxanes,	or	second	
line	treatment	with	trastuzumab,	and	non-cardiotoxic	treatment	that	included	all	other	
chemotherapies.3-9	
Assessment	of	breast	cancer	therapy	in	the	period	of	two	years	before	the	cohort	entry	
date	 included	breast	 surgery	 (yes/no),	 hormonal	 therapy	 (yes/no),	 chemotherapy	 (yes/
no),	and	radiation	therapy	(yes/no).	Data	on	radiation	therapy	were	only	available	for	the	
sub	 sample	of	patients	 registered	 in	 the	ECR.	Moreover,	hospital	 admissions	 for	breast	
cancer	or	other	types	of	cancer	were	determined	in	the	period	of	two	years	before	the	
cohort	entry	date.
In	addition,	type	of	chemotherapy	at	baseline	and	during	follow-up	was	classified	based	
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on	the	most	frequently	used	combinations.	Chemotherapy	was	stratified	in	first,	second	
and	third	line	therapy,	with	switch	from	first	to	second	line	or	second	to	third	line	therapy	
based	on	the	start	of	a	different	type	of	chemotherapy	agent,	or	a	different	combination	
of	chemotherapy.	
Cardiovascular co-morbidity 
Cardiovascular	co-morbidity	was	assessed	based	on	drug	use	and	hospital	admissions	as	
indicator	for	cardiovascular	problems,	in	the	period	of	two	years	before	cohort	entry	date.	
This	included	use	of	anti-hypertensive	drugs	(ATC	code:	C02-C09),	anti-diabetics	(ATC	code:	
A10),	nitrates	(ATC	code:	C01DA),	anti-arrhythmics	(ATC	code	C01B),	digitalis	 (ATC	code:	
C01AA05),	 anticoagulants/haemostatics	 (ATC	 code:	 B01)	 and	 lipid	 lowering	drugs	 (ATC	
code:	C10AA).	Hospital	admissions	for	cardiovascular	disease	(ICD-9-CM	codes:	390-459;	
with	 valve	disease:	 394-397,	 424;	 hypertensive	disease:	 401-405;	myocardial	 infarction:	
410,	412,	429.7;	angina	pectoris:	413;	cardiomyopathy:	425;	cardiac	disturbances:	426-427;	
heart	failure:	428;	cerebrovascular	disease:	430-438	and	disease	of	arteries:	440-448)	and	
diabetes	 (ICD-9-CM	code:	250)	were	also	determined.	 In	addition,	 the	potential	 impact	
of	cardiovascular	co-morbid	conditions	was	classified	into	none/light	impact,	moderate	
impact	or	high	impact	by	using	a	slightly	adapted	version	of	the	conceptual	model	“Life	
Threat”	by	Yancik	et	al.14	
Cardiovascular events
To	identify	incident	cardiovascular	adverse	events,	hospital	admissions	for	cardiovascular	
diseases	 and	 cardiovascular	 drug	 use	 during	 the	 first	 year	 of	 follow-up	 and	 the	 total	
follow-up	period	were	evaluated.	Hospital	admissions	were	always	defined	as	an	incident	
adverse	event.	Drugs	were	considered	new	and	contributed	to	incidence	rates	if	they	had	
not	been	dispensed	to	the	patient	in	the	two	years	before	the	cohort	entry	date.	
The	 incidence	 rate	 for	a	 specific	adverse	event	was	calculated	by	dividing	 the	number	
of	patients	with	that	specific	incident	adverse	event	by	the	sum	of	days	of	follow-up	of	
all	patients.	Patients	were	 followed	from	cohort	entry	date	until	 that	specific	 incidence	
adverse	event,	end	of	registration	in	PHARMO	RLS	(death	or	loss	to	follow-up),	or	end	of	
study	period	(31	December	2003),	whichever	came	first.	
Statistical analysis
Baseline	 characteristics	 of	 patients	 treated	 with	 cardiotoxic	 chemotherapy	 were	
compared	with	 patients	 treated	with	 non-cardiotoxic	 chemotherapy	 using	 Student’s	 t	
test	(continuous	variables)	Chi-square	(non-dichotomous	categorical	variables)	or	Fischer	
Exact	(dichotomous	variables).	The	incidence	rates	of	cardiovascular	adverse	events	were	
calculated,	stratified	for	patients	receiving	cardiotoxic	and	non-cardiotoxic	chemotherapy	
and	 assessed	 during	 the	 first	 year	 of	 follow-up	 and	 during	 total	 follow-up	 (long	 term	
adverse	 events).	 The	 incidence	 rates	 of	 cardiovascular	 adverse	 events	 were	 expressed	
in	 95%	 confidence	 intervals	 based	 on	 Byar’s	 approximation.15	 Hazard	 ratios,	 including	
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95%	confidence	intervals,	for	cardiovascular	adverse	events	in	the	cardiotoxic	treatment	
group,	compared	with	 the	non-cardiotoxic	 treatment	group,	were	calculated	using	the	
Cox	proportional	hazards	regression	analysis.	Hazard	ratios	were	also	shown	adjusted	for	
age,	year	of	cohort	entry	date	and	stage	of	cancer.	All	analyses	were	performed	using	SAS	
V9.1	UNIX	(Cary,	NC,	USA).
Results
In	 total,	 4,856	 patients	 with	 a	 hospital	 admission	 for	 breast	 cancer	 were	 identified	 of	
whom	complete	data	were	 available	 in	 the	period	 1992	 to	 2003.	About	 20%	 (n =	953)	
of	 these	patients	 received	chemotherapy	and	finally	648	patients	were	 included	 in	 the	
study	cohort	based	on	available	breast	tumour	staging	data	and	the	inclusion	criteria.	A	
flowchart	of	the	patient	selection	for	the	study	cohort	is	shown	in	Figure	1.	The	median	
follow-up	of	the	patients	included	in	the	study	cohort	was	545	days	(interquartile	range:	
240-1,045	days)	and	more	than	half	of	these	patients	received	cardiotoxic	chemotherapy	
(54%).
Figure 1. Flowchart of patient selection for the study cohort 
Baseline	 characteristics	 stratified	 per	 cardiotoxic	 and	 non-cardiotoxic	 chemotherapy	 of	
patients	included	in	the	study	cohort	are	shown	in	Table	1.	Patients	who	received	cardiotoxic	
chemotherapy	compared	with	patients	receiving	non-cardiotoxic	chemotherapy	at	cohort	
Patients hospitalized for breast cancer in the period 1992-2003 selected from
11 hospitals which could supply additional chemotherapy data for this study n = 4,856
Patients hospitalized for breast cancer and treated with chemotherapy   n =    953
Patients with known breast tumour stage and treated with chemotherapy  n =    815
Study cohort: 
Patients with known breast tumour stage, treated with chemotherapy, 
female, history of 2 years in the PHARMO RLS and ≥ 18 years   n =    648
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entry	date	were	younger	(50	years	versus	53	years,	respectively;	p =	0.002),	more	likely	to	
have	started	chemotherapy	in	recent	years	(68%	versus	54%	in	2001-2003,	respectively;	p <	
0.001),	more	likely	to	be	diagnosed	at	stage	III	(18%	versus	6%,	respectively; p <	0.001)	and	
less	likely	to	be	diagnosed	at	stage	IV	(5%	versus	19%,	respectively; p <	0.001).	For	breast	
cancer	therapy	two	years	before	the	cohort	entry	date	the	following	can	be	noted:	Patients	
who	received	cardiotoxic	chemotherapy	compared	with	patients	receiving	non-cardiotoxic	
chemotherapy	were	more	likely	to	undergo	radiation	therapy	(66%	versus	44%,	respectively;	
p <	0.001),	less	likely	to	have	received	chemotherapy	(1%	versus	7%,	respectively;	p <	0.001)	
and	more	likely	to	have	been	hospitalised	for	breast	cancer	(86%	versus	78%,	respectively;	p 
=	0.017).	Patients	who	received	cardiotoxic	chemotherapy	compared	with	patients	receiving	
non-cardiotoxic	chemotherapy	had	experienced	less	cardiovascular	co-morbidities	 in	the	
two	years	before	the	cohort	entry	date:	They	less	often	received	anticoagulants/haemostatics	
(5%	versus	11%,	respectively;	p =	0.012)	and	were	less	often	hospitalized	for	pre-existing	
cardiovascular	diseases	(1%	versus	5%,	respectively;	p =	0.007).	
Table 1. Characteristics of breast cancer patients at baseline1
Characteristics Total Chemotherapy 
Cardiotoxic Non-Cardiotoxic 
n % n % n % p-value
Characteristics at the cohort entry date1
Total 648 100.0 353 100.0 295 100.0
Age 0.002
18-39 62 9.6 37 10.5 25 8.5
40-49 245 37.8 140 39.7 105 35.6
50-59 193 29.8 108 30.6 85 28.8
60-69 104 16.0 56 15.9 48 16.3
70+ 44 6.8 12 3.4 32 10.8
mean ± SD 51.6 ± 10.7 50.4 ± 9.8 53.1 ± 11.5
Year of cohort entry date1 <0.001 
1992-1997 79 12.2 24 6.8 55 18.6
1998-2000 169 26.1 88 24.9 81 27.5
2001-2003 400 61.7 241 68.3 159 53.9
Stage of cancer <0.001 
I 99 15.3 49 13.9 50 16.9
II 392 60.5 221 62.6 171 58.0
III 81 12.5 64 18.1 17 5.8
IV 76 11.7 19 5.4 57 19.3
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Characteristics Total Chemotherapy 
Cardiotoxic Non-Cardiotoxic 
n % n % n % p-value
Breast cancer therapy two years before the cohort entry date1
Prior radiation therapy2 <0.001
radiation therapy 158 53.6 83 65.9 75 44.4
no radiation therapy / unknown 137 46.4 43 34.1 94 55.6
Prior hormonal therapy 128 19.8 64 18.1 64 21.7 0.276
Prior chemotherapy 25 3.9 5 1.4 20 6.8 <0.001
Prior cardiotoxic chemotherapy 6 0.9 5 1.4 1 0.3 0.228
Prior breast surgery 519 80.1 288 81.6 231 78.3 0.324
Hospitalisations
breast cancer 533 82.3 302 85.6 231 78.3 0.017
non-breast cancer 8 1.2 3 0.8 5 1.7 0.479
Cardiovascular co-morbidity two years before the cohort entry date1
Severity of cardiovascular co-morbidity 0.188  
none/light impact 323 49.8 174 49.3 149 50.5
moderate impact 176 27.2 105 29.7 71 24.1
high impact 149 23.0 74 21.0 75 25.4
Co-medication
anti-hypertensive drugs 120 18.5 66 18.7 54 18.3 0.919
anti-diabetic drugs 27 4.2 15 4.2 12 4.1 0.998
nitrates 21 3.2 10 2.8 11 3.7 0.657
anti-arrhythmics 2 0.3 0 0.0 2 0.7 0.207
digitalis 3 0.5 1 0.3 2 0.7 0.594
anticoagulants/haemostatics 51 7.9 19 5.4 32 10.8 0.012
lipid lowering drugs 33 5.1 19 5.4 14 4.7 0.858
Hospitalisations 
cardiovascular disease 18 2.8 4 1.1 14 4.7 0.007
diabetes 2 0.3 2 0.6 0 0.0 0.503
1 Baseline: at and before cohort entry date, the date on which patients received their first chemotherapy, less than 
two months before or within six months after diagnosis with breast tumour stage III or IV; 2 Information on radiation 
therapy was only available for 295 patients whose data originated from the Eindhoven Cancer Registry; SD: standard 
deviation
As	the	outcomes	of	this	study	are	cardiovascular	events	during	follow-up,	 it	was	determined	
whether	the	baseline	characteristics:	use	of	anticoagulants/haemostatics	and	hospitalisation	for	
pre-existing	cardiovascular	diseases,	predicted	the	type	of	chemotherapy	(cardiotoxic	or	non-
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cardiotoxic)	a	patient	received	at	baseline.	This	was	performed	by	using	logistic	regression	by	
which	baseline	characteristics	that	showed	statistically	significant	difference	between	the	two	
chemotherapy	groups	(see	Table	1),	were	entered	into	the	multiple	logistic	regression	model.	
Patients	who	had	been	using	anticoagulants/haemostatics	in	the	two	year	period	prior	to	the	
cohort	entry	date	did	not	have	a	significant	lower	chance	to	receive	cardiotoxic	chemotherapy	
at	 baseline	 compared	 with	 non-cardiotoxic	 chemotherapy,	 after	 adjustment	 for	 possible	
confounders	(odds	ratio	(OR)	0.74,	95%	confidence	interval	(CI)	0.36,	1.51),	while	patients	who	had	
been	hospitalized	for	cardiovascular	diseases	in	the	two	years	prior	to	the	cohort	entry	date	had	
a	significant	lower	chance	to	receive	cardiotoxic	chemotherapy	at	baseline	than	non-cardiotoxic	
chemotherapy	even	after	adjustment	for	possible	confounders	(OR	0.27,	95%CI:	0.08,	0.94).
Table 2. Type of chemotherapy of breast cancer patients at cohort entry and during follow-up
At cohort entry date During follow-up
Type of chemotherapy First line1 Second line Third line
n % n % n %
Any	chemotherapy	 648 100 88 100 28 100
Most frequently used combinations
CMF 187 28.9 17 19.3 2 7.1
FAC2 21 3.2 0 0.0 0 0.0
FEC2 153 23.6 9 10.2 0 0.0
AC2 149 23.0 22 25.0 4 14.3
EC2 25 3.9 4 4.5 2 7.1
Other chemotherapies
NFL2 1 0.2 0 0.0 1 3.6
PH2 0 0.0 0 0.0 1 3.6
antracyclines2 4 0.6 0 0.0 1 3.6
other chemotherapy3 108 16.7 36 40.9 17 60.7
Cardiotoxic chemotherapy
yes 353 54.5 35 39.8 9 32.1
no 295 45.5 53 60.2 19 67.9
1 First line treatment: treatment at the cohort entry date; 2 Cardiotoxic chemotherapies; 3 other non-cardiotoxic che-
motherapies: cyclophosphamide, methotrexate, taxanes, pyrimidine antagonists, vinka alkaloids; CMF: cyclophos-
phamide, methotrexate, fluorouracil; FAC: fluorouracil, doxorubicin, cyclophosphamide; FEC: fluorouracil, epirubicin, 
cyclophosphamide; AC: doxorubicin, cyclophosphamide; EC: epirubicin, cyclophosphamide; NFL; mitoxantrone, 
fluorouracil, folic acid; PH: paclitaxel, trastuzumab
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The	type	of	chemotherapy	patients	received	at	the	cohort	entry	date	and	during	follow-up	is	
shown	in	Table	2.	The	most	frequently	used	combinations	of	cytotoxic	chemotherapy	agents	at	
cohort	entry	date	were	CMF	(cyclophosphamide,	methotrexate,	fluorouracil),	FEC	(fluorouracil,	
epirubicin,	methotrexate)	and	AC	(doxorubicin,	cyclophosphamide)	of	which	AC	and	FEC	were	
considered	cardiotoxic.	Chemotherapy	combinations	CMF	and	AC	were	also	the	most	frequently	
used	 combinations	 during	 follow-up.	 A	 total	 of	 32	 patients	 not	 treated	 with	 cardiotoxic	
chemotherapy	at	cohort	entry	date	received	cardiotoxic	chemotherapy	during	follow-up.	
The	incidence	rates	of	cardiovascular	adverse	events	after	one	year	and	total	follow-up,	
stratified	by	cardiotoxic	and	non-cardiotoxic	chemotherapy,	are	shown	in	Table	3.	Highest	
incidence	rates	of	hospital	admissions	were	observed	for	admissions	for	cerebrovascular	
diseases,	heart	failure	and	cardiovascular	disease	admissions	other	than	those	classified	
in	Table	 3.	 Highest	 incidence	 rates	 of	 new	 cardiovascular	 drug	 use	were	 observed	 for	
anticoagulants/haemostatics,	 anti-diabetics	 and	 lipid	 lowering	 drugs.	 None	 of	 the	
patients	included	in	the	study	cohort	was	admitted	for	valve	disease,	hypertensive	disease,	
myocardial	infarction	or	cardiomyopathy,	during	follow-up.
The	 overall	 incidence	 rate	 of	 cardiovascular	 events	 during	 the	 first	 year	 of	 follow-up	
based	on	the	first	cardiovascular	admission	or	new	cardiovascular	drug	use	was	69/1,000	
person	years	(py)	for	patients	treated	with	cardiotoxic	chemotherapy	and	98/1,000	py	for	
patients	treated	with	non-cardiotoxic	chemotherapy.	These	incidence	rates	did	not	differ	
significantly:	 hazard	 rate	 (HR)	 adjusted	 for	 age,	 year	of	 cohort	 entry	date	 and	 stage	of	
cancer	was	0.74	(95%CI:	0.39,	1.41).	The	overall	incidence	rate	was	81/1,000	py	for	patients	
treated	with	cardiotoxic	 chemotherapy	and	92/1,000	py	 for	patients	 treated	with	non-
cardiotoxic	chemotherapy	for	the	total	follow-up	period	(HR	0.81,	95%CI:	0.54,	1.20).
A	sub	analysis	was	performed	in	patients	with	low	pre-existing	cardiovascular	co-morbidity	
(none/light	impact,	n	=	323).	The	overall	incidence	rates	of	cardiovascular	adverse	events	in	
this	sub	population	were	51/1,000	py	(95%CI:	24,	110)	for	patients	treated	with	cardiotoxic	
chemotherapy	and	55/1,000	py	(95%CI:	22,	101)	for	patients	treated	with	non-cardiotoxic	
chemotherapy	(HR	1.01,	95%CI:	0.35,	2.92).	After	total	follow-up,	the	overall	incidence	rates	
were	65/1,000	py	(95%CI:	42,	99)	versus	66/1,000	py	(95%CI:	(41,	97)	for	patients	treated	
with	cardiotoxic	chemotherapy	and	non-cardiotoxic	chemotherapy,	respectively	(HR	0.94,	
95%CI:	0.51,	1.73).
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Discussion 
This	population-based	 retrospective	 cohort	 study	 showed	 incidence	 rates	of	 cardiovascular	
adverse	events	among	breast	cancer	patients	receiving	chemotherapy.	The	study	shows	that	
the	overall	incidence	rates	of	cardiovascular	events	during	follow-up	were	around	70-100	per	
1,000	person	years	 in	daily	clinical	practice.	 Incidence	rates	were	similar	 for	patients	treated	
with	cardiotoxic	or	non-cardiotoxic	chemotherapy.	However,	prior	to	start	of	chemotherapy,	
patients	who	received	cardiotoxic	chemotherapy	were	somewhat	younger,	had	received	less	
anticoagulants/haemostatics	and	were	less	often	hospitalized	for	cardiovascular	diseases	than	
patients	treated	with	non-cardiotoxic	chemotherapy.	
In	this	database	study,	cardiovascular	events	were	based	on	drug	use	and	hospital	admissions,	
which	resulted	in	an	incidence	rate	of	7-10%	per	person	year	in	this	study	cohort.	Reported	
incidences	 for	 cardiotoxic	events	 after	 chemotherapy	are	 in	 the	 range	of	0.5%	 to	20%	and	
mostly	based	on	clinical	studies.4,	6,	10,	11	The	occurrence	of	cardiovascular	events	depends	on	
treatment-related	factors	such	as	dose	and	rate	of	administration	and	patient-related	factors	
such	as	age	and	pre-existing	cardiovascular	co-morbidity.4-8,	10,	11		
Recently,	a	population-based	study	by	Doyle	et al.	reported	a	1.4	times	increased	risk	for	heart	
diseases	 in	patients	 receiving	doxorubicin	and	a	1.2	 times	 increased	 risk	 in	elderly	patients	
treated	with	any	chemotherapy	compared	to	no	chemotherapy.16	The	increased	risk	associated	
with	chemotherapy	was	particularly	seen	with	cardiomyopathy,	also	resulting	 in	differences	
between	cardiotoxic	and	non-cardiotoxic	chemotherapy.	These	risks	were	found	in	patients	65	
years	and	older	and	it	is	known	that	elderly	breast	cancer	patients	have	more	co-morbidities	
and	thus	may	be	at	a	particularly	high	risk	of	treatment-related	cardiotoxicity.16-21	
Stratification	of	incidence	rates	for	cardiotoxic	and	non-cardiotoxic	chemotherapy	in	our	study	
makes	it	possible	to	consider	both	treatment	groups	separately.	The	fact	that	we	did	not	find	any	
differences	in	incidence	rates	of	cardiovascular	adverse	events	between	patients	treated	with	
cardiotoxic	or	non-cardiotoxic	chemotherapy,	may	be	explained	by	the	favourable	cardiac	risk	at	
baseline.	Older	patients,	patients	with	prior	use	of	anticoagulants/haemostatics	or	patients	with	
a	prior	hospitalisation	for	cardiovascular	diseases	were	less	likely	to	receive	cardiotoxic	chemo-
therapy.	Though,	in	a	sub	analysis	in	patients	with	a	low	cardiac	risk	at	baseline	also	no	differenc-
es	in	incidence	rates	of	cardiovascular	adverse	events	between	the	two	chemotherapy	groups	
were	found.	Caution	is	warranted	because	of	low	numbers	involved.	Similar	results	in	incidence	
rates	of	the	two	chemotherapy	groups	may	indicate	that	also	other	factors	such	as	rate	of	admin-
istration	and	cumulative	dose	were	taken	into	account	for	the	different	cytotoxic	chemotherapy	
agents,	thereby	decreasing	the	cardiotoxic	risk	of	the	treatment.3-5,	16,	22	Unfortunately,	informa-
tion	on	dose	and	rate	of	administration	of	chemotherapy	were	not	available	in	our	database.	It	
is	most	likely	that	specialists	are	aware	of	the	risk	factors	for	cardiotoxicity,	and	take	these	into	
account	when	treating	the	breast	cancer	patient.	We	also	found	that	during	follow-up,	certain	
patients	switched	from	non-cardiotoxic	to	cardiotoxic	chemotherapy	(11%),	which	may	lead	to	
a	reduction	in	the	difference	between	the	two	chemotherapy	groups.	At	the	same	time,	some	
of	the	patients	starting	cardiotoxic	chemotherapy	received	non-cardiotoxic	chemotherapy	as	
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second-line	therapy	(8%).	We	did	not	investigate	the	effect	of	treatment	switch	on	the	results.	
Radiation	therapy	has	been	reported	to	increase	the	risk	on	cardiovascular	events.23,	24	This	did	
not	seem	to	affect	the	outcomes	in	our	study	as	patients	receiving	cardiotoxic	chemotherapy	
compared	with	patients	receiving	non-cardiotoxic	chemotherapy	were	more	likely	to	undergo	
radiation	therapy,	but	did	not	have	significant	more	cardiovascular	events	during	follow-up.	
Though,	in	this	study,	information	on	radiation	therapy	was	limited	to	a	subpopulation.
Several	limitations	of	this	study	need	to	be	addressed.	The	numbers	of	patients	included	in	the	
study	are	small,	therefore	stratification	of	incidence	rates	of	cardiovascular	adverse	events	by	
baseline	characteristic	was	not	appropriate	 (data	not	shown).	The	occurrence	of	cardiotoxic	
events	were	 based	 on	 drug	 use	 and	 hospital	 admissions	 as	more	 detailed	 information	 on	
electrocardiograph	(ECG)	changes	and	laboratory	values	such	as	left	ventricular	ejection	fraction	
(LVEF)	was	not	available.	Other	methods	to	define	cardiotoxic	events	might	have	resulted	in	
different	incidence	rates	and	also	different	rates	between	the	two	chemotherapy	groups.	The	
classification	of	cardiotoxic	and	non-cardiotoxic	chemotherapy	may	not	be	as	strict	as	used	in	
our	study,	which	could	lead	to	a	reduction	in	the	difference	between	the	two	chemotherapy	
groups.	However,	our	classification	was	based	on	the	consultation	of	a	specialist	and	reflects	
experience	in	clinical	practice.	In	addition,	anthracyclines	are	considered	the	most	cardiotoxic	
agents	compared	with	other	cytotoxic	chemotherapy	agents.3-6,	8,	9
Our	study	was	not	designed	to	 identify	which	chemotherapy	agents	are	cardiotoxic,	but	to	
provide	 insight	 into	 real-world	 cardiotoxic	 and	 non-cardiotoxic	 chemotherapy	 use	 among	
breast	 cancer	 patients	 suffering	 from	 co-morbidities	 and	 the	 occurrence	 of	 incidence	 of	
cardiovascular	adverse	events	in	clinical	practice.	With	novel	agents	such	as	trastuzumab	still	
being	potential	cardiotoxic	and	with	the	aging	of	the	population	and	the	growing	number	of	
survivors	of	breast	cancer	with	co-morbid	conditions,	adverse	events	of	chemotherapy	remain	
relevant.8,	25	Therefore,	specialists	should	remain	alerted	to	the	risk	factors	for	cardiotoxicity,	such	
as	pre-existing	cardiovascular	disorders,	age,	dose	and	rate	of	administration.	
The	 present	 population-based	 cohort	 study	 among	 breast	 cancer	 patients	 receiving	
chemotherapy	showed	that	the	overall	incidence	rates	of	cardiovascular	adverse	events	were	
around	70-100	per	1,000	person	years	and	were	similar	after	cardiotoxic	or	non-cardiotoxic	
chemotherapy.	Patients	with	more	cardiovascular	co-morbidity	at	baseline	received	less	often	
cardiotoxic	chemotherapy,	indicating	that	specialists	took	pre-existing	cardiovascular	diseases	
into	account	when	treating	the	breast	cancer	patient.
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Abstract
Background: 
Patients	with	breast	cancer	are	at	increased	risk	of	venous	and	arterial	thrombosis	
due	to	cancer	itself	and	its	related	treatment.	Although	some	studies	have	assessed	
the	incidence	of	venous	thromboembolism	among	breast	cancer	patients,	data	
on	the	occurrence	of	specific	venous	and	arterial	thrombotic	events	is	scarce.
Objectives: 
To	study	the	occurrence	of	myocardial	 infarction	(MI),	 ischaemic	stroke	(IS)	and	
pulmonary	embolism	(PE)	before	and	after	breast	cancer	hospitalisation	compared	
with	cancer-free	controls.	
Methods: 
For	 this	 cohort	 study,	 women	with	 a	 first	 breast	 cancer	 hospitalisation	 during	
2000-2007	were	 selected	 from	 the	PHARMO	Record	Linkage	System,	 including	
drug	use	and	hospitalisations	of	three	million	inhabitants	in	the	Netherlands,	and	
matched	1:10	by	age	to	cancer-free	controls.	The	occurrence	of	MI,	IS	and	PE	were	
assessed	in	the	12	months	before	and	after	breast	cancer	hospitalisation.
Results: 
The	analysis	 included	11,473	breast	 cancer	patients,	with	a	mean	 (±SD)	age	of	
59	 (±14)	years.	Breast	cancer	patients	were	two	to	three	times	as	 likely	as	 their	
cancer-free	controls	to	have	had	a	hospitalisation	for	PE,	MI	or	IS	in	the	12	months	
before	diagnosis,	though	prevalence	was	<1%	in	all	groups.	Breast	cancer	patients	
experienced	 an	 extreme	 high	 risk	 of	 PE	 in	 the	 first	 six	months	 after	 diagnosis	
(Hazard	Ratio	(HR)=23.5	[95%CI:11.1-49.7]	compared	to	controls),	which	declined	
gradually	 to	 a	 four	 times	 increased	 risk	 (HR=3.6	 [95%CI:2.4-5.5])	more	 than	 12	
months	after	breast	cancer	hospitalisation.	However,	incidence	was	low:	less	than	
5	events	per	1,000	person	years	during	all	time	periods.	For	MI	and	IS	we	did	not	
observe	significant	increased	HRs	after	breast	cancer	hospitalisation	compared	to	
controls.
Conclusions: 
Breast	cancer	patients	seem	to	have	a	higher	risk	profile	to	develop	MI	and	IS,	and	
receive	treatment	that	increases	the	risk	of	PE	compared	to	cancer-free	controls,	
although	the	frequency	of	hospitalisations	was	low.
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Introduction 
The	association	between	cancer	 and	 thrombosis,	 especially	 venous	 thrombosis,	 is	well	
recognized.1-3	Cancer	patients	are	at	increased	risk	for	thromboembolic	complications	due	
to	the	release	of	pro-coagulants,	compression	or	invasion	of	blood	vessels,	or	as	a	result	of	
prolonged	immobilization,	surgery	or	treatment	with	chemotherapeutic	agents.3-6	Several	
studies	suggest	that	the	frequency	of	thromboembolism	in	cancer	patients,	especially	PE,	
is	increasing.6,	7	This	is	alarming	as	thrombotic	complications	among	cancer	patients	are	
associated	with	decreased	survival.8,	9	
While	the	rate	of	venous	thromboembolism	among	cancer	patients	has	been	determined	in	
several	retrospective	cohort	studies,6-8,	10-14	published	epidemiologic	data	on	the	incidence	
of	 the	 specific	 types	of	venous	and	arterial	 thromboembolism15	 is	 scarce.	Moreover,	 as	
the	risk	of	thrombosis	varies	within	the	cancer	patient	during	the	course	of	malignancy1	
timing	of	the	occurrence	of	thrombotic	events	needs	further	research.	
This	study	focused	on	the	occurrence	of	specific	thromboembolic	events	in	different	time	
intervals	among	women	with	a	hospitalisation	for	breast	cancer.	Although	reported	rates	
of	venous	thromboembolism	among	breast	cancer	patients	are	one	of	the	lowest	among	
cancer	patients6-8,	this	highly	prevalent	cancer	can	contribute	significantly	to	the	overall	
burden	of	 venous	 thromboembolism14.	We	 studied	 the	more	 serious	 and	well-defined	
venous	and	arterial	thromboembolic	events,	which	are	myocardial	infarction,	ischaemic	
stroke	and	pulmonary	embolism.		All	three	will	result	directly	in	a	hospitalisation	and	may	
contribute	significantly	to	the	risk	of	mortality	among	breast	cancer	patients.	The	rates	of	
these	three	events	were	determined	before	and	after	breast	cancer	hospitalisation	and	
compared	with	cancer-free	controls.	 In	addition,	 risk	 factors	 for	developing	myocardial	
infarction,	ischaemic	stroke	and	pulmonary	embolism	after	breast	cancer	hospitalisation	
were	defined.		
Methods
Data source
Data	 were	 obtained	 from	 the	 PHARMO	 Record	 Linkage	 System	 (PHARMO	 RLS)	 which	
consists	of	multiple	observational	databases	linked	on	a	patient	level,	covering	3	million	
inhabitants	of	geographic	defined	areas	in	the	Netherlands.		Databases	relevant	for	this	
study	include	the	Dutch	National	Medical	Register	(LMR)16		and	the	community	pharmacy	
database	 (out-patient).	 The	 hospital	 records	 contain	 detailed	 information	 concerning	
admissions	 for	more	 than	24	hours	 and	 admissions	 for	 less	 than	24	hours	 for	which	 a	
bed	 is	 required,	 including	 primary	 and	 secondary	 diagnoses,	 procedures	 and	 dates	 of	
hospital	admission	and	discharge.	All	diagnoses	are	coded	according	to	the	International	
Classification	 of	 Diseases,	 Ninth	 Revision,	 Clinical	 Modification	 (ICD-9-CM).	 The	 drug	
dispensing	histories	 from	community	pharmacies	contain	data	on	 the	dispensed	drug,	
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prescriber,	dispensing	date,	amount	dispensed,	prescribed	dose	regimens,	and	thus	the	
duration	of	use.	All	drugs	are	coded	according	to	the	Anatomical	Therapeutic	Chemical	
(ATC)	Classification.	
Study population
New	hospitalized	breast	cancer	women	 (ICD-9-CM	code:	174)	 in	 the	period	 January	1st	
2000	to	December	31st	2007	were	selected	from	the	Dutch	National	Medical	Register	of	
the	PHARMO	RLS.	Date	of	first	breast	cancer	hospitalisation	was	defined	as	 the	cohort	
entry	date	and	patients	with	any	cancer	hospitalisation	(ICD-9-CM	codes:	140-239)	in	the	
period	of	ten	years	before	the	cohort	entry	date	(or	as	far	as	history	was	available	in	the	
Dutch	National	Medical	Register	of	the	PHARMO	RLS)	were	excluded.	To	be	able	to	define	
co-morbidities	 in	 recent	 history	 based	 on	 drug	 use	 -next	 to	 hospitalisations-,	 patients	
needed	to	have	at	least	12	months	of	history	in	the	community	pharmacy	database	of	the	
PHARMO	RLS.		All	patients	were	followed	from	cohort	entry	until	end	of	data-collection	in	
the	PHARMO	RLS	(i.e.	the	patient	moves	out	of	the	PHARMO	RLS	catchment	area),	death,	
or	end	of	the	study	period	(December	31st	2008),	whichever	occurred	first.
Cancer-free controls
Controls	were	selected	from	all	women	included	in	the	PHARMO	RLS;	a	large,	population-
based	cohort	of	cancer	and	cancer-free	patients	with	thorough	and	unbiased	information	
on	medications	and	hospitalisations.	The	 selection	of	 the	control	 cohort	was	 stepwise.	
First,	for	each	breast	cancer	patient	we	matched	randomly	1:20	by	age	with	breast	cancer-
free	women	(i.e.	never	hospitalized	for	breast	cancer	(ICD-9-CM	code:	174)).	Each	of	these	
potential	controls	was	assigned	the	cohort	entry	date	of	the	cancer	patient	case	match.	
Second,	we	eliminated	from	the	pool	of	20	possible	controls	per	case,	any	control	that	did	
not	have	12	months	of	history	before	cohort	entry	date	in	the	PHARMO	RLS	and/or	who	
had	a	hospitalisation	with	a	primary	diagnosis	for	any	cancer	(ICD-9-CM	codes:	140-239)	in	
the	period	from	10	years	before	the	cohort	entry	date (or	as	far	as	history	is	available	in	the	
Dutch	National	Medical	Register	of	the	PHARMO	RLS)	until	December	31st	2008.	Finally,	
out	of	the	remaining	controls	that	fulfilled	the	above	criteria,	ten	per	case	were	randomly	
selected	and	included	in	the	control	cohort.
Outcomes
Only	thromboembolic	events	that	are	likely	to	lead	to	a	hospitalisation	were	included	in	
this	study	and	selected	by	using	primary	discharge	diagnosis	codes:	myocardial	infarction	
(ICD-9-CM:	 410)17,	 ischaemic	 stroke	 (ICD-9-CM:	 433,	 434,	 437.1)18,	 19	 and	 pulmonary	
embolism	(ICD-9-CM:	415.1)20,	21.	These	three	events	were	defined	in	12	months	of	history	
and	during	follow-up	(0	to	6	months,	6	to	12	months	and	12	months	to	total	follow-up).
Patient characteristics
The	 following	 characteristics	 were	 determined:	 age,	 duration	 of	 follow-up	 and	 use	 of	
138
Myrthe van Herk-Sukel
7
C h a p t e r  7
the	following	cardiovascular	drugs	in	the	year	before	cohort	entry	based	on	ATC	codes:	
platelet	aggregation	 inhibitors	 (B01AC),	other	anti-thrombotic	drugs	 (including	aspirin,	
B01A	excl.	B01AC),	lipid-lowering	drugs	(C10),	anti-hypertensives	(C02,	C03	(excl.	C03C),	
C07,	C08,	C09	(excl.	C09X)),	other	cardiovascular	drugs	(e.g.	anti-arrhythmics,	vasodilators	
and	vasoprotectives;	C01,	C04,	C05)	and	anti-diabetic	drugs	(A10).	In	addition,	in	the	six	
months	after	cohort	entry	we	also	determined	the	use	of	chemotherapy	based	on	hospital	
discharge	 diagnoses	 (ICD-9-CM	 code:	 V58.1)	 and/or	 oral	 chemotherapies	 supplied	 by	
community	pharmacies	(ATC	code:	L01	excl.	targeted	drug	therapies:	L01XC	and	L01XE),	
anti-neoplastic	hormonal	therapy	(L02),	breast	cancer-related	surgery	(hospital	procedure	
codes:	5-860	to	5-869,	5-870	to	5-879	and	5-400	to	5-409)	and	cumulative	duration	of	any	
hospital	stay	(0-10,	>10	days).
Analyses
Prior	drug	use	was	compared	between	breast	 cancer	patients	and	 their	 controls	using	
the	Chi-square	test.	Prevalence	proportions	 in	the	12	months	before	cohort	entry	were	
assessed	 for	 each	 thromboembolic	 event	 and	 expressed	 with	 accompanying	 95%	
confidence	intervals	(CI).	Conditional	logistic	regression	was	used	to	calculate	odds	ratios	
with	95%	CI.	For	patients	with	five	year	history	 in	the	PHARMO	RLS	sensitivity	analyses	
were	performed	including	prevalence	proportions	in	five	years	before	cohort	entry.	For	
incidence	calculations,	patients	with	a	previous	event	(i.e.	myocardial	infarction,	ischaemic	
stroke	or	pulmonary	embolism	 in	 the	12	months	prior	 to	 cohort	 entry)	were	 removed	
from	the	at-risk	population	for	that	specific	event.	Incidence	rates	per	1000	person-years	
with	accompanying	95%	CI	based	on	Byar’s	approximation22	were	calculated	for	the	three	
distinct	periods	of	follow-up	time.	Cox	proportional	hazards	regression	analysis	was	used	
to	compare	the	incidence	of	the	thromboembolic	events	between	breast	cancer	patients	
and	their	cancer-free	controls	including	correction	for	possible	confounders.	To	visualize	
the	 time	course	of	pulmonary	embolism	among	breast	cancer	patients	 the	proportion	
of	patients	with	pulmonary	embolism	(including	95%	CI)	was	determined	at	0	to	6	and	
6	to	12	months	before	breast	cancer	hospitalisation	and	0	to	6	and	6	to	12	months	after	
breast	cancer	hospitalisation	among	patients	with	complete	follow-up	during	these	four	
periods.	Cox	proportional	hazards	regression	models	were	also	fit	to	identify	independent	
risk	factors	for	developing	myocardial	infarction,	ischaemic	stroke	or	pulmonary	embolism	
in	the	complete	follow-up	after	hospitalisation	for	breast	cancer.	The	above	mentioned	
patient	characteristics	were	considered	as	potential	risk	factors.	All	risk	factors	associated	
with	the	outcome	in	the	univariate	analyses	were	included	in	the	multivariate	analyses.	
Statistical	significance	was	defined	at	an	alpha	level	of	0.05.	Data	were	analysed	using	SAS	
(SAS	Institute	Inc.,	Cary,	NC,	USA).	
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Results
A	total	of	11,473	women	with	a	first	hospitalisation	for	breast	cancer	during	2000-2007	
was	selected	from	the	PHARMO	RLS	and	matched	to	114,730	cancer-free	women.	Mean	
(±standard	deviation:	SD)	age	of	patients	was	59	(±14)	years.	The	mean	(±SD)	duration	of	
follow-up	was	3.7	(±2.2)	years	for	breast	cancer	patients	and	3.9	(±2.2)	years	for	the	cancer-
free	controls.	Use	of	the	various	types	of	cardiovascular	drugs	and	anti-diabetic	drugs	prior	
to	breast	cancer	hospitalisation	as	presented	in	Table	1	was	significantly	higher	among	
breast	cancer	patients	compared	to	their	cancer-free	controls	(p<0.0001).	Similar	use	of	
these	drugs	was	found	during	the	first	six	months	after	breast	cancer	hospitalisation	(data	
not	 shown).	Of	 the	 breast	 cancer	 patients,	 20%	 received	 chemotherapy,	 32%	 received	
anti-neoplastic	hormonal	therapy	and	92%	received	breast	cancer	related	surgery	during	
or	within	six	months	after	the	first	breast	cancer	hospitalisation.	Data	on	radiation	therapy	
was	not	available	in	the	PHARMO	RLS.	Median	duration	of	breast	cancer	hospitalisation	at	
cohort	entry	was	2	days	(interquartile	range=1-5	days).
Table 1. Age and prior drug use of breast cancer patients and cancer-free controls
Patients with breast cancer
(N=11,473)
Cancer-free control cohort
(N=114,730)
N (%) N (%)
Age in years (mean ± SD) 59 (± 14) 59 (± 14)
Prior drug use 1,2
Platelet aggregation inhibitors 1,166 (10) 7,912 (7)
Other anti-thrombotic drugs 524 (5) 2,684 (2)
Lipid-lowering drugs 1,292 (11) 8,765 (8)
Anti-hypertensives 3,914 (34) 23,353 (20)
Other cardiovascular drugs3 1,096 (10) 6,270 (6)
Anti-diabetic drugs 808 (7) 4,779 (4)
SD: Standard Deviation; 1In the 12 months before cohort entry; 2Results on prior drug use differ significantly be-
tween patients with breast cancer and their cancer-free controls (p<0.0001); 3Other cardiovascular drugs, such as 
anti-arrhythmics, vasodilators and vasoprotectives. 
Table	2	presents	the	proportion	of	patients	with	myocardial	infarction,	ischaemic	stroke	
or	pulmonary	embolism	in	the	12	months	before	breast	cancer	hospitalisation	compared	
to	cancer-free	controls.	Breast	cancer	patients	were	three	times	as	likely	as	their	cancer-
free	 controls	 to	 have	 had	 a	 myocardial	 infarction	 or	 pulmonary	 embolism	 and	 two	
times	as	likely	to	have	had	an	ischaemic	stroke.	However,	frequency	of	events	was	low:	
less	than	1%	in	both	the	breast	cancer	cohort	and	their	cancer-free	controls.	Sensitivity	
analysis	including	proportions	over	a	period	of	5	years	before	cohort	entry	showed	similar	
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results,	with	OR=1.8	(95%CI:	1.3-2.6)	for	myocardial	infarction,	OR=1.7	(95%CI:	1.1-2.5)	for	
ischaemic	stroke	and	OR=3.0	(95%CI:	1.7-5.1)	for	pulmonary	embolism.	
Table 2. Proportion of patients with myocardial infarction, ischaemic stroke or pulmonary embolism 12 
 months before breast cancer hospitalisation, compared to a non-cancer population
Patients with breast cancer
(N=11,473)
Cancer-free control cohort
(N=114,730)
Odds ratio 
(OR)
N % (95% CI) N % (95% CI) (95% CI)
Myocardial infarction 32 0.28 (0.19-0.39) 112 0.10 (0.08-0.12) 2.9 (1.9-4.2)
Ischaemic stroke 15 0.13 (0.07-0.22) 85 0.07 (0.06-0.09) 1.8 (1.0-3.1)
Pulmonary embolism 11 0.10 (0.05-0.17) 33 0.03 (0.02-0.04) 3.4 (1.7-6.7)
95% CI: 95% confidence interval
Table 3. Incidence rates of myocardial infarction, ischaemic stroke or pulmonary embolism during three 
 periods of follow-up since breast cancer hospitalisation, compared to a non-cancer population 
Patients with breast cancer Cancer-free control cohort Hazard Ratio (HR)
Event 
N
Follow-
up PY
IR per 1000 
PY (95% CI)
Event 
N
Follow-
up PY
IR per 1000 
PY (95% CI)
Crude 
(95% CI)
Adjusted1 
(95%CI)
0 to 6 months after breast cancer hospitalisation
Myocardial infarction 9 5,497 1.6 (0.7-3.1) 75 55,559 1.3 (1.1-1.7) 1.2 (0.6-2.5) 1.0 (0.5-2.0)
Ischaemic stroke 8 5,505 1.5 (0.5-2.9) 46 55,580 0.8 (0.6-1.1) 1.8 (0.8-3.8) 1.1 (0.5-2.5)
Pulmonary embolism 26 5,506 4.7 (3.1-6.9) 16 55,610 0.3 (0.2-0.5) 17.3 (9.2-32.6) 23.5 (11.1-49.7)
6 to 12 months after breast cancer hospitalisation
Myocardial infarction 8 5,082 1.6 (0.6-3.1) 60 51,695 1.2 (0.9-1.5) 1.4 (0.7-3.0) 1.5 (0.7-3.1)
Ischaemic stroke 9 5,089 1.8 (0.8-3.3) 39 51,730 0.8 (0.5-1.0) 2.4 (1.1-4.9) 1.8 (0.8-3.9)
Pulmonary embolism 14 5,085 2.8 (1.6-4.5) 15 51,765 0.3 (0.2-0.5) 9.2 (4.4-19.1) 9.0 (4.2-19.5)
12 months to total follow-up  after breast cancer hospitalisation 
Myocardial infarction 55 31,360 1.8 (1.3-2.3) 404 334,133 1.2 (1.1-1.3) 1.5 (1.1-2.0) 1.3 (1.0-1.7)
Ischaemic stroke 50 31,438 1.6 (1.2-2.1) 349 334,624 1.0 (0.9-1.2) 1.5 (1.1-2.1) 1.2 (0.9-1.6)
Pulmonary embolism 31 31,430 1.0 (0.7-1.4) 93 335,363 0.3 (0.2-0.3) 3.6 (2.4-5.4) 3.6 (2.4-5.5)
PY: person years; IR: Incidence rate; 95% CI: 95% confidence interval; 1Hazard Ratio for myocardial infarction ad-
justed for prior use of anti-thrombotic drugs, lipid-lowering drugs and anti-hypertensive drugs. Hazard Ratio for 
ischaemic stroke adjusted for prior use of anti-thrombotic drugs, lipid-lowering drugs, anti-hypertensive drugs and 
other cardiovascular drugs. Hazard Ratio for pulmonary embolism adjusted for prior use of anti-thrombotic drugs, 
lipid-lowering drugs and other cardiovascular drugs.
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Incidence	 rates	 of	myocardial	 infarction,	 ischaemic	 stroke	 or	 pulmonary	 embolism	 are	
presented	for	three	distinct	periods	of	follow-up	time	(Table	3).	The	incidence	of	myocardial	
infarction	and	ischaemic	stroke	among	hospitalized	breast	cancer	patients	ranged	from	
1.5	to	1.8	per	1,000	person	years	(py)	for	the	various	follow-up	periods.	
Compared	 to	 the	 cancer-free	 control	 cohort	 after	 correction	 for	possible	 confounders,	 the	
hazard	ratio	(HR)	for	myocardial	infarction	was	1.0	(95%CI:	0.5-2.0)	in	0	to	6	months,	1.5	(95%CI:	
0.7-3.1)	in	6	to	12	months	and	1.3	(95%	CI:	1.0-1.7)	in	12	months	to	total	follow-up.	For	ischaemic	
stroke	these	were	1.1	(95%CI:	0.5-2.5),	1.8	(95%CI:	0.8-3.9)	and	1.2	(95%	CI:	0.9-1.6)	respectively.	
In	contrast,	the	incidence	of	pulmonary	embolism	decreased	over	time	from	4.7	per	1,000	py	
in	0	to	6	months	after	breast	cancer	hospitalisation,	to	1.0	per	1,000	py	in	12	months	to	total	
follow-up.	Compared	to	the	controls,	the	risk	of	pulmonary	embolism	was	largely	increased,	
especially	shortly	after	hospitalisation.	In	the	first	six	months,	the	adjusted	HR	was	23.5	(95%CI:	
11.1-49.7),	while	the	HR	was	9.0	(95%CI:	4.2-19.5)	between	6	to	12	months,	and	3.6	(95%CI:	
2.4-5.5)	12	months	and	later	after	breast	cancer	hospitalisation.	This	change	in	the	proportion	
of	breast	cancer	patients	with	pulmonary	embolism	over	time	is	visualized	in	Figure	1.	The	
proportion	of	patients	with	pulmonary	embolism	increased	over	time	before	breast	cancer	
diagnosis,	with	the	highest	peak	directly	after	diagnosis	and	a	decrease	thereafter.
Figure 1. Patients with pulmonary embolism (including 95% confidence intervals) in the 12 months before 
 and 12 months after breast cancer hospitalisation
	
Multivariate	 analyses	 in	 Table	 4	 show	 that	 independent	 risk	 factors	 for	 developing	
myocardial	 infarction	 in	 the	 complete	 follow-up	 after	 hospitalisation	 for	 breast	 cancer	
were:	 older	 age	 (≥70	 years	 vs.	 ≤	 49	 years;	 HR=5.9;	 95%CI:	 2.0-17.2),	 prior	 use	 of	 anti-
hypertensives	 (HR=1.6;	95%CI:	1.0-2.8)	and	cumulative	duration	of	hospital	 stay	 longer	
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than	10	days	(irrespective	of	type	of	hospitalisation)	during	the	first	six	months	of	follow-
up	(HR=1.6;	95%CI:	1.0-2.6).	
Table 4. Risk factors for developing myocardial infarction, ischaemic stroke or pulmonary embolism after 
 hospitalisation for breast cancer 
Myocardial infarction Ischaemic stroke Pulmonary embolism
Characteristics
HR Multi-
variate1 95% CI
HR Multi-
variate1 95% CI
HR Multi-
variate1 95% CI
Age at diagnosis
≤ 49 years 1 reference 1 reference 1 reference
50-69 years 3.5 (1.2-9.9) 2.5 (0.7-8.6) 2.3 (1.1-4.6)
≥ 70 years 5.9 (2.0-17.2) 5.8 (1.7-20.0) 3.0 (1.3-6.7)
Prior drug use2
Platelet aggregation inhibitors 1.5 (0.8-2.7) 1.9 (1.1-3.4)
Other anti-thrombotic drugs 1.6 (0.8-3.4)
Lipid-lowering drugs 1.2 (0.6-2.2) 0.7 (0.4-1.5)
Anti-hypertensives 1.6 (1.0-2.8) 2.6 (1.4-4.8)
Other cardiovascular drugs3 1.0 (0.5-1.8) 1.0 (0.5-1.9)
Anti-diabetic drugs 1.7 (0.9-3.2) 2.4 (1.3-4.3)
Treatment4
Chemotherapy 2.4 (1.3-4.5)
Anti-neoplastic hormonal therapy 2.1 (1.3-3.4)
Duration of any hospitalisation4
0-10 days 1 reference 1 reference
>10 days 1.6 (1.0-2.6) 2.6 (1.6-4.3)
HR: hazard ratio; 95% CI: 95% confidence interval; 1The multivariate model included all factors that were univariately 
associated with the outcome; 2Defined in the 12 months before breast cancer hospitalisation; 3Other cardiovascular 
drugs, such as anti-arrhythmics, vasodilators and vasoprotectives; 4Defined during the first six months after breast 
cancer hospitalisation.
Independent	risk	factors	for	developing	ischaemic	stroke	were:	older	age	(≥70	years	vs.	≤	
49	years;	HR=5.8;	95%CI:	1.7-20.0)	and	prior	use	of	platelet	aggregation	inhibitors	(HR=1.9;	
95%CI:	1.1-3.4),	anti-hypertensives	(HR=2.6;	95%CI:	1.4-4.8)	or	anti-diabetic	drugs	(HR=2.4;	
95%CI:	1.3-4.3).	Independent	risk	factors	for	developing	pulmonary	embolism	in	complete	
follow-up	after	correction	for	other	risk	factors	were:	older	age	(≥70	years	vs.	≤	49	years;	
HR=3.0;	95%CI:	1.3-6.7),	use	of	chemotherapy	(HR=2.4;	95%CI:	1.3-4.5)	or	anti-neoplastic	
hormonal	 therapy	 (HR=2.1;	 95%CI:	 1.3-3.4)	 and	 total	 hospital	 stay	 >10	 days	 (HR=2.6;	
95%CI:	1.6-4.3)	during	the	first	6	months	of	follow-up.	
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Discussion
Our	large	population-based	study	showed	that	the	proportion	of	breast	cancer	patients	
hospitalized	 for	 pulmonary	 embolism	 changed	 remarkably	 over	 time.	 Breast	 cancer	
patients	were	three	times	as	likely	as	their	cancer-free	controls	to	have	had	a	hospitalisation	
for	 pulmonary	 embolism	 in	 the	 12	 months	 before	 breast	 cancer	 diagnosis.	 Directly	
after	 breast	 cancer	 hospitalisation	 a	 24-fold,	 significant	 increased	 risk	 for	 pulmonary	
embolism	was	 found	and	 this	 risk	declined	gradually	 to	a	 four	 times	 increased	 risk	 for	
thromboembolism	more	than	12	months	after	breast	cancer	hospitalisation.	Regarding	
arterial	thromboembolism,	breast	cancer	patients	were	three	times	as	likely	to	have	had	
a	myocardial	infarction	and	two	times	as	likely	as	to	have	had	an	ischaemic	stroke	before	
breast	 cancer	 hospitalisation	 compared	 to	 their	 cancer-free	 controls,	 but	 we	 did	 not	
observe	significant	increased	hazard	ratios	after	breast	cancer	hospitalisation.	
Similar	 proportions	 of	 venous	 thromboembolism	 before	 breast	 cancer	 diagnosis,	 i.e.	
0.06%-0.1%,	were	 found	 in	 previous	 studies.10,	 12	 However,	 in	 the	 study	 of	White	 et al.,	
venous	thromboembolism	rates	before	breast	cancer	diagnosis	among	patients	registered	
in	the	California	Cancer	registry	were	similar	 to	the	age-,	 race-	and	sex-specific	rates	 in	
California.12	A	higher	incidence	of	pulmonary	embolism	in	the	first	six	months	after	breast	
cancer	hospitalisation	and	decrease	 in	the	periods	afterwards	was	also	 found	by	Chew	
et al.	who	reported	1.2	events	of	venous	thrombosis	per	100	py	during	the	first	half-year	
and	0.6	per	100	py	during	the	second	half-year	of	follow-up.11	When	taking	into	account	
that	in	the	study	of	Chew	et al.	both	deep	vein	thrombosis	and	pulmonary	embolism	were	
included	and	that	the	former	occurs	two	to	three	times	more	often	than	the	latter,6,	7	these	
incidences	of	venous	thrombosis	are	similar	to	ours:	4.7	per	1,000	py	in	the	first	half-year	
and	2.8	per	1,000	py	in	the	second	half-year	after	breast	cancer	hospitalisation.	Chew	et al.	
also	found	a	4-fold	higher	risk	of	venous	thrombotic	events	among	breast	cancer	patients	
in	the	first	year	after	breast	cancer	diagnosis	compared	with	the	general	population.11	
The	increased	rate	of	pulmonary	embolism	before	breast	cancer	hospitalisation	might	be	
caused	by	the	presence	of	occult	cancer.23,	24	The	increased	risk	of	pulmonary	embolism	
directly	after	breast	cancer	hospitalisation	can	be	explained	by	the	cancer	 itself	and	 its	
related	treatment,	 including	surgery,	chemotherapy,	 radiotherapy,	or	hormone	therapy	
and	immobilization	following	treatment.3,	4,	13	The	low	proportion	of	patients	using	anti-
thrombotic	drugs	in	the	first	six	months	after	breast	cancer	hospitalisation	(16%)	suggests	
that	patients	often	did	not	receive	thromboprophylaxis	after	breast	cancer	hospitalisation.	
Independent	 risk	 factors	 for	 developing	 pulmonary	 embolism	 in	 complete	 follow-up	
after	correction	for	other	risk	factors	were:	older	age	and	breast	cancer	treatment-related	
factors:		use	of	chemotherapy	or	anti-neoplastic	hormonal	therapy	and	total	hospital	stay	
of	more	than	10	days	during	the	first	6	months	of	follow-up.	To	our	knowledge,	there	are	
no	previous	studies	reporting	risk	factors	for	solely	pulmonary	embolism	among	breast	
cancer	 patients.	 One	 study	 reported	 the	 following	 risk	 factors	 for	 developing	 venous	
thrombosis,	 including	 pulmonary	 embolism	 as	 well	 as	 deep	 vein	 thrombosis,	 within	
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2	 years	 after	 breast	 cancer	 diagnosis:	 age,	 the	 number	 of	 chronic	 co-morbidities	 and	
advancing	cancer	stage.11	Other	studies	among	various	types	of	cancer	found	that	next	
to	cancer	 site,	 the	 following	 factors	 influence	 the	 risk	of	cancer-associated	 thrombosis:	
tumour	 stage,	 age,	 gender,	 co-morbidities	 (e.g.	 hypertension,	 diabetes,	 obesity	 and	
hyperlipidaemia)	 and	 cancer	 treatment	 (e.g.	 surgery,	 radiation	 therapy,	 chemotherapy	
and	hormonal	therapy)6,	13,	25.	
Regarding	arterial	 thrombotic	events,	our	data	suggest	 that	women	developing	breast	
cancer	 are	 more	 likely	 to	 suffer	 from	 cardiovascular	 co-morbidity:	 rates	 of	 arterial	
thrombosis	before	breast	cancer	diagnosis	as	well	as	prior	cardiovascular	drug	use	were	
higher	 among	 breast	 cancer	 patients	 than	 their	 cancer-free	 controls.	 This	 might	 be	
explained	by	the	fact	that	arterial	thromboembolism	and	breast	cancer	share	similar	risk	
factors	such	as	obesity.26,	27
The	 rate	 of	 arterial	 thrombotic	 events	 did	 not	 change	 over	 time	 after	 breast	 cancer	
hospitalisation.	Risk	factors	for	developing	myocardial	infarction	or	ischaemic	stroke	were	
prior	use	of	cardiovascular	drugs,	while	chemotherapy	or	hormonal	therapy	 in	the	first	
six	months	after	breast	cancer	hospitalisation	were	not	significantly	related	to	the	risk	of	
developing	myocardial	infarction	or	ischaemic	stroke.	This	might	be	due	to	the	fact	that	
patients	are	treated	less	aggressively	when	cardiovascular	co-morbidities	are	present28,	29;	
therefore,	the	increased	risk	of	arterial	thrombosis	after	chemotherapy,	or	anti-neoplastic	
hormonal	therapies	which	is	seen	in	other	studies,30-33	was	not	seen	in	our	study.	
Our	 study	 has	 some	 limitations	 that	 need	 to	 be	 discussed.	 First	 of	 all,	 we	 used	 a	
hospitalisation	database	to	identify	venous	and	arterial	thromboembolic	events.	Using	an	
administrative	database	to	define	these	events	is	less	accurate	than	clinical	chart	review.	
However,	we	included	in	our	study	only	the	more	serious	and	well-defined	venous	and	
arterial	thromboembolic	events	that	lead	to	a	hospitalisation17-21.	We	did	not	include	e.g.	
deep	vein	thrombosis	as	many	of	these	patients	might	be	treated	outside	the	hospital,34	
resulting	 in	 an	underestimation	of	 the	 incidence	of	deep	vein	 thrombosis	when	using	
hospitalisation	data.	 	Another	 limitation	is	that	we	were	not	able	to	 include	risk	factors	
such	 as	 tumour	 stage,	 radiation	 therapy,	 obesity,	 positive	 family	 history	 of	 coronary	
artery	 disease,	 cigarette	 smoking	 and	 increased	 psychological	 distress,	 as	 these	 were	
not	recorded	in	the	used	databases.	We	could	have	retrieved	data	on	tumour	stage	and	
radiation	therapy	for	a	subset	of	patients35.	However,	as	the	incidence	of	thromboembolism	
among	breast	cancer	patients	 is	 low,	 the	sample	size	was	 too	small	 to	study	 these	 risk	
factors	for	myocardial	infarction,	ischaemic	stroke	and	pulmonary	embolism	separately.	
Furthermore,	 our	 population	 was	 restricted	 to	 patients	 hospitalized	 for	 breast	 cancer.	
Validation	of	a	sub-cohort	by	linking	the	PHARMO	RLS	and	the	Eindhoven	Cancer	Registry35	
showed	more	than	95%	of	the	patients	diagnosed	with	breast	cancer	in	the	Netherlands	
to	have	been	hospitalized.	The	small	proportion	of	patients	that	are	not	hospitalized	and	
therefore	not	in	our	current	study	population	are	more	likely	to	be	80	years	or	older,	have	
metastatic	breast	cancer	and	are	institutionalized.
To	 achieve	optimal	 treatment	 and	prognosis	 among	breast	 cancer	 patients,	 this	 study	
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contributes	to	the	awareness	of	the	incidence	of	thromboembolic	events	among	breast	
cancer	patients	and	the	risk	factors	and	risk	periods	of	thrombosis.	Breast	cancer	patients	
seem	 to	 have	 a	 higher	 risk	 profile	 to	 develop	 arterial	 thromboembolism	 and	 receive	
treatment	 that	 increases	 the	 risk	 of	 venous	 thromboembolism.	 However,	 incidence	 of	
hospitalisations	for	myocardial	infarction,	ischaemic	stroke	and	pulmonary	embolism	was	
low.	
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Introduction to the discussion
The	 primary	 aim	 of	 this	 thesis	 was	 to	 create	 a	 new	 data	 source	 that	 enables	
pharmacoepidemiological	studies	in	the	area	of	oncology.	For	this,	a	linkage	was	created	
between	the	Eindhoven	Cancer	Registry	(ECR)	and	the	PHARMO	Record	Linkage	System	
(PHARMO	 RLS).	 In	 Chapter 2.3	 we	 showed	 that	 this	 probabilistic	 record	 linkage	 was	
feasible	and	valid.	The	new	ECR-PHARMO	cohort	 includes	tumour	 information	(such	as	
tumour	histology,	grade	and	stage)	of	incident	cancers	obtained	from	the	ECR	and	data	
on,	 among	 other	 things,	 drug	 treatment	 (out-patient	 and	 in-patient),	 hospitalisations,	
and	clinical	laboratory	measurements	obtained	from	the	PHARMO	RLS.	In	this	thesis	we	
focused	on	the	most	frequent	cancer	among	women:	breast	cancer.	We	presented	studies	
possible	using	solely	the	data	from	the	ECR	(Chapter 3),	or	the	PHARMO	RLS	(Chapter 
7).	Whereas	the	added	value	of	both	databases	combined	was	described	in	Chapter 4, 5 
and 6.	The	choice	of	data	source	(the	ECR,	PHARMO	RLS	or	the	ECR-PHARMO	cohort)	for	a	
specific	research	depends	on	the	research	question	and	study	design.	
Before	discussing	the	results	of	the	studies	on	systemic	breast	cancer	treatment,	and	the	
studies	on	new	morbidities	after	breast	cancer	diagnosis	and	treatment,	we	address	the	
uniqueness	of	the	data	available	in	the	ECR-PHARMO	cohort.	For	this,	the	ECR-PHARMO	
linkage	is	set	out	against	other	comparable	database	linkages	available	in	Northern	America	
and	Europe.	Finally,	we	will	end	the	discussion	with	a	section	on	future	perspectives.	

CHAPTER 8  OvERvIEW, DISCUSSION AND CONCLUSION
8.2 Record linkage for pharmacoepidemiological studies in 
 cancer patients
Myrthe	P.P.	van	Herk-Sukel,	Valery	E.P.P.	Lemmens,	Lonneke	V.	van	de	Poll-Franse,	Ron	M.C.	
Herings,	Jan	Willem	W.	Coebergh		
Pharmacoepidemiology and Drug Safety 2011, in press
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Abstract
Background: 
An	 increasing	 need	 has	 developed	 for	 the	 post-approval	 surveillance	 of	 (new)	
anti-cancer		drugs	by	means	of	pharmacoepidemiology	and	outcomes	research	
in	the	area	of	oncology.
Objectives: 
To	 create	 an	overview	 that	makes	 researchers	 aware	of	 the	 available	database	
linkages	in	Northern	America	and	Europe	which	facilitate	pharmacoepidemiology	
and	outcomes	research	in	cancer	patients.
Methods: 
In	addition	to	our	own	database,	i.e.	the	Eindhoven	Cancer	Registry	(ECR)	linked	to	
the	PHARMO	Record	Linkage	System,	we	considered	database	linkages	between	a	
population-based	cancer	registry	and	an	administrative	healthcare	database	that	
at	 least	contains	 information	on	drug	use	and	offers	a	 longitudinal	perspective	
on	healthcare	utilization.	 Eligible	database	 linkages	were	 limited	 to	 those	 that	
had	 been	 used	 in	multiple	 published	 articles	 in	 English	 language	 included	 in	
Pubmed.	The	HMO	Cancer	Research	Network	(CRN)	in	the	US	was	excluded	from	
this	 review,	 as	 an	overview	of	 the	 linked	databases	participating	 in	 the	CRN	 is	
already	provided	elsewhere.	Researchers	who	had	worked	with	the	data	sources	
included	in	our	review	were	contacted	for	additional	information	and	verification	
of	the	data	presented	in	the	overview.	
Results: 
The	following	database	linkages	were	included:	the	Surveillance,	Epidemiology,	
and	 End-Results–Medicare;	 cancer	 registry	 data	 linked	 to	 Medicaid;	 Canadian	
cancer	registries	linked	to	population-based	drug	databases;	the	Scottish	cancer	
registry	 linked	 to	 the	 Tayside	 drug	 dispensing	 data;	 linked	 databases	 in	 the	
Nordic	 Countries	 of	 Europe:	 Norway,	 Sweden,	 Finland	 and	 Denmark;	 and	 the	
ECR-PHARMO	linkage	in	the	Netherlands.	Descriptives	of	the	included	database	
linkages	comprise	population	size,	generalizability	of	the	population,	year	of	first	
data	availability,	 contents	of	 the	cancer	 registry,	 contents	of	 the	administrative	
healthcare	 database,	 the	possibility	 to	 select	 a	 cancer-free	 control	 cohort,	 and	
linkage	to	other	healthcare	databases.	
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Conclusions: 
The	linked	databases	offer	a	longitudinal	perspective,	allowing	for	observations	
of	health	care	utilization	before,	during,	and	after	cancer	diagnosis.	They	create	
new	powerful	data	sources	for	the	monitoring	of	post-approval	drug	utilization,	
as	well	as	a	framework	to	explore	the	(cost-)effectiveness	of	new,	often	expensive,	
anti-cancer	drugs	as	used	in	everyday	practice.
Myrthe van Herk-Sukel
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Introduction
In	 recent	years	 there	has	been	an	enormous	growth	 in	the	number	of	new	anti-cancer	
agents	being	investigated	and	approved	for	the	treatment	of	cancer1.	While	effectiveness	
and	 safety	of	 these	new	 therapies	are	 thoroughly	 studied	 in	 randomized	clinical	 trials,	
little	data	are	available	on	 these	parameters	 in	everyday	clinical	practice.	 Effectiveness	
of	 anti-cancer	 drugs	may	be	 different	 than	 expected	 as	 daily	 practice	 differs	 from	 the	
experimental	setting	with	respect	to	the	heterogeneity	of	patients,	their	age,	treatments	
and	comorbidity.	Moreover,	important	safety	issues	may	not	be	detectable	in	clinical	trials	
since	the	frequency	of	many	adverse	events	is	low	and	adverse	effects	of	cancer	therapies	
may	occur	many	years	after	drug	administration2,	3.		With	the	ageing	of	the	population,	the	
increasing	survival	of	cancer	patients,	and	the	often	accelerated	FDA	(US	Food	and	Drug	
Administration)	and	EMA	(European	Medicines	Agency	approval	of	new	anti-cancer	drugs,	
pharmacoepidemiological	studies	in	the	area	of	oncology	are	increasingly	important.	
Therefore,	maybe	even	more	important	than	for	most	other	drugs,	systems	that	facilitate	
post-approval	 drug	 utilization	 and	 (cost-)effectiveness	 studies	 on	 anti-cancer	 drugs	
should	be	 in	place.	Cancer	 registry	data	 linked	 to	administrative	healthcare	databases,	
such	as	medical	claims	databases	or	electronic	medical	records,	make	this	type	of	research	
in	 cancer	 patients	 possible.	Data	 from	 cancer	 registries	 contain	 important	 information	
(such	 as	 tumor	 histology,	 grade	 and	 stage)	 necessary	 to	 analyze	 the	 treatment	 and	
safety	of	a	particular	cancer	treatment	 in	a	certain	group	of	cancer	patients.	Data	 from	
administrative	healthcare	databases	contain	information	on	treatment	of	the	cancer	itself	
and	other	morbidities,	 including	data	about	 the	 type	of	drug	or	combination	of	drugs	
and/or	 treatment	modalities,	 duration	 of	 treatment,	 and	 dosage.	With	medical	 record	
linkage	of	both	data	sources	a	new	valuable	source	is	created	which	can	be	used	to	shed	
light	on	the	burden	of	cancer,	disease	management,	safety	aspects,	comorbidity	patterns	
and	outcomes	assessments,	and	follow-up	of	patients	before	and	after	cancer	diagnosis	
in	routine	daily	practice.	
In	this	article	we	will	give	an	overview	that	can	serve	to	make	researchers	aware	of	the	
various	database	 linkages	available	 that	contain	 the	abovementioned	 information.	The	
linked	databases	include	1)	a	cancer	registry	and	2)	an	administrative	healthcare	database	
that	 includes	 information	on	drug	use,	preferably	with	 information	on	morbidity	other	
than	cancer.	Moreover,	we	discuss	their	unique	potential	for	post-approval	surveillance	of	
anti-cancer	drugs.		
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Cancer registries linked to administrative healthcare databases 
In	this	overview	we	restrict	consideration	to	existing	database	linkages	in	Northern	America	
and	Europe	that	have	been	used	in	multiple	published	articles	that	can	be	retrieved	via	
Pubmed.	 As	 our	 focus	 is	 to	 provide	 databases	 that	 allow	 studies	 on	 cancer	 treatment	
and	its	related	outcomes,	we	only	included	cancer	registry	data	linked	to	administrative	
healthcare	databases	that	at	least	contain	information	on	drug	use	and	possible	data	on	
other	morbidities	 during	 follow-up.	 Not	 included	 are	 potential	 sources	 in	 non-English	
literature,	those	not	(yet)	described	in	published	literature,	or	those	not	used	for	scientific	
purposes.	Researches	who	have	worked	with	the	included	data	sources	were	contacted	
for	verification	and	additional	information.	
The	 identified	data	 sources	 and	most	 important	 aspects	 of	 these	 linked	databases	 for	
safety	and	outcomes	research	in	cancer	patients	are	presented	in	Table	1.	We	determined	
what	 type	 of	 characteristics	 these	 databases	 had	 with	 respect	 to	 the	 facilitation	 of	
pharmacoepidemiology	 studies,	 such	 as	 population	 size,	 ability	 to	 select	 cancer-free	
control	groups,	and	linkage	to	other	databases.	While	it	is	beyond	the	scope	of	this	paper	
to	describe	the	linked	databases	in	detail,	a	brief	description	of	the	source	population,	the	
contents	of	the	cancer	registries	and	the	administrative	healthcare	databases,	including	
information	on	drug	use	and	other	clinical	outcomes,	are	described	below.
Included linked data sources
The	most	extensively	described	database	includes	the	SEER	(Surveillance,	Epidemiology,	
and	 End-Results)-Medicare	 linked	 database4-6	 in	 the	 US.	 Other	 US	 claims	 databases	
that	have	been	linked	to	cancer	registry	data	are	Medicaid	databases	of	which	only	the	
North	 Carolina	 (NC)	 Central	 Cancer	 Registry	 (CCR)	 linked	 to	 the	NC	Medicaid	 Claims7-9	
is	 included	 in	Table	1	as	a	 representative	example.	Others	 include,	 for	example,	cancer	
registries	that	participate	in	the	SEER	program	linked	to	Medicaid	databases,	such	as	the	
California	Cancer	 Registry	 linked	 to	California	Medicaid10	 and	 the	Metropolitan	Detroit	
Cancer	Surveillance	System	 linked	 to	 the	Michigan	Medicaid	data11.	Three	examples	of	
cancer	 registries	 linked	 to	 administrative	 healthcare	 databases	 located	 in	 Canada	 are	
the	British	Columbia	(BC)	linked	Cancer	Registry	and	Health	data12,	13,		the	Saskatchewan	
Health	Plan	Databases14-16	and	Manitoba	Health	databases17-19.	Of	the	latter	two,	only	the	
Saskatchewan	Health	Plan	Databases	are	included	in	Table	1	as	similarities	exist	between	
Saskatchewan	 and	Manitoba	 (both	 have	 similar	 health	 care	 data	 recording	 processes,	
including	large,	longitudinal,	administrative	health	care	utilization	databases	that	include	
all	residents	of	the	province),	however,	prescription	drug	and	cancer	services	data	were	
used	more	often	in	studies	using	the	Saskatchewan	databases20,	21.	Other	good	examples	
of	cancer	registries	linked	to	administrative	healthcare	databases	are	found	in	the	Nordic	
Countries	of	Europe:	Norway22,	23,	Sweden24,	25,	Finland26,	27	and	Denmark28-31.	In	the	rest	of	
Europe	 two	other	good	examples	are	 the	Scottish	 cancer	 registry	 linked	 to	 the	Health	
Informatics	Centre	(HIC)	drug	dispensing	database32-34	and	the	Eindhoven	Cancer	Registry	
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Table 1. Features of examples of database linkages between a cancer registry and an administrative 
 healthcare database in Northern America and Europe 
Northern America - United States
SEER-Medicare North Carolina#
Linkage
Using Matching algorithm of social security 
number, first and last name, dates of birth 
and death, and sex.
Matching algorithm of social security 
number, first and last name, date of birth, 
and county of residence
Availability of data since** 1991 1998
Source population
Population covered 26% of the US population*** 9.4 million 
Inclusion and generalizability of the 
population
Only  elderly (≥65 years), persons with 
end-stage renal disease and some disa-
bled 
Only low-income and one of the follow-
ing: ≥65 years, blind or disabled, pregnant 
or parent of a child <19
Content of cancer registry the SEER program NC Central Cancer Registry (CCR)
Patients diagnosed with a new primary 
tumor
Yes Yes
Information on patient and primary 
tumor characteristics
Yes Yes
Information on first course of treat-
ment (e.g. surgery, radiotherapy, 
chemotherapy (yes/no))
Yes Yes
Vital status Yes Yes
Content of administrative healthcare 
database including information on 
drug use and comorbidity
Medicare claims database NC Medicaid claims database
Pharmacy dispensing or prescriptions: 
(co-)medication
Claims data for covered healthcare 
services* 
Claims data for covered healthcare 
services*
Data on type of chemotherapeutics Yes; sensitivity of claims data varies by 
the agent  
Yes; sensitivity of claims data varies by 
the agent  
Information on comorbidity Yes; claims data for covered healthcare 
services*
Yes; claims data for covered healthcare 
services*
Other information
Cancer-free control cohort Yes Yes
Linkage to other healthcare databases Yes; e.g. US Census Bureau, physicians’ 
claims
Yes; e.g. US Census Bureau, US Social 
Security Master Death File
Additional information$ http://healthservices.cancer.gov/seer-
medicare; Study example, see52
http://www.schs.state.nc.us/SCHS/CCR/ 
and http://www.cms.gov/home/medic-
aid.asp; Study example, see53
SEER: Surveillance, Epidemiology and End Results; **Date represents the start date of one of the two linked databases that 
started the most recent with data collection; ***From 2000 onwards, the following population-based cancer registries are part 
of the SEER program: Alaska Native Tumor Registry, Arizona Indians, Los Angeles, San Francisco-Oakland, San Jose-Monterey, 
Greater California, Connecticut, Detroit, Atlanta, Rural Georgia, Hawaii, Iowa, Kentucky, Louisiana, New Jersey, New Mexico, Seat-
tle-Puget Sound and Utah; *Claims data for covered healthcare services, including hospital, physician, outpatient, home health 
and hospice bills; $ Web pages last accessed on 13 May 2011; # Serves as an example of a cancer registry linked to Medicaid. 
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Table 1. Features of examples of database linkages between a cancer registry and an administrative 
 healthcare database in Northern America and Europe (continued)
Northern America - Canada
British Columbia Saskatchewan 
Linkage
Using Internal personal identifier Unique health service number (HIRF regis-
tration number)
Availability of data since** 1980 1976
Source population
Population covered 4.2 million ~ 1 million 
Inclusion and generalizability of the 
population
Only cancer patients Excluding drug beneficiaries of another 
government agency (<10%)
Content of cancer registry BC Cancer Agency Cancer Registry
Patients diagnosed with a new primary 
tumor
Yes Yes
Information on patient and primary 
tumor characteristics
Yes Yes
Information on first course of treat-
ment (e.g. surgery, radiotherapy, 
chemotherapy (yes/no))
Yes Yes
Vital status Yes Yes, through death certificates and hos-
pital reports
Content of administrative healthcare 
database including information on 
drug use and comorbidity
BC Cancer Agency pharmacy database Prescription drug plan database
Pharmacy dispensing or prescriptions: 
(co-)medication
No; only anti-cancer drugs Yes
Data on type of chemotherapeutics Yes No
Information on comorbidity Not routinely available Yes; via Saskatchewan Health Hospital File
Other information
Cancer-free control cohort No Yes
Linkage to other healthcare databases No Yes; e.g. hospitalizations, medical services
Additional information$ http://www.bccancer.bc.ca; Study ex-
ample, see54  
http://www.saskcancer.ca/ and 
http://www.health.gov.sk.ca/drug-plan-
benefits; Study example, see55  
**Date represents the start date of one of the two linked databases that started the most recent with data collection; 
$ Web pages last accessed on 13 May 2011.
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Table 1. Features of examples of database linkages between a cancer registry and an administrative 
 healthcare database in Northern America and Europe (continued)
Europe - Nordic countries of Europe
Norway Sweden
Linkage
Using Unique personal identity number* National registration number 
Availability of data since** 2004 2005
Source population
Population covered 4.9 million 9.2 million
Inclusion and generalizability of the 
population
Nationwide Nationwide
Content of cancer registry Cancer Registry of Norway Swedish Cancer Registry
Patients diagnosed with a new primary 
tumor
Yes Yes
Information on patient and primary 
tumor characteristics
Yes Yes
Information on first course of treat-
ment (e.g. surgery, radiotherapy, 
chemotherapy (yes/no))
Yes No
Vital status Yes, via linkage with Statistics Norway Yes, via linkage to the causes of death 
register
Content of administrative healthcare 
database including information on 
drug use and comorbidity
Norwegian Prescription Database (NorPD) 
based on all dispensed drugs from phar-
macies
Prescribed drug register or data of phar-
macy dispensings
Pharmacy dispensing or prescriptions: 
(co-)medication
Yes Yes
Data on type of chemotherapeutics No; drug use in-hospital is not recorded No; drug use in-hospital is not recorded
Information on comorbidity Yes; via Norwegian Patient Register and 
via indication for prescribing (from 2009 
onwards)
Yes; via hospitalization data
Other information
Cancer-free control cohort Yes Yes
Linkage to other healthcare databases Yes; e.g. Medical birth registry (MBRN), 
causes of death registry
Yes; e.g. In-Patient Registry, causes of 
death registry
Additional information$ http://www.kreftregisteret.no/ and  
www.nhv.se/norpen; Study example, see56 
http://www.socialstyrelsen.se/register/
halsodataregister/cancerregistret/ and  
www.nhv.se/norpen; Study example, see57 
*Currently there are ongoing projects including linkage between Norwegian prescription database and cancer 
registry, however not yet published; **Date represents the start date of one of the two linked databases that started 
the most recent with data collection; $ Web pages last accessed on 13 May 2011.
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OPED: Odense university Pharmacoepidemiology Database; PDNJ: Pharmacoepidemiology Prescription Database 
in Northern Jutland; **Date represents the start date of one of the two linked databases that started the most recent 
with data collection; $ Web pages last accessed on 13 May 2011.
Table 1. Features of examples of database linkages between a cancer registry and an administrative 
 healthcare database in Northern America and Europe (continued)
Europe - Nordic countries of Europe
Finland Denmark
Linkage
Using Unique personal identification number Central person registration number 
Availability of data since** 1993 1990
Source population
Population covered 5.3 million 5.5 million/ 1.2 million, 1.7 million
Inclusion and generalizability of the 
population
Nationwide Nationwide/ Regional databases are rep-
resentative for the Danish population 
Content of cancer registry Finnish Cancer Registry Danish Cancer Registry
Patients diagnosed with a new primary 
tumor
Yes Yes
Information on patient and primary 
tumor characteristics
Yes Yes 
Information on first course of treat-
ment (e.g. surgery, radiotherapy, 
chemotherapy (yes/no))
Yes Yes 
Vital status Yes, via the Finnish Cancer Registry or 
Statistics Finland
Yes, via linkage with the Death Registry or 
registration in cancer registry
Content of administrative healthcare 
database including information on 
drug use and comorbidity
Reimbursed pharmacy dispensings from 
Social Insurance Institution 
National Register of Medicinal  
Product Statistics, OPED or PDNJ
Pharmacy dispensing or prescriptions: 
(co-)medication
Yes Yes
Data on type of chemotherapeutics No; drug use in-hospital is not recorded No; drug use in-hospital is not recorded
Information on comorbidity Yes; via hospitalization data Yes; via hospitalization data 
Other information
Cancer-free control cohort Yes Yes
Linkage to other healthcare databases Yes; e.g. Statistics Finland for date and 
cause of death
Yes; e.g. Danish  Patient Registry
Additional information$ http://www.cancer.fi/syoparekisteri/ and 
www.nhv.se/norpen; Study example, see58 
http://www.cancer.dk/Epi+Research/ and 
www.nhv.se/norpen; Study example, see59 
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Table 1. Features of examples of database linkages between a cancer registry and an administrative 
 healthcare database in Northern America and Europe (continued)
Europe - Western Europe
Scotland Southeastern Netherlands
Linkage
Using Community Health Index Number Probabilistic linkage of gender, date of 
birth, 1st initial, 1st letter and soundex code 
of last name, first 4 characters of zip code 
Availability of data since** 1989 1998
Source population
Population covered ~ 400,000 ~ 1 million
Inclusion and generalizability of the 
population
Demographic breakdown and health 
status of Tayside resembles the rest of 
Scotland
Representative for the Southeastern 
Netherlands
Content of cancer registry Cancer Registration Database (SMR 6) Eindhoven Cancer Registry
Patients diagnosed with a new primary 
tumor
Yes Yes
Information on patient and primary 
tumor characteristics
Yes Yes
Information on first course of treat-
ment (e.g. surgery, radiotherapy, 
chemotherapy (yes/no))
Yes Yes
Vital status Yes, via linkage with the General Register 
Office
Yes, via linkage to the death registry of the 
Central Bureau of Genealogy
Content of administrative healthcare 
database including information on 
drug use and comorbidity
Health Informatics Centre (HIC) drug 
dispensing database
PHARMO Record Linkage System
Pharmacy dispensing or prescriptions: 
(co-)medication
Yes Yes
Data on type of chemotherapeutics No; drug use in-hospital is not recorded Yes; via in-hospital pharmacy
Information on comorbidity Yes; via hospital admission database 
(SMR1)
Yes; via ECR: comorbidity at diagnosis and 
via PHARMO RLS: hospital database
Other information
Cancer-free control cohort Yes Yes
Linkage to other healthcare databases Yes; e.g. maternity admissions; mental 
health admissions
Yes;  e.g. clinical lab, general practitioners, 
pathology (PALGA)
Additional information$ http://www.isd.scot.nhs.uk/isd/3535.html 
and http://www.dundee.ac.uk/hic; Study 
example, see60  
http://www.ikcnet.nl and http://www.
pharmo.com; Study example, see61  
SMR: Scottish Morbidity Record; **Date represents the start date of one of the two linked databases that started the 
most recent with data collection; $ Web pages last accessed on 13 May 2011.
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(ECR)	linked	to	the	PHARMO	Record	Linkage	System35,	36.	A	description	of	the	data	included	
in	these	database	linkages	is	presented	in	Table	1.
Next	to	the	database	linkages	included	in	Table	1,	the	HMO	Cancer	Research	Network	(CRN)	
in	the	US	also	includes	cancer	registries	linked	to	administrative	healthcare	databases37-40.	
An	overview	of	the	contents	of	the	healthcare	systems	participating	in	the	CRN,	including	
size	 of	 the	population,	 available	 data	 sources	 and	 year	 of	 availability,	 can	be	 found	 in	
previous	published	articles37,	38.	The	CRN	consists	of	the	research	programs	and	enrollee	
populations	of	14	integrated	health	systems,	including	Group	Health	Cooperative,	Harvard	
Pilgrim	 Health	 Care,	 Henry	 Ford	 Health	 System/Health	 Alliance	 Plan,	 HealthPartners	
Research	Foundation,	Lovelace	Health	System,	Fallon	Community	Health	Plan,	Geisinger	
Health	System,	Marshfield	Clinic/Security	Health	Plan	and	Kaiser	Permanente	in	six	regions:	
Colorado,	Georgia,	Hawaii,	Northwest	(Oregon	and	Washington),	Northern	California,	and	
Southern	 California.	 Collectively,	 these	 organizations	 provide	 care	 to	 nearly	 11	million	
individuals.37,	39	Cancer	registries	are	in	place	at	11	of	the	CRN	systems	and	all	systems	have	
electronic	databases	that	contain	information	on	enrollment,	demographics,	outpatient	
pharmacy,	outpatient	visit	claims,	and	hospitalization	claims.37,	38	Laboratory,	pathology,	
radiology	procedures	and	death	data	will	also	be	incorporated.37	Research	studies	might	
either	be	conducted	including	all	the	CRN	systems	or	within	the	individual	CRN	member	
systems.
Source population
When	performing	research	with	a	cancer	registry	linked	to	an	administrative	healthcare	
database,	it	is	important	to	define	the	population	covered	by	both	databases	to	be	able	
to	determine	the	generalizability	and	heterogeneity	of	the	data.	The	numbers	of	patients	
covered	in	each	linked	database	included	in	this	overview	are	described	in	Table	1.	Most	
databases	cover	all	age	categories	and	are	either	nationwide	or	representative	for	the	total	
population	covered	in	a	country	or	state.	However,	the	BC	cancer	agency	covers	only	new	
patients	with	cancer	and	cancer-free	patients	are	not	included12,	13.	The	US-based	sources	
cover	 selected	populations	due	 to	 the	 restrictions	of	 the	claims	data.	For	example,	 the	
SEER-Medicare	only	includes	patients	≥65	years,	and	patients	<65	years	who	are	disabled	
or	have	end-stage	 renal	disease.4,	6	The	NC	CCR	 linked	 to	 the	NC	Medicaid	Claims	only	
includes	patients	who	have	a	 low-income	and	are	≥65	years,	blind,	disabled,	pregnant,	
or	the	parent	or	caretaker	of	a	child	who	is	younger	than	19	years8.	Due	to	the	selected	
populations	most	 investigators	 have	 focused	 their	 analysis	 on	patients	≥65	 years6.	 For	
types	of	 cancers	 that	predominate	among	elderly	patients,	 like	 lung,	 colorectal,	breast	
and	prostate	cancer,	 the	databases	can	provide	a	comprehensive	sample	of	 the	cancer	
population,	but	for	other	malignancies,	such	as	testicular	cancer,	leukemia	and	lymphoma,	
the	databases	provides	a	more	limited	insight.6	
Cancer registries
Cancer	 registries	 included	 in	 this	 review	 all	 record	 information	 of	 newly	 diagnosed	
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cancer	patients	 including	patient	characteristics	and	information	on	the	primary	tumor	
such	as	histology,	stage,	or	grade.	Information	on	the	initial	course	of	treatment	directly	
after	 diagnosis	 (e.g.	 surgery,	 chemotherapy	 and	 radiotherapy)	 is	 also	 included	 in	 all	
cancer	 registries	except	 for	 the	Swedish	cancer	 registry24.	The	ECR	of	 the	Southeastern	
Netherlands	is	the	only	cancer	registry	that	since	1995	also	includes	routinely	available	
information	 on	 comorbidity	 at	 diagnosis	 obtained	 from	 the	 clinical	 record	 by	 trained	
registry	personell.36,	41	Other	registries	might	obtain	this	information	from	linkage	to	other	
healthcare	databases	or	via	additional	data	collection.	
Cancer	registries	often	do	not	register	clinical	information	on	disease	progression	as	this	is	
very	time	consuming.	Date	of	death	and	sometimes	cause	of	death	is	mainly	used	as	the	
final	outcome.	However,	as	for	research	purposes	longitudinal	information	on	the	progress	
of	cancer	is	often	desirable,	several	actions	are	undertaken	to	obtain	this	information.	First	
of	all,	data	on	cancer	relapse	can	be	registered	additionally	for	a	specific	study42.		Second,	
data	can	be	obtained	by	linkage	to	other	healthcare	databases	such	as	pathology	(biopsy	
confirmed	recurrences)	and/or	hospitalization	data43.	Finally,	clinical	algorithms	might	be	
developed	to	identify	cancer	relapse.	For	example,	if	there	is	a	gap	between	chemotherapy	
or	radiotherapy	administration	and	treatment	is	started	somewhere	during	follow-up,	it	
might	be	assumed	that	this	was	for	relapsed	disease44.	Such	a	clinical	algorithm	can	only	
be	used	if	almost	all	patients	are	treated	shortly	after	relapse.	A	check	should	assure	that	
a	second	primary	cancer	has	not	developed,	e.g.	by	using	data	from	the	cancer	registry.	
Moreover,	patients	with	cancer	relapse	will	be	missed	if	they	relapsed	very	quickly	after	
diagnosis	or	if	they	did	not	opt	for	any	treatment,	e.g.	because	of	coexisting	illness,	or	poor	
performance	status.
Information on drug use
Administrative	healthcare	databases	included	in	this	review	all	contain	information	on	drug	
use.	Prescription	and	pharmacy	dispensing	databases	include	information	on	drug	use	for	
various	indications.	These	databases	can	be	used	to	study	drug	treatment	before	cancer	
diagnosis	(e.g.	to	measure	preexisting	morbidities	that	might	influence	decisions	on	the	
treatment	of	cancer)	and	drug	treatment	of	a	patient	after	cancer	diagnosis,	including	the	
drug	treatment	of	other	morbidities.	However,	the	prescription	and	pharmacy	dispensing	
databases	of	Saskatchewan,	the	Nordic	countries	and	Scotland	do	not	record	the	drugs	
dispensed	to	individuals	during	a	hospital	stay.	This	means	that	drug	treatment	of	cancer	
and	 other	morbidities	 for	which	 the	 patient	 is	 hospitalized	 are	 not	 recorded,	 creating	
possible	observation	gaps45.	Whether	the	two	US	medical	claims	databases	(Medicare	and	
Medicaid),	 also	 include	 drugs	 supplied	 for	 various	 indications	 before	 cancer	 diagnosis	
depends	on	the	covered	services6,	8.	
Administrative	 healthcare	 databases	 that	 include	 information	 on	 the	 drug	 treatment	
of	 cancer	 to	 study	 patterns	 of	 cancer	 care	 should	 be	 divided	 into	 those	 that	 include	
information	on	oral	anti-cancer	drugs	and	those	that	include	information	on	intravenously	
administered	chemotherapy.	While	most	community	pharmacies	include	information	on	
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oral	 anti-cancer	 drugs,	 such	 as	 hormonal	 treatment	 for	 breast	 cancer46,	 administrative	
healthcare	databases	that	include	data	on	intravenous	chemotherapy	for	the	treatment	of	
cancer	are	less	common.	The	pharmacy	database	of	the	BC	Cancer	Agency	is	unique	as	this	
database	includes	all	chemotherapeutic	agents	that	are	provided	by	the	same	centralized	
pharmacy13.	However,	this	database	only	includes	information	on	anti-cancer	drugs	and	
does	 not	 include	 drugs	 of	 these	 patients	 supplied	 for	 other	 indications12,	 13.	 The	 only	
administrative	healthcare	database	in	Table	1	that	includes	both	prescriptions	that	have	
been	dispensed	by	community	pharmacies	as	well	as	in-hospital	pharmacies	(including	
chemotherapeutics)	 is	 the	PHARMO	RLS36.	Having	data	of	both	data	 sources	 facilitates	
studies	on	total	cancer	treatment	of	a	patient	 including	oral	anti-cancer	drugs	via	data	
from	the	community	pharmacies,	and/or	intravenously	administered	chemotherapeutics	
via	data	from	the	in-hospital	pharmacies.	
Longitudinal	 information	on	chemotherapy	administration	in	the	US	located	databases	
was	recently	evaluated.	When	comparing	automated	clinical	data	on	chemotherapy	in	the	
CRN	systems	with	medical	charts,	the	sensitivity	was	good	(89.5%)47.		The	sensitivity	of	the	
Medicare	claims	to	identify	persons	undergoing	chemotherapy	was	comparable	to	that	
of	the	CRN	(≥88%).	However,	with	respect	to	identifying	specific	agents	in	the	Medicare	
claims,	the	sensitivity	varied	by	the	specific	drugs	used	to	treat	a	cancer	type48.	
Information on other clinical outcomes 
To	study	the	long-term	outcomes	of	cancer	patients	after	initial	cancer	care,	longitudinal	
information	on	health	care	utilization	of	cancer	and	other	morbidities	is	needed.	Medical	
claims	databases	contain	not	only	medical	claims	on	drug	use	but	also	medical	claims	
on,	for	example,	hospitalizations,	cancer	tests,	and	procedures6,	8,	37.	This	results	in	a	high	
variety	of	studies	that	are	possible	with	these	data4,	39.	For	the	prescription	and	pharmacy	
dispensing	 databases,	 information	 on	 morbidities	 is	 often	 obtained	 via	 linkage	 to	
hospitalization	data.	
All	 existing	 database	 linkages	 can	 be	 enriched	 by	 new	 healthcare	 databases,	 such	 as	
clinical	laboratory	data	or	medical	birth	registries,	ad	hoc	collected	data	on	variables	not	
available	in	the	databases,	as	well	as	detailed	clinical	data	and	biosamples.	These	data	can	
additionally	be	linked	to	the	existing	databases	in	the	same	way	as	the	current	linkages	
are	performed,	creating	even	more	research	possibilities.
Opportunities for post-approval surveillance of anti-cancer drugs
The	 record-linkage	of	 a	 cancer	 registry	 and	a	 longitudinal	healthcare	database	 creates	
new	opportunities	for	postapproval	evaluation	of	anti-cancer	drugs.	The	cancer	registry	
data	provide	detailed	tumor	information	of	incident	cancer	patients,	which	is	not	possible	
to	 derive	 from	 other	 databases	 such	 as	 medical	 claims	 data,	 hospitalization	 data,	 or	
data	 from	general	 practices,49	whereas	 the	 administrative	healthcare	databases	 offer	 a	
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longitudinal	perspective,	making	it	possible	to	look	at	healthcare	utilization	before,	during	
and	after	cancer	diagnosis.	First	of	all,	data	on	drug	use	and	comorbidities	before	cancer	
diagnosis	can	be	used	to	measure	preexisting	morbidities	that	might	influence	decisions	
on	 the	 treatment	of	 cancer.	 Secondly,	data	on	drug	use	directly	after	 cancer	diagnosis	
can	be	used	to	study	the	pattern	of	cancer	care:	the	precise	type	of	chemotherapeutics	
administered	as	initial	treatment,	but	also	as	follow-up	treatment	or	palliative	care.	Finally,	
data	on	drug	use	and	comorbidities	after	cancer	diagnosis	and	treatment	can	be	used	to	
monitor	the	effectiveness	and	safety	of	cancer	treatments.	Whether	the	linked	databases	
are	a	good	data	source	for	all	these	types	of	studies	depends	on	the	size	of	the	underlying	
population	and	the	specific	data	available	in	the	separate	data	sources.	Besides	monitoring	
the	effectiveness	and	safety	of	cancer	treatments,	these	databases	also	allow	the	study	of	
the	relationship	between	drug	use	and	the	risk	of	cancer32,	50.
The	strengths	and	limitations	of	the	separate	existing	databases	are	maintained	after	linkage.	
The	additional	value	of	 the	 linkage	 itself	 is	 that	 it	greatly	 improves	 the	utility	of	existing	
healthcare	 databases	 for	 pharmacoepidemiological	 research	 in	 the	 area	 of	 oncology.	
Retrieving	the	data	on	drug	use	and	comorbidities	via	linkage	to	an	administrative	database	
instead	of	additional	data	collection,	has	the	following	advantages.	Data	from	administrative	
healthcare	 databases	 are	 available	 at	 relatively	 low	 cost	 and	 pharmacoepidemiological	
studies	with	 these	data	 can	often	be	 conducted	with	 little	delay.	These	databases	 allow	
continuous	 post-approval	 surveillance	 of	 drug	 dissemination	 and	 drug	 effects,	 the	 two	
core	elements	of	pharmacoepidemiology.	Their	representativeness	of	routine	clinical	care	
makes	it	possible	to	study	real-world	effectiveness.	As	administrative	healthcare	databases	
automatically	register	all	interventions,	the	adverse	drug	reactions	that	were	not	anticipated	
via	results	 from	clinical	 trials	are	still	 recorded	and	can	be	evaluated.	However,	one	must	
keep	in	mind	that	only	the	complications	that	require	an	intervention	are	recorded,	which	
mostly	includes	the	more	severe	and	acute	events.		Another	advantage	is	that	linkage	to	a	
longitudinal	healthcare	database	allows	the	selection	of	a	cancer-free	control	cohort.	This	
creates	the	opportunity	to	compare	the	rate	of	developed	morbidities	 in	cancer	patients	
following	cancer	 treatment	with	 the	 rate	of	morbidities	 found	 in	 the	general	population	
and	it	allows	the	study	of	the	relationship	between	drug	use	and	the	risk	of	cancer.	Finally,	
administrative	healthcare	databases	often	cover	large	populations,	which	will	shorten	the	
time	necessary	to	identify	a	sufficient	number	of	users	of	a	newly	marketed	drug.	However,	
the	 population	 required	 to	 detect	 an	 association	 between	 a	 particular	 anti-cancer	 drug	
and	adverse	event	depends	upon	the	type	of	event,	the	proportion	of	patients	using	the	
drug,	 the	 homogeneity	 of	 the	 population	 (specific	 cancer	 type	 and	 disease	 stage),	 the	
previous	received	anti-cancer	treatments,	and	the	magnitude	of	the	risk.	For	monitoring	the	
effectiveness	and	safety	of	new	cancer	treatments	the	size	of	the	cohorts	are	often	too	small	
as	new	 targeted	drugs	are	merely	administered	 in	patients	with	a	 specific	disease	 stage	
(advanced	disease),	 concurrently	or	 in	 specified	sequential	 regimens	with	 the	 traditional	
cytotoxic	agents.	However,	by	combining	the	linked	data	sources	as	presented	in	Table	1,	
large	enough	study	populations	may	soon	become	available.
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If	the	research	question	and	study	design	lend	themselves	to	utilize	one	of	the	described	
linked	databases	as	a	data	source,	 it	 is	the	responsibility	of	the	investigator	to	consider	
the	strengths	and	weaknesses	 in	deciding	whether	to	use	the	linked	database	for	their	
research.	Procedures	to	obtain	data	from	a	linked	database	vary	depending	on	the	data	
source.	 Release	 of	 the	 data	 is	 generally	 project	 specific	 and	 the	 project	 must	 first	 be	
approved	before	data	can	be	obtained,	as	is	the	case	when	requesting	SEER-Medicare	data.	
However,	in	contrast	to	the		longstanding	SEER-Medicare	data,	in	most	cases	a	researcher	
will	need	to	get	permission	from	both	the	cancer	registry	and	the	pharmacoepidemiology	
database	separately	as	technically,	the	data	belong	to	different	data	providers.	Moreover,	
not	all	databases	provide	direct	access	to	the	datasets.	For	example,	the	Scottish	HIC	drug	
dispensing	database	and	 the	Dutch	ECR-PHARMO	cohort	only	provide	data	directly	 to	
(local)	scientists,	while	for	e.g.	pharmaceutical	companies,	local	researchers	would	work	
with	these	private	companies	in	developing	the	research	question	and	design,	performing	
the	analysis	and	providing	the	results.	Regarding	the	Nordic	prescription	databases,	data	
can	be	accessed	as	previously	described45	and	knowledge	exchange,	research	and	training	
of	the	various	databases	is	facilitated	via	the	Nordic	Pharmacoepidemiological	Network	
(NorPEN)51.	 In	 Table	 1	 websites	 are	 presented	 that	 provide	 additional	 information	 on	
the	process	of	accessing	the	data	from	the	different	databases.	Researchers	can	contact	
the	 concerning	database(s)	 and	 submit	 an	 application	 for	 the	 required	 data	 including	
information	on	the	funding	source.	Timelines	of	getting	permission	for	obtaining	the	data	
and	accessing	the	data	very	much	depend	on	what	type	of	data	the	researcher	is	seeking	
and	 whether,	 next	 to	 the	 linked	 database,	 also	 data	 from	 other	 healthcare	 databases	
are	needed.	Other	 conditions	on	using	 the	data,	 such	 as	 security	 of	 the	data,	 are	 also	
determined	for	each	data	source	separately.	Finally,	a	researcher	must	be	familiar	with	the	
data	sources	and	understand	how	the	individual	databases	were	generated,	before	using	
the	linked	databases	for	their	research.
Conclusion
For	the	post-approval	surveillance	of	(new)	anti-cancer	drugs	there	is	an	increasing	need	
for	detailed	data	on	cancer	diagnosis,	drug	use	and	other	morbidities	from	representative	
populations	with	 lengthy	follow-up.	Due	to	this	demand,	the	 linkage	of	cancer	registry	
data	 with	 other	 clinical	 data	 is	 a	 rapidly	 evolving	 field	 across	 the	 world.	 In	 this	 brief	
overview	we	gave	examples	of	existing	database	linkage	initiatives	in	Northern	America	
and	Europe	including	a	cancer	registry	and	an	administrative	healthcare	database	that	at	
least	includes	information	on	drug	use	and	comorbidities.	Currently,	many	new	database	
linkages	 are	 initialized	 and	we	 recognize	 that	 the	 list	 provided	 in	 this	 overview	 is	 not	
exhaustive;	it	is	simply	a	starting	point.	This	overview	can	serve	to	make	researchers	aware	
of	the	various	valuable	sources	of	information	available	to	study	the	disease	management	
of	cancer	including	safety	aspects,	comorbidity	patterns	and	outcomes	assessments.		An	
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emerging	field	in	which	these	new	databases	play	an	important	role	is	the	ability	to	serve	
as	a	tool	to	raise	hypotheses	and	allow	for	certain	(cost-)	effectiveness	approaches	of	new,	
often	 expensive,	 anti-cancer	 drugs	 in	 the	 context	 of	 cancer	 care	 in	 community-based	
settings.	
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General discussion of breast cancer studies
In	this	thesis	the	current	treatment	patterns	of	anti-cancer	drugs	in	patients	with	breast	
cancer	as	well	as	the	new	morbidities	that	may	occur	after	breast	cancer	diagnosis	and	
treatment	were	 addressed.	Both	 the	observed	 treatment	 and	new	morbidities	may	be	
different	than	expected	from	clinical	trials	due	to	the	heterogeneity	of	patients,	their	age,	
co-morbidity,	co-medication	and	treatment	compliance.
Systemic breast cancer treatment
In	Chapter 3 it	was	shown	that	the	use	of	adjuvant	systemic	treatment	for	patients	with	
early	stage	breast	cancer	increased	significantly	over	time,	from	37%	during	1990-1997,	
to	53%	of	all	breast	cancer	patients	 in	2002-2006.	This	 increase	was	especially	seen	 for	
patients	with	node-negative	breast	cancer.	The	growing	number	of	breast	cancer	patients	
receiving	 anti-cancer	 drugs	 stresses	 the	 need	 for	more	 pharmacoepidemiology	 in	 the	
field	of	oncology.	Its	role	is	to	provide	population-based	evidence	that,	added	to	evidence	
obtained	from	randomized	controlled	trials,	would	support	the	decision	making	process	
of	clinicians	when	treating	the	breast	cancer	patient.	
Regarding	chemotherapy,	we	observed	a	large	variety	in	the	types	of	chemotherapeutic	
agents	 administered	 to	 breast	 cancer	 patients	 (Chapter 4).	 While	 patients	 receiving	
chemotherapy	in	the	adjuvant	setting	were	in	general	treated	according	to	the	guidelines,	
there	was	a	large	variation	in	the	palliative	setting,	probably	due	to	the	high	variability	in	
individual	presentation.	Information	on	the	administration	of	chemotherapy	in	everyday	
clinical	practice	 is	especially	 important	 for	 the	drugs	 that	are	currently	allowed	on	 the	
Dutch	 list	of	high-cost	medicines	 (e.g.	 trastuzumab	and	bevacizumab)1.	As	 these	drugs	
are	 currently	 temporary	 admitted	 on	 this	 list,	 the	 Dutch	 government	 will	 allow	 80%	
reimbursement.	However,	 effectiveness	 research	 for	 these	drugs	 is	 needed	 in	 order	 to	
determine	 if	 the	 drugs	 should	 definitively	 be	 allowed	 on	 the	 list	 and	 the	 subsequent	
special	reimbursement	rule2.	For	this,	more	insight	into	the	administration	of	trastuzumab	
and	 bevacizumab	 in	 daily	 practice	 is	 needed,	 which	 is	 provided	 in	 the	 current	 study.	
Though,	a	larger	cohort	of	breast	cancer	patients	receiving	these	drugs	is	required	to	be	
able	to	perform	effectiveness	research.		
Regarding	adjuvant	hormonal	therapy,	the	major	concern	is	continuation	of	treatment.	
Without	this	information,	the	effect	of	a	drug	cannot	be	interpreted	realistically.	Again,	a	
population-based	setting	is	needed	to	determine	true	rates	of	discontinuation	as	patients	
appear	to	discontinue	their	medications	at	higher	rates	in	practice	settings	than	in	clinical	
trials3.	 For	 example,	 the	 proportion	 of	 breast	 cancer	 patients	 discontinuing	 hormonal	
therapy	in	randomized	clinical	trials	is	reported	to	be	10-28%	depending	on	the	length	of	
follow-up,4-6	whereas	in	our	study,	51%	of	the	patients	followed	for	five	years	discontinued	
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this	therapy	(Chapter 5).	This	early	discontinuation	of	hormonal	therapy	in	daily	practice	
is	reported	to	be	associated	with	increased	mortality7.	The	exact	risk	is	difficult	to	assess	
in	 a	 population-based	 setting	 as	 factors	 related	 to	 treatment	 discontinuation	 (adverse	
events)	might	also	be	associated	with	the	increased	risk	of	mortality.	However,	the	results	
of	population-based	studies	can	serve	as	a	tool	to	generate	hypotheses	for	clinical	trials.	
New morbidities after breast cancer diagnosis and treatment
With	the	number	of	prevalent	breast	cancer	patients	increasing	considerably,	many	more	
individuals	will	be	undergoing	cancer	treatment,	coping	with	progressive	disease,	or	living	
cancer-free	after	diagnosis	and	treatment.	For	this	reason,	it	becomes	increasingly	important	
to	 determine	 morbidities	 that	 occur	 after	 breast	 cancer	 diagnosis	 and	 treatment	 and	
eliminate	those	that	are	chronic	and	irreversible.	As	side	effects	of	breast	cancer	treatment	
may	not	always	be	detectable	in	clinical	trials,	post-approval	evaluation	of	treatments	in	
daily	practice	is	essential.	In	this	thesis	addressed	whether	the	multidisciplinary	approach	
to	treat	breast	cancer	generated	new	morbidities.
The	risk	of	morbidity	associated	with	treatment	for	breast	cancer	depends	on,	among	other	
things,	 the	type	of	 treatment	administered.	Cardiotoxicity	of	certain	chemotherapeutics	
is	well	 recognized8.	When	specialists	are	aware	of	the	risk	factors	for	cardiotoxicity,	such	
as	 pre-existing	 cardiovascular	 morbidity	 or	 increased	 age,	 patients	 will	 be	 less	 likely	
to	 receive	 cardiotoxic	 chemotherapy	 or	 adaptations	 will	 be	 made	 in	 dose	 and	 rate	 of	
administration.	The	 results	 of	 our	 study	 support	 this	 as	we	did	 not	 find	 a	 difference	 in	
incidence	 of	 cardiovascular	morbidity	 between	 patients	who	 underwent	 cardiotoxic	 or	
non-cardiotoxic	 chemotherapy	 (Chapter 6).	 However,	 in	 this	 study	 648	 patients	 were	
included	with	a	median	follow-up	of	1.5	years,	while	cardiotoxicity	may	occur	many	years	
after	anthracycline	administration9.	Future	studies	including	longer	follow-up	time	should	
determine	the	incidence	of	late	cardiac	abnormalities	after	anthracyclines.
Another	 well-recognized	 morbidity	 associated	 with	 the	 treatment	 of	 breast	 cancer	
is	 thrombosis10.	 In	 our	 study	 we	 determined	 the	 more	 serious	 venous	 and	 arterial	
thromboembolic	 events	 using	 hospitalisation	 data	 to	 define	 myocardial	 infarction,	
ischaemic	stroke	and	pulmonary	embolism	(Chapter 7).	While	the	incidence	of	these	events	
was	less	than	1%,	recognition	of	patients	at-risk	is	important	as	outcomes	included	might	
be	fatal	and	patients	may	survive	longer	in	absence	of	these	morbidities11,	12.	Due	to	this	low	
expected	incidence	we	selected	the	largest	breast	cancer	cohort	possible	by	using,	instead	
of	the	linked	ECR-PHARMO	cohort,	only	the	data	from	the	PHARMO	RLS.	This	more	than	
doubled	the	cohort	size,	however,	resulted	in	not	having	information	on	radiation	therapy	
and	 tumour	 stage;	with	 radiation	 therapy	being	associated	with	myocardial	 infarction13	
and	metastatic	disease	being	a	 risk	 factor	 for	developing	thromboembolic	disease14.	An	
enlargement	of	the	ECR-PHARMO	cohort	in	the	future	is	needed	to	allow	studies	on	rare	
events	after	breast	cancer	diagnosis	and	treatment	without	loss	of	information.
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Future perspective
This	thesis	demonstrated	a	new	data	source	for	pharmacoepidemiology	and	outcomes	
research	 in	 the	 area	 of	 oncology:	 the	 linked	 Eindhoven	 Cancer	 Registry	 (ECR)	 and	
PHARMO	Record	Linkage	System	(PHARMO	RLS).	In	this	chapter	we	discuss	whether	the	
new	created	ECR-PHARMO	cohort	is	representative	for	the	Dutch	population,	the	current	
data	 limitations	 of	 the	 linked	 cohort	 and	possible	ways	 to	 overcome	 these	 limitations	
in	the	future.	Moreover,	we	want	to	present	the	various	valuable	sources	of	information	
available	in	the	ECR-PHARMO	cohort,	and	the	many	other	types	of	studies	possible,	next	
to	those	presented	in	this	thesis.	Finally,	we	discuss	important	aspects	for	continuation	of	
this	cohort	in	the	future,	including	data	confidentiality,	governance	and	research	ethics.	
Representativeness of ECR-PHARMO cohort 
Cancer	patients	included	in	the	linked	ECR-PHARMO	cohort	were	representative	for	those	
included	 in	 the	 total	 ECR	 (Chapter 2.3).	However,	we	 showed	 that	patients	who	were	
linked	were	 slightly	 older	 and	were	 diagnosed	with	 the	more	 common	 tumour	 types	
compared	 to	 the	 total	 ECR.	This	may	 reflect	a	need,	 ability	and	willingness	of	 younger	
patients	and	the	patients	with	uncommon	tumours,	to	travel	further	to	receive	treatment	
not	emphasized	 in	 their	 local	area	 (non-academic	hospitals).	Moreover,	 the	 linkage	ran	
more	efficiently	when	patients	were	diagnosed	more	recently.	This	might	be	explained	
by	time	dependent	linkage	variables	(e.g.	zip	code)	that	have	changed	in	one	of	the	two	
registries	over	time,	hindering	linkage	in	the	older	years.	
The	 ECR	 itself	 is	 fairly	 representative	 for	 the	 total	 Dutch	 population.	 However,	 the	
incidence	of	cancer	may	vary	within	the	regions	of	the	Netherlands	due	to	differences	in	
exposure	to	risk	factors,	interventions	for	early	detection	(screening)	or	the	characteristics	
of	the	underlying	population1.	The	region	covered	by	the	ECR	(southeastern	Netherlands)	
does	 not	 contain	 academic	 or	 specialized	 cancer	 hospitals,	 does	 not	 include	 one	 of	
the	top	three	 largest	cities	 in	the	Netherlands,	 includes	fewer	 immigrants	compared	to	
the	western	Netherlands,	 and	 the	population	 	 is	 somewhat	older	 than	 the	 total	Dutch	
population2.	However,	extrapolation	of	patient	numbers	 to	 the	Netherlands	 is	possible	
as	well	as	(inter)national	comparison	of	cancer	incidence	as	incidence	rates	can	be	age-
standardised	to	the	standard	European	population	(European	Standard	Rate	[ESR]).					
Data limitations
A	 limitation	of	 the	 ECR-PHARMO	cohort	 is	 the	 current	 cohort	 size.	 For	monitoring	 the	
effectiveness	and	safety	of	new	cancer	 treatments	 the	size	of	 the	current	cohort	 is	 too	
small:	new	targeted	drugs	are	merely	administered	in	patients	with	a	specific	disease	stage	
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(advanced	disease),	concurrently	or	in	specified	sequential	regimens	with	the	traditional	
cytotoxic	agents,	resulting	in	a	small	study	population	of	cancer	patients	to	begin	with.	
Detecting	an	association	between	a	rare	adverse	event	and	a	particular	anti-cancer	drug	
administered	to	a	homogeneous	group	of	cancer	patients	is	therefore	impossible	using	
the	current	cohort.	
Another	limitation	is	the	fact	that	the	PHARMO	RLS	records	only	complications	that	require	
an	intervention,	which	mostly	includes	the	more	severe	and	acute	events.	This	especially	
accounts	 for	 the	 hospitalisation	 database	which	 only	 registers	 hospital	 admissions	 for	
more	than	24	hours	and	admissions	 for	 less	than	24	hours	 for	which	a	bed	 is	 required.	
Additionally,	 for	hospitalisations,	primary	diagnoses	are	mainly	used	in	research,	as	 it	 is	
difficult	to	distinguish	whether	secondary	diagnoses	are	complications	or	prevalent	co-
morbidities.	Regarding	the	pharmacy	data,	a	general	problem	using	dispensing	data	to	
assess	drug	use	 is	 that	we	do	not	 know	 if	 and	when	 the	dispensed	drugs	are	 actually	
ingested	by	the	patients.	Moreover,	the	community	and	in-hospital	pharmacy	database	
do	not	include	information	on	the	indication	of	treatment.	In	the	near	future	the	PHARMO	
general	practitioner	database	will	be	linked	to	the	ECR-PHARMO	cohort,	making	it	possible	
to	 look	at	 less	 severe	co-morbidities	and	 indication	of	drug	use.	Finally,	drugs	used	by	
patients	in	nursing	homes	are	not	(completely)	recorded	in	the	PHARMO	RLS.	The	same	
is	observed	 in	 the	ECR,	with	outpatients	with	a	clinical	diagnosis	only	 (no	pathological	
diagnosis),	generally	not	recorded	by	the	cancer	registry.	However,	this	systematic	under	
registration	is	limited	(<2%)	and	the	ECR	is	considered	to	be	more	than	95%	complete3.	
Expansion of the ECR-PHARMO cohort
Expansion	 of	 the	 ECR-PHARMO	 cohort	 in	 the	 near	 future	 is	 of	 utmost	 importance	 for	
research	 in	 study	 cohorts	 of	 less	 frequent	 cancer	 types,	 specific	 disease	 stages,	 or	 for	
patients	with	a	specific	cancer	treatment.	Of	course,	the	ECR-PHARMO	cohort	will	expand	
after	every	annual	update,	resulting	in	a	longer	follow-up	of	existing	cancer	patients	and	
including	new	incident	cancer	patients,	but,	this	increase	will	not	be	immense.	Moreover,	
more	data	of	recent	cancer	patients	are	needed	if	we	want	to	study	the	use	of	new	anti-
cancer	drugs.	
At	 the	 time	of	 the	first	 ECR-PHARMO	 linkage,	 linkage	was	performed	 for	patients	who	
were	diagnosed	with	cancer	in	the	period	1998-2006	(Chapter 2.3).	Since	then,	a	second	
linkage	was	performed	adding	2007	and	2008.	At	 that	time,	 the	ECR	and	the	PHARMO	
RLS	collected	data	of	more	than	2	and	3	million	inhabitants,	respectively,	with	only	45%	
of	the	catchment	areas	(approximately	1	million	inhabitants)	overlapping.	Currently,	the	
PHARMO	Institute	 is	stimulating	pharmacists,	general	practitioners	and	others	 to	share	
their	data	needed	to	expand	the	data	collection	of	its	databases	in	the	region	of	the	ECR,	
resulting	in	a	larger	overlap	between	the	ECR	and	PHARMO	RLS	as	presented	in	Figure	1.	
Myrthe van Herk-Sukel
187
Medication use among women with breast cancer in the Netherlands
8
F u t u r e  p e r s p e c t i v e
Figure 1. The current area of the Eindhoven Cancer Registry (ECR) and overlap with the area of the PHARMO 
 record linkage system (PHARMO RLS) and expansion of this area in 2010.
This	 increased	 overlap	 does	 not	 comprise	 all	 databases	 included	 in	 the	 PHARMO	RLS.	
It	 currently	 includes	 the	 community	 pharmacy	 database	 and	 the	 national	 databases	
linked	 to	 the	 PHARMO	 community	 pharmacy	 database	 such	 as	 the	 Dutch	 National	
Medical	Register.	Expansion	of	the	other	PHARMO	databases	(e.g.	in-hospital	pharmacy,	
clinical	laboratory	data	and	general	practitioner	data)	as	well	as	further	expansion	of	the	
community	pharmacy	database	is	needed	for	complete	overlap	of	the	ECR	and	PHARMO	
RLS.	With	 this,	 the	overlap	 region	will	 be	doubled	 from	approximately	 1	million	 to	2.4	
million	inhabitants.	However,	this	still	will	not	be	enough	for	the	study	of	rare	cancers	and	
rare	adverse	events,	but	 it	will	 increase	the	research	possibilities	for	the	more	common	
cancers.	
Next	to	expansion	of	the	data	collection	of	the	PHARMO	RLS,	the	data	from	the	cancer	
registry	can	be	expanded	by	adding	data	from	another	regional	cancer	registry,	or	using	
data	from	all	eight	Dutch	regional	cancer	registries:	the	Netherlands	Cancer	Registry4,	5.	
Currently,	if	a	specific	study	question	requires	a	larger	cohort	of	cancer	patients	linked	to	
e.g.	the	PHARMO	community	database,	other	national	databases	that	include	information	
on	cancer	diagnosis	are	used	such	as	 the	Dutch	National	Medical	Register	 (Chapter 7) 
or	 the	Dutch	nationwide	network	and	registry	 for	histo-	and	cytopathology	 (PALGA)6,	7.	
However,	expansion	of	the	cancer	registry	data	is	preferred	as	both	the	Dutch	National	
Medical	Register	and	PALGA	do	not	contain	detailed	tumour	information	(such	as	stage)	
necessary	to	analyse	the	treatment	and	safety	of	a	particular	cancer	treatment	in	a	certain	
group	of	cancer	patients.	
Area ECR
Overlap area ECR and PHARMO RLS
Expansion overlap area ECR and PHARMO RLS in 2010
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Although	expansion	might	be	possible	from	a	technical	point	of	view,	it	also	requires	the	
willingness	and	 the	 trust	 to	participate	of	a	wide	variety	of	caregivers	and	 institutions:	
those	hosting	the	data.	Such	participation	is	guided	by	the	focus	of	both	the	ECR	and	the	
PHARMO	RLS;	that	data	are	collected	primarily	not	for	science	but	to	support	caregivers	
(e.g.	medical	 specialists,	general	practitioners	and	pharmacists).	For	 this,	 information	 is	
provided	 as	 feedback	 on	 a	 regular	 basis.	 A	 close	 cooperation	 between	 caregivers	 and	
researchers	is	essential	as	caregivers	will	assure	adequate	interpretation	of	the	study	results.	
The	construct	of	the	current	ECR-PHARMO	cohort	took	several	years	of	negotiations,	data	
cleaning	and	creating	the	right	governance	to	cooperate	and	to	secure	the	continuity	of	
the	linkage	systems.
Research possibilities using the ECR-PHARMO cohort
Cancer	surveillance	covers	the	spectrum	from	primary	prevention	to	end-of-life	care.	The	
linkage	between	the	ECR	and	the	PHARMO	RLS	creates	a	new	unique	source	for	numerous	
types	of	studies	related	to	cancer	control	(Figure	2).	
Before cancer 
diagnosis
Treatment of cancer Follow-up after 
cancer diagnosis and 
treatment
Death
Pre-existing morbidities 
and the risk of cancer
Pattern of cancer care Follow-up treatment,  
palliative care
Survival 
Drug use and the risk of 
cancer
Pharmacogenetics for 
personalized medicine
Patient reported out-
comes
Morbidities that influence 
the treatment of cancer
Late effects of treatment
Drug–drug interactions Disease progression
Acute adverse events
Figure 2. From cradle to grave: pharmacoepidemiology and outcomes research in the area of oncology 
 using the ECR-PHARMO cohort
Before cancer diagnosis
In	 this	 thesis	 we	 gave	 an	 example	 of	 the	 assessment	 of	 pre-existing	morbidities	 (e.g.	
myocardial	 infarction,	 ischaemic	 stroke	 or	 pulmonary	 embolism)	 before	 breast	 cancer	
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hospitalisation	and	determined	whether	the	prevalence	of	these	morbidities	was	higher	
compared	 to	 cancer-free	 controls	 (Chapter 7).	 Future	 studies	 may	 have	 as	 primary	
objective	 to	determine	whether	 certain	morbidities	 increase	 the	 risk	of	 cancer	 such	as	
hepatitis	C	infection	and	hepatocellular	carcinoma,8	or	diabetes	and	the	risk	of	cancer9.	
Studies	on	drug	use	and	the	risk	of	cancer	were	not	included	in	this	thesis	as	this	concerns	
another	major	topic,	that	of	pharmacovigilance.	Next	to	the	fact	that	certain	drugs	may	
increase	 the	 risk	 of	 cancer,	 other	 existing	 drugs	 might	 have	 unforeseen	 benefits	 and	
decrease	cancer	risk.	Examples	of	studies	in	both	fields	that	can	be	performed	with	data	
from	the	ECR-PHARMO	cohort	are:	cancer	occurrence	after	the	use	of	anti-diabetics10,	non-
steroidal	anti-inflammatory	drugs	(NSAIDs)11,	12,	or	statins6,	13.	The	additional	value	of	using	
cancer	registry	over	hospitalisation	or	general	practitioner	data	as	outcome	database	is	
that	it	provides	the	identification	of	all	incident	patients,	which	is	not	possible	using	the	
other	two	databases14.	Future	studies	can	use	the	ECR-PHARMO	linkage	to	determine	the	
relationship	between	drug	exposure	and	the	risk	of	cancer.
Treatment of cancer
Regarding	pattern	of	cancer	care,	data	on	the	initial	treatment	(e.g.	surgery,	chemotherapy,	
hormonal	 therapy	 and	 radiotherapy)	 can	 be	 extracted	 from	 the	 ECR,	 while	 follow-up	
treatment,	detailed	information	on	e.g.	the	type	of	anti-cancer	drugs	and	the	duration	of	
use	can	be	retrieved	from	the	in-	and	outpatient	pharmacy	database	of	the	PHARMO	RLS.	In	
this	thesis	we	gave	two	examples	of	treatment	pattern	studies:	the	type	of	chemotherapy	
and	endocrine	 treatment	used	by	patients	with	breast	cancer	 (Chapter 4 and 5).	With	
expansion	 of	 the	 in-hospital	 pharmacy	 database	 of	 the	 PHARMO	 RLS	 presenting	 the	
various	chemotherapy	regimens	for	smaller	cancer	cohorts	will	become	possible	as	well	
as	 for	 the	 larger	 cancer	 cohorts	presenting	 the	various	 chemotherapy	 regimens	by	 for	
example	nodal	status	and	age,	and	taking	performance	status	and	socio-economic	status	
into	account.	
The	ECR-PHARMO	cohort	can	be	used	to	determine	treatment	patterns	and	outcomes	of	
patients	whose	genetic	profile	has	been	assessed,	as	has	been	done	in	previous	studies	
using	the	PHARMO	RLS15,	16.	Pharmacogenetics	is	studying	the	interindividual	differences	
in	drug	 response	at	 the	genetic	basis	 to	achieve	personalized	drug	 therapy.	 In	 studies	
using	 the	ECR-PHARMO	data	 it	can	be	determined	why	some	patients	 respond	well	 to	
cancer	therapy	and	others	do	not17.
Whether	co-morbidities	at	the	time	of	diagnosis	influence	the	cancer	treatment	received	
by	cancer	patients	can	be	determined	with	data	from	solely	the	ECR18,	19	as	this	registry	
includes	 information	 on	 co-morbidity	 at	 diagnosis	 obtained	 from	 the	 clinical	 record20,	
21.	However,	next	to	evaluating	whether	a	patient	with	co-morbidities	receives	a	certain	
treatment	yes	or	no,	changes	in	chemotherapy	such	as	dose	delays,	dose	reductions,	early	
discontinuation,	or	excluding	a	specific	cytostatic,	may,	among	other	things,	be	based	on	
the	presence	of	co-morbidities22.	To	study	whether	the	choice	in	type	of	cytotoxic	agents	
varies	when	co-morbidities	are	present,	data	from	the	in-	and	outpatient	pharmacy	data	
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from	the	PHARMO	RLS	can	be	used.	In	our	study	on	cardiovascular	events	in	breast	cancer	
patients	 receiving	chemotherapy,	we	hypothesized	that	 the	similar	 results	 in	 incidence	
rates	 of	 the	 cardiotoxic	 and	 non-cardiotoxic	 chemotherapy	 groups	 may	 indicate	 that	
specialists	 took	 pre-existing	 cardiovascular	 diseases	 into	 account	 when	 choosing	 the	
type	of	chemotherapy	administered	to	the	breast	cancer	patient	(Chapter 6).	This	can	be	
determined	in	a	future	study	assessing	whether	patients	with	present	(cardiac)	co-morbidity	
do	not	receive	specific	cytostatics	such	as	anthracyclines	followed	by	taxanes,	as	advised	in	
the	Dutch	guidelines23.	Moreover,	studies	on	co-morbidities	and	early	discontinuation	can	
be	performed	using	data	from	the	ECR-PHARMO	cohort.	Unfortunately,	studies	on	dose	
delays	or	dose	reductions	are	more	difficult	as	dose	is	not	available	for	all	data	obtained	
from	the	in-patient	pharmacies.	
Related	 to	 the	 influence	 of	 co-morbidities	 on	 the	 treatment	 of	 cancer	 is	 the	 effect	 of	
the	 medications	 for	 other	 morbidities	 on	 the	 outcome	 of	 systemic	 cancer	 treatment.	
Data	from	the	ECR-PHARMO	cohort	can	be	used	to	provide	insight	in	the	prevalence	of	
potential	drug–drug	interactions	between	anti-cancer	drugs	and	non	anti-cancer	drugs24.	
Moreover,	 it	 can	be	 studied	whether	 concurrent	use	of	 co-medication	 and	anti-cancer	
drugs	leads	to	reduced	effectiveness	of	the	anti-cancer	drugs17.
Studies	on	acute	adverse	events	directly	influencing	the	cancer	treatment	can	be	performed	
in	the	ECR-PHARMO	cohort	using	e.g.	clinical	laboratory	data.	Study	examples	that	can	be	
performed	with	data	from	the	ECR-PHARMO	cohort	are:	assessing		myelotoxicity,	anaemia	
and	neutropenia	in	cancer	patients	who	underwent	chemotherapy25,	or	determining	the	
values	of	serum	liver	biochemical	tests	(i.e.	albumin,	alanine	aminotransferase,	aspartate	
aminotransferase,	bilirubin	and	gamma	glutamyl	transpeptidase)	in	patients	with	cancer	
during	chemotherapeutic	treatment26.
Follow-up after cancer diagnosis and treatment
The	in-	and	out-patient	pharmacy	data	and	the	hospitalisation	data	of	the	PHARMO	RLS	
can	be	used	to	determine	treatment	after	 initial	cancer	care.	For	example,	 in	our	study	
on	chemotherapy	 in	breast	cancer	patients	 (Chapter 4)	we	determined	administration	
of	 palliative	 chemotherapy	 after	 initial	 adjuvant	 treatment	 by	 assuming	 that	 restart	
of	 chemotherapy	 after	 90	 days	 indicated	 a	 distant	 recurrence	 as	 secondary	 adjuvant	
chemotherapy	 for	 the	 treatment	 of	 a	 local	 recurrence	 is	 not	 recommended27.	 Another	
example	is	switching	endocrine	treatment	during	follow-up	as	we	presented	in	our	study	
on	treatment	continuation	of	endocrine	treatment	in	breast	cancer	patients	(Chapter 5).
The	ECR-PHARMO	cohort	can	serve	to	select	cancer	patients	with	certain	characteristics	to	
be	included	in	a	population-based	cross-sectional	survey.	This	has	been	done	in	previous	
studies	using	data	from	the	ECR.28,	29	In	this	way	the	data	from	the	ECR-PHARMO	cohort	
can	be	enriched	via	information	obtained	from	questionnaires,	such	as	long-term	health-
related	quality	 of	 life,	 diet	 and	 smoking	habits,	 adverse	drug	 reactions,	 and	 treatment	
compliance.
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Late	effects	of	 treatment	and	their	costs	can	be	evaluated	with	the	data	 from	the	ECR-
PHARMO	RLS	by	using,	 for	 example,	 the	hospitalisation	database	of	 the	PHARMO	RLS.	
As	 all	 hospitalisations	 are	 automatically	 registered	 in	 this	 administrative	 database,	 the	
hospitalisations	 related	 to	 e.g.	 adverse	 drug	 reactions	 that	 were	 not	 anticipated	 via	
results	 from	 clinical	 trials	 are	 still	 recorded	 and	 can	 be	 evaluated.	 However,	 one	must	
keep	in	mind	that	the	hospitalisation	database	records	only	the	more	severe	and	acute	
morbidities	that	require	a	hospital	admission	for	more	than	24	hours	and	admissions	for	
less	than	24	hours	for	which	a	bed	is	required.	Less	severe	and	more	chronic	conditions	
might	be	 captured	by	using	 the	dispensed	medications	 included	 in	 the	PHARMO	out-
patient	pharmacy.	This	 thesis	presented	two	studies	 in	which	the	morbidities	of	breast	
cancer	patients	after	diagnosis	and	treatment	were	determined	using	the	hospitalisation	
and	out-patient	pharmacy	database	of	the	PHARMO	RLS	(Chapter 6 and 7).	Moreover,	in	
future	studies	 less	severe	events	can	be	captured	via	the	PHARMO	general	practitioner	
database.	Outcome	studies	assessing	adverse	events	of	specific	chemotherapeutic	agents	
administered	to	cancer	patients	might	be	possible	in	the	near	future	after	expansion	of	
the	 ECR-PHARMO	 cohort,	 and	more	 specifically,	 the	 in-hospital	 pharmacy	 database	 of	
the	PHARMO	RLS.	This	is	important	as	with	the	increasing	number	of	new	agents	being	
investigated	and	approved	for	treatment	of	patients	with	breast	cancer	and	the	increasing	
number	of	breast	 cancer	patients	 living	 cancer-free	 after	diagnosis	 and	 treatment,	 the	
long-term	toxicity	profiles	of	new	anti-cancer	drugs	come	into	focus.	
Studies	 on	 disease	 progression	 have	 been	 performed	 by	 the	 ECR	 with	 data	 retrieved	
via	additional	 registration	of	 local	 recurrences	and	metachronous	metastases	 from	 the	
clinical	 record	 based	 on	 a	 periodical	 active	 or	 passive	 follow-up30-32.	 However,	 data	 on	
disease	 progression	 can	 also	 be	 obtained	 via	 the	 ECR-PHARMO	 cohort.	 For	 example,	
biopsy	confirmed	recurrences	can	be	obtained	via	the	Dutch	National	Pathology	Registry	
(PALGA),	 as	 the	 PHARMO	 RLS	 is	 also	 linked	 to	 this	 database.33,	 34	 Next	 to	 this,	 data	 on	
recurrences	 can	 be	 obtained	 via	 the	 PHARMO	 hospitalisation	 database17.	 Moreover,	
specifically	for	prostate	cancer,	the	PHARMO	clinical	laboratory	database	might	be	used	
for	 surveillance	 of	 patients	 with	 localized	 prostate	 cancer	 via	 PSA	 (prostate-specific	
antigen)	measurements35.	Finally,	 clinical	algorithms	might	be	developed	 to	determine	
cancer	relapse.	For	example,	if	there	is	a	gap	between	administration	of	chemotherapy	or	
radiotherapy	and	treatment	is	started	somewhere	during	follow-up,	it	might	be	assumed	
that	this	was	for	relapsed	disease36.	Such	a	clinical	algorithm	can	only	be	used	if	almost	all	
patients	are	treated	shortly	after	relapse	and	when	second	primary	cancer	are	excluded	
by	using	data	from	the	cancer	registry.	
Death
Finally,	 studies	 on	 survival	 after	 cancer	 diagnosis	 can	 be	 performed	 using	 the	 ECR-
PHARMO	cohort.	This	has	been	done	in	many	previous	published	studies	using	the	data	
from	the	ECR,	with	information	on	vital	status	obtained	from	the	municipal	registers	and	
the	Central	Bureau	for	Genealogy37-39.	
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Data confidentiality and governance
The	ECR	is	governed	and	regulated	by	the	Comprehensive	Cancer	Centre	South	(CCCS)	
and	the	PHARMO	RLS	by	the	PHARMO	Institute.	With	governance	we	refer	to	the	set	of	
rules	and	regulations	that	secure	the	continuity	of	the	individual	data	sources.	The	main	
concern	 is	 to	guarantee	optimal	use	of	 the	data	 thereby	maintaining	confidentiality	of	
patients	as	well	 as	data	providers	and	 registration	holders.	To	ensure	confidentiality	of	
personal	information,	first	of	all,	the	PHARMO	Institute	collects	only	non-directly	patient	
identifiers	such	as	gender,	date	of	birth	and	zip	code,	which	are	used	in	the	linking	process.	
In	 the	ECR	direct	patient	 identifiers	 such	as	first	and	 last	name	are	collected,	however,	
in	both	the	ECR	and	the	PHARMO	RLS	data	are	de-identified	(i.e.,	all	personal	identifiers	
are	removed	from	the	file)	and	the	researchers	do	not	have	direct	access	to	identifiable	
information.	
Patients	are	informed	of	the	existence	of	the	PHARMO	RLS	by	leaflets	and	posters	in	the	
offices	of	 the	data	 suppliers.	Each	patient	can	object	 the	use	of	his	or	her	data	 for	 the	
PHARMO	RLS.	To	opt-out,	the	patient	informs	the	data	supplier	of	his/her	objection	to	the	
use	of	 the	data.	The	technical	 infrastructure	of	 the	PHARMO	RLS	allows	 individual	data	
suppliers	to	withdraw	data	on	the	level	of	all	data	related	to	a	certain	patient,	or	specific	
data	elements.	 If	data	are	withdrawn,	 a	message	 is	 sent	 to	 the	PHARMO	 Institute,	 and	
the	data	will	subsequently	be	removed	from	the	PHARMO	RLS.	The	CCCS	considers	the	
research	performed	with	the	ECR	as	being	part	of	the	process	of	quality	assessment	aimed	
to	facilitate	the	attending	physicians	to	deliver	optimal	cancer	care.	Such	observational	
research	is	not	considered	‘experimental’	for	which	informed	consent	should	be	obtained.	
The	fact	 that	caregivers	receive	aggregated	feedback	on	the	data	they	submitted	does	
not	change	that.
The	record	linkage	process	(using	indirectly	identifiable	patient	information)	of	the	ECR	
and	the	PHARMO	RLS	is	executed	in	a	separate	department	of	the	PHARMO	Institute.	The	
original	patients	 variables	used	 in	 the	 linking	process	will	be	kept	 separately	 from	 the	
data	analysis	files.	After	the	linkage	data	is	available	for	research	in	the	PHARMO	Research	
Database	(PRD)	where	patients	can	be	recognized	by	a	PHARMO	generated	anonymized	
patient	number	linked	to	the	anonymized	ECR	patient	number.	Variables	that	might	allow	
for	 the	 re-identification,	 such	as	exact	date	of	birth	and	 zip	 code,	have	been	 removed	
or	 recoded.	Only	 year	 of	 birth	 and	 gender	 of	 each	 patient	 is	 available	 in	 the	 research	
dataset.	
After	 linkage,	 it	 is	necessary	that	the	privacy	regulations	of	the	CCCS	and	the	PHARMO	
RLS	 are	 similar,	 because	 otherwise	 the	 confidentiality	 of	 the	 PHARMO	 RLS	 might	 be	
violated	when	accessing	the	ECR-PHARMO	cohort	via	the	ECR,	or	the	other	way	around.	
As	a	 result	of	 the	 linkage,	more	specific	event	 information	of	a	single	patient	becomes	
available	 potentially	 leading	 to	 indirectly	 identifiability	 of	 the	 patient.	 Hence	 the	 ECR-
PHARMO	cohort	should,	next	to	the	governance	rules	of	the	CCCS	and	the	PHARMO	RLS,	
also	comply	with	a	third,	separate	set	of	governance	rules	specifically	of	the	ECR-PHARMO	
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cohort.	 In	the	future,	further	privacy	protection	of	the	data	of	the	ECR-PHARMO	cohort	
will	be	achieved	by	deleting	certain	datasets	or	by	aggregating	to	a	more	general	level	
and	converting	the	 records	 to	files	 that	do	not	contain	original	 time	stamped	event	of	
patients,	but	do	allow	observational	research.	
Research ethics
The	 use	 of	 the	 ECR-PHARMO	 cohort	 is	 controlled	 by	 an	 independent	 regional	 privacy	
committee,	which	consists	of	representatives	of	the	participating	data	suppliers,	patient	
representatives	and	an	 independent	privacy	expert.	Every	study	requires	permission	of	
this	committee.	For	each	study,	not	only	 the	 research	question,	but	also	 the	data	used	
for	the	study,	the	methods	used	to	analyse	the	data,	and	the	people/organisations	who	
commissioned	the	study	have	to	be	described.	All	decisions	of	the	privacy	committee	are	
based	on	 the	 involved	 legislation	 in	 the	Netherlands,	e.g.	 the	Personal	Data	Protection	
Act	(Wet	bescherming	persoonsgegevens;	Wbp))	and	the	Medical	Treatment	Contract	Act	
(Wet	Geneeskundige	Behandelings	Overeenkomst;	WGBO).	Within	this	legal	framework,	
the	Code	of	Conduct	“Use	of	Data	in	Health	Research”40	is	an	important	document	for	the	
interpretation	of	 the	use	of	 this	 kind	of	data	 for	 scientific	 research	 in	 the	Netherlands,	
and	 is	 approved	 by	 the	 Dutch	 Data	 Protection	 Authority	 (College	 Bescherming	
Persoonsgegevens; CBP).	For	the	renewal	of	this	approval,	which	expires	every	five	years,	
a	policy	document	on	Trusted	Third	Parties	(TTP)	is	currently	being	processed41.
In	some	cases	the	privacy	committee	can	advise	review	by	a	medical	ethical	committee.	
However,	 research	 projects	 that	 are	 based	 solely	 on	 registry	 data	 or	 existing	medical	
records	(i.e.,	without	contact	with	the	registered	subjects)	are	exempt	from	review	by	an	
ethics	committee	provided	that	confidentiality	and	anonymity	of	patients	is	assured,	as	
described	 above.	These	 research	projects	 are	often	discussed	 in	 tumour	 study	groups,	
because	the	studies	somehow	reflect	quality	of	care	and	therefore	require	involvement	
of	the	various	specialists	who	are	then	made	partly	responsible	for	interpretation	of	the	
study	results.	Ethical	review	of	a	certified	ethical	committee	is	mandatory	if	the	project	
entails	any	form	of	intervention,	change	in	routine	care	or	a	direct	contact	with	a	patient,	
which	has	any	impact	on	patients’	mental	integrity42.	For	example,	when	patients	are	to	
be	enrolled	 in	prospective	 studies	 (e.g.	 extensive	questionnaire	 studies	or	 studies	 that	
require	 additional	 tests	or	procedures	which	might	hamper	 safety	of	patients)	 and	 re-
identification	of	patients’	information	is	needed,	then	the	Dutch	law	mandates	informed	
consent.	
The	governance	 rules	of	 the	CCCS	and	 the	PHARMO	 Institute	as	described	above,	also	
define	whether	third	parties	(researchers	other	than	those	from	the	CCCS	or	the	PHARMO	
Institute)	can	have	access	to	the	data.	First	of	all,	data	from	the	ECR-PHARMO	cohort	may	
under	no	circumstances	be	transferred	for	purposes	other	than	scientific	research.	It	is	the	
responsibility	of	the	 investigator	to	consider	the	strengths	and	weaknesses	 in	deciding	
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whether	to	use	the	linked	ECR-PHARMO	cohort	for	their	research.	A	researcher	must	be	
trained	and	familiar	with	the	data	included	in	both	databases	and	understand	how	the	
individual	databases	were	generated,	before	using	 the	data	 for	 research.	This	prevents	
inexperienced	researchers	to	make	decisions	that	might	harm	data	providers	or	interfere	
with	the	common	practice	of	care	delivery.	 Investigators	who	wish	to	obtain	data	from	
the	linked	ECR-PHARMO	cohort	need	to	get	permission	from	both	the	CCCS	(where	the	
relevant	tumour	study	group	will	be	consulted)	and	the	PHARMO	Institute,	as	technically	
they	 should	 respect	 the	governance	 rules	of	both	data	providers.	Contracts	 should	be	
in	 place	 that	 enable	 control	 of	 the	 compliance	 of	 third	 parties	with	 governance	 rules.	
Publications	of	results	require	the	previous	consent	of	both	the	CCCS	and	the	PHARMO	
Institute.	In	this	way,	the	continuity	of	access	for	other	researchers	to	the	ECR-PHARMO	
cohort	is	safeguarded.	
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Concluding remarks
The	ECR-PHARMO	cohort	created	in	this	thesis	is	a	valuable	source	available	to	researchers	
for	pharmacoepidemiological	studies	in	the	area	of	oncology.	It	is	particularly	useful	for	
epidemiologists	dealing	with	outcomes	 involving	effectiveness	and	safety	of	oncology	
drugs,	especially	with	the	new	morbidities	the	new	anti-cancer	drugs	may	create.
The	size	of	the	cohort	of	approximately	one	million	inhabitants	is	still	relatively	limited	for	
studies	in	rare	types	of	cancer;	however,	we	demonstrated	that	pharmacoepidemiological	
studies	in	a	cohort	of	breast	cancer	patients	are	feasible.	This	thesis	only	presented	a	few	
examples	 of	 such	 studies	 and	 many	 aspects	 of	 the	 pharmacoepidemiology	 in	 breast	
cancer	patients	still	need	to	be	addressed.	Next	to	breast	cancer,	other	common	cancers	
types	such	as	colorectal	cancer,	lung	cancer	and	prostate	cancer	can	also	be	studied	using	
the	current	ECR-PHARMO	cohort,	including	the	research	possibilities	as	described	in	the	
previous	section.	
The	ECR-PHARMO	cohort	 serves	as	a	 tool	 to	 raise	hypotheses	and	provide	population-
based	 evidence	 that,	 added	 to	 evidence	 obtained	 from	 randomized	 controlled	 trials,	
would	protect	cancer	patients	from	unnecessary	risk	while	preserving	treatment	benefits.	
The	ultimate	goal	of	 this	cohort	 is	 to	ensure	 that	 the	pharmacologic	aspects	of	cancer	
control	 becomes	measurable	 and	 a	 subject	 of	 objective	 evaluation	 to	 support	 public	
health	efforts.	Its	goal	is	to	improve	cancer	surveillance,	or,	more	specifically,	to	improve	
evaluation	of	cancer	treatment	outcome	and	safety	of	cancer	patients.	
C o n c l u d i n g  r e m a r k s
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Summary
The	number	of	patients	ever	diagnosed	with	breast	cancer	in	the	Netherlands	is	growing	
considerably	due	to	the	increasing	breast	cancer	 incidence	and	the	improving	survival.	
Recent	decades	have	brought	a	dramatic	 increase	 in	 the	number	of	new	agents	being	
investigated	and	approved	for	the	treatment	of	breast	cancer.	New	drugs	can	increase	the	
efficacy	of	breast	cancer	treatment,	but	may	also	generate	late	morbidities	which	may	not	
be	detectable	in	clinical	trials.	
This	 thesis	 describes	 the	 results	 of	 population-based	observational	 studies	 on	 the	use	
of	 systemic	 treatment	 (chemotherapy	 and	 endocrine	 therapy)	 in	 patients	 with	 breast	
cancer,	 as	well	 as	 studies	 on	morbidities	 that	may	 occur	 after	 breast	 cancer	 diagnosis	
and	 treatment.	 Both	 the	observed	 treatment	 and	new	morbidities	may	be	different	 in	
everyday	practice	than	expected	from	randomized	clinical	trials	due	to	the	heterogeneity	
of	patients,	their	age,	co-morbidity,	co-medication	and	treatment	compliance.	
To	 be	 able	 to	 perform	 pharmacoepidemiological	 studies	 in	 a	 cohort	 of	 breast	 cancer	
patients	in	the	Netherlands,	a	new	data	source	was	created	by	linking	the	Eindhoven	Cancer	
Registry	(ECR)	and	the	PHARMO	Record	Linkage	System	(PHARMO	RLS)	as	described	in	
Chapter 2.3. The	 linked	ECR-PHARMO	cohort	consists	of	40,004	cancer	patients	newly	
diagnosed	 in	 the	period	1998-2006,	 including	5,545	patients	with	breast	 cancer,	 4,804	
with	colon	and	 rectum	cancer,	4,395	with	 lung	cancer,	and	3,835	with	prostate	cancer.	
The	patient-centric	data	available	from	this	linkage	included,	among	other	things,	tumour	
information	(histology,	grade	and	stage)	of	incident	cancers	obtained	from	the	ECR	and	
data	on	drug	treatment	(out-patient	and	in-patient)	and	hospitalisations	obtained	from	
the	PHARMO	RLS,	offering	a	longitudinal	perspective.	
The	 extent	 to	 which	 adjuvant	 systemic	 treatment	 patterns	 among	 women	 with	 early	
stage	breast	cancer	have	changed	from	1990	through	2006	in	the	southeastern	part	of	the	
Netherlands	was	assessed	using	data	from	solely	the	ECR	(Chapter 3).	The	use	of	adjuvant	
systemic	treatment	for	patients	with	breast	cancer	increased	significantly	over	time,	from	
37%	 in	 1990-1997,	 to	 53%	 of	 all	 early	 stage	 breast	 cancer	 patients	 in	 2002-2006.	This	
increase	was	especially	seen	among	patients	with	node-negative	breast	cancer.	Marked	
variations	were	observed	between	hospitals,	 illustrating	there	have	been	early	and	late	
adopters	of	the	treatment	guidelines	in	the	southeastern	part	of	the	Netherlands.
Not	only	more	breast	cancer	patients	received	primary	systemic	treatment,	there	is	also	an	
increase	in	the	number	of	drugs	being	approved	for	the	treatment	of	patients	with	breast	
cancer.	Data	from	the	ECR	breast	cancer	cohort	linked	with	data	from	the	PHARMO	RLS	
allowed	us	to	investigate	trends	in	type	of	chemotherapy	regimens	administered	to	early	
stage	or	metastatic	breast	cancer	patients	(Chapter 4).	Early	stage	breast	cancer	patients	
receiving	chemotherapy	in	the	adjuvant	setting	were	in	general	treated	according	to	the	
guidelines.	For	breast	cancer	patients	who	received	palliative	chemotherapy	at	diagnosis	
or	after	breast	cancer	recurrence,	there	was	a	large	variation	in	chemotherapy	regimens	
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administered,	which	 is	 probably	 due	 to	 the	 high	 variability	 in	 individual	 presentation.	
Presenting	results	on	the	administration	of	chemotherapeutics	in	everyday	clinical	practice	
is	a	way	to	give	feedback	to	specialists	as	they	are	able	to	compare	their	practice	patterns	
with	the	overall	observed	treatment	patterns	of	breast	cancer	patients	in	the	region.
Adjuvant	 endocrine	 treatment	 is	 recommended	 for	 women	 with	 hormone	 receptor-
positive	 early	 stage	 breast	 cancer.	 The	 major	 concern	 in	 daily	 clinical	 practice	 is	 that	
patients	should	continue	their	endocrine	treatment	over	the	recommended	period	of	five	
years.	A	population-based	setting	is	needed	to	determine	rates	of	discontinuation	in	daily	
practice	as	patients	appear	 to	discontinue	their	medications	at	higher	 rates	 in	practice	
settings	than	in	clinical	trials.	Data	from	the	PHARMO	community	pharmacy	database	was	
used	to	determine	the	treatment	pattern	of	endocrine	therapy	use	of	patients	with	breast	
cancer	included	in	the	ECR-PHARMO	cohort	(Chapter 5).	This	observational	study	showed	
that	 of	 patients	with	 early	 stage	 breast	 cancer	who	 started	 tamoxifen	 treatment,	 49%	
continuously	used	endocrine	treatment	 (tamoxifen	and/or	aromatase	 inhibitors)	over	a	
five	year	follow-up	period.	Older	age	(older	than	70	versus	50-69	years)	and	two	or	more	
concomitant	diseases	(versus	none)	were	independently	associated	with	discontinuation	
of	endocrine	 therapy.	These	 results	will	 assist	 the	clinician	 to	 identify	patients	who	are	
at	 increased	 risk	of	discontinuation	of	endocrine	 treatment,	 so	 that	 these	patients	 can	
receive	more	intensive	follow-up	care	to	prevent	early	discontinuation.
Defining	the	 incidence	of	new	morbidities	after	breast	cancer	diagnosis	and	treatment	
becomes	 increasingly	 important	 as	 a	 growing	 number	 of	 breast	 cancer	 patients	 live	
cancer-free	after	diagnosis	and	treatment.	In Chapter 6 the	incidence	of	cardiovascular	
morbidities	were	assessed	among	breast	cancer	patients	 included	 in	 the	ECR-PHARMO	
cohort	 who	 had	 received	 chemotherapy.	 Incidence	 rates	 of	 cardiovascular	 morbidity	
were	 similar	 for	 breast	 cancer	 patients	who	 underwent	 cardiotoxic	 or	 non-cardiotoxic	
chemotherapy	during	a	median	 follow-up	of	1.5	years.	 In	 this	study,	patients	with	pre-
existing	 cardiovascular	 morbidity	 or	 older	 age	 were	 less	 likely	 to	 receive	 cardiotoxic	
chemotherapy.	If	specialists	are	aware	of	the	cardiotoxicity	of	a	certain	chemotherapeutic,	
patients	with	breast	cancer	at	risk	for	cardiovascular	events	will	be	less	likely	to	receive	
such	chemotherapeutics	or	adaptations	will	be	made	in	dose	and	rate	of	administration.	
In	Chapter 7 the	occurrences	of	the	more	serious	venous	and	arterial	thromboembolic	
events	 were	 determined	 in	 patients	 with	 breast	 cancer	 by	 using	 hospitalisation	 data.	
This	study	showed	that	compared	to	cancer-free	controls,	breast	cancer	patients	had	a	
more	than	two	times	higher	risk	to	have	had	a	hospitalisation	for	myocardial	infarction,	
ischaemic	 stroke	 and	 pulmonary	 embolism	 in	 the	 12	 months	 before	 breast	 cancer	
hospitalisation.	This	might	be	explained	by	 the	 fact	 that	breast	cancer	and	 thrombosis	
share	 similar	 risk	 factors	 such	 as	 obesity.	 Directly	 after	 breast	 cancer	 hospitalisation,	
patients	 experienced	 an	 extreme	 high	 risk	 of	 pulmonary	 embolism,	 which	 declined	
gradually	during	 follow-up.	 Breast	 cancer	 treatment-related	 factors,	 such	 as	 the	use	of	
chemotherapy,	 hormonal	 therapy	 or	 duration	 of	 hospital	 stay	 were	 independent	 risk	
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factors	for	developing	pulmonary	embolism.	To	achieve	optimal	treatment	and	prognosis	
among	patients	diagnosed	with	breast	cancer,	this	study	contributes	to	the	awareness	of	
presence	of	thrombosis	at	breast	cancer	diagnosis	and	the	incidence	of	thromboembolic	
morbidities	after	breast	cancer	diagnosis	and	treatment.	
Next	to	the	studies	described	 in	this	thesis,	 the	created	ECR-PHARMO	cohort	 facilitates	
many	pharmacoepidemiology	and	outcomes	research	in	various	other	cancer	types.	The	
uniqueness	of	the	data	available	in	the	ECR-PHARMO	cohort	was	addressed	by	comparing	
this	linkage	to	other	database	linkages	in	Northern	America	and	Europe	(Chapter 8.2).	Two	
exceptional	features	of	the	ECR-PHARMO	cohort	compared	to	the	other	linked	databases	
are	that	the	ECR	is	the	only	cancer	registry	that	includes	information	on	co-morbidity	at	
diagnosis	of	 cancer	and	 the	PHARMO	RLS	 includes	data	on	all	 (anti-cancer)	drugs	 that	
have	been	dispensed	by	community	pharmacies	as	well	as	in-hospital	pharmacies.	These	
data	were	not	available	in	the	other	database	linkages.	
In	 the	 future	 perspective,	 the	 representativeness	 of	 the	 ECR-PHARMO	 cohort	 was	
considered	as	well	as	the	current	data	limitations	and	possible	ways	to	overcome	these	
limitations	 in	 the	 future	 by,	 for	 example,	 expansion	 of	 the	 data	 collection.	 Moreover,	
an	 overview	 of	 the	 many	 other	 pharmacoepidemiological	 studies	 possible	 using	 the	
ECR-PHARMO	cohort	was	provided.	 Examples	 are:	 studies	 on	drug	use	 and	 the	 risk	 of	
cancer,	studies	on	potential	drug–drug	interactions	between	anti-cancer	drugs	and	non	
anti-cancer	drugs	 and	 studies	on	 follow-up	 treatment	of	 cancer	patients	 after	primary	
treatment.	Finally,	 important	aspects	 for	continuation	of	 this	cohort	 in	 the	 future	were	
discussed,	including	data	confidentiality,	governance	and	research	ethics.
In	conclusion,	this	thesis	presents	how	patients	with	breast	cancer	are	systemically	treated	
in	daily	clinical	practice,	as	well	as	the	morbidities	that	are	present	and	may	occur	after	
breast	cancer	diagnosis	and	treatment.	For	this,	the	ECR,	the	PHARMO	RLS	and	the	new	
created	ECR-PHARMO	cohort	were	used.	The	ECR-PHARMO	cohort	 is	a	valuable	source	
especially	for	epidemiologists	and	clinicians	dealing	with	treatment	patterns,	effectiveness	
and	safety	of	(new)	oncology	drugs.	
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Samenvatting
Het	 aantal	 vrouwen	waarbij	 ooit	 borstkanker	 is	 gediagnosticeerd	neemt	 toe.	Dit	 komt	
enerzijds	door	een	stijging	van	het	aantal	nieuwe	gevallen	van	borstkanker,	anderzijds	
doordat	de	kans	op	overleven	na	diagnose	is	verbeterd.	Deze	hogere	kans	op	overleven	
is	onder	meer	te	danken	aan	de	introductie	van	nieuwe	geneesmiddelen	in	de	afgelopen	
decennia.	Naast	verbetering	van	de	behandeling	van	borstkanker	kunnen	deze	medicijnen	
op	 de	 langere	 termijn	 echter	 ook	 ziekten	 veroorzaken	 die	 niet,	 of	 beperkt,	 in	 klinisch	
onderzoek	zijn	waargenomen.	
In	dit	proefschrift	worden	de	resultaten	besproken	van	observationele	studies	waarin	de	
behandeling	van	borstkankerpatiënten	met	chemotherapie	of	hormoontherapie	centraal	
staat.	Daarnaast	wordt	het	ontstaan	van	ernstige	aandoeningen	na	borstkankerdiagnose	
en	–behandeling	onderzocht.	Zowel	de	behandeling	als	ziekten	na	behandeling	kunnen	
in	 de	 dagelijkse	 praktijk	 afwijken	 van	 wat	 er	 verwacht	 wordt	 op	 basis	 van	 klinisch	
vergelijkend	 onderzoek	 aangezien	 patiënten	 in	 de	 dagelijkse	 praktijk	 vaak	 ouder	 zijn,	
minder	therapietrouw	zijn	en	meer	bijkomende	ziekten	hebben.
Om	farmaco-epidemiologisch	onderzoek	bij	kankerpatiënten	mogelijk	te	maken	is	er	een	
nieuwe	Nederlandse	onderzoeksdatabank	gecreëerd.	Hiervoor	is	de	kankerregistratie	van	
het	Integraal	Kankercentrum	Zuid	(IKZ;	Eindhoven	Cancer	Registry:	ECR)	gekoppeld	aan	
de	databanken	van	het	PHARMO	 Instituut	 (PHARMO	Record	Linkage	System:	PHARMO	
RLS),	zoals	beschreven	 in	Hoofdstuk 2.3.	Het	gekoppelde	 IKZ-PHARMO	cohort	bestaat	
uit	40.004	kankerpatiënten,	gediagnosticeerd	in	de	periode	1998-2006.	Het	cohort	bevat	
onder	andere	5.545	patiënten	met	borstkanker,	4.804	met	dikkedarmkanker,	4.395	met	
longkanker	 en	 3.835	 met	 prostaatkanker.	 Gedetailleerde	 tumorgegevens	 (stadium,	
histologie	 en	 gradering)	 van	 deze	 patiënten	 zijn	 beschikbaar	 via	 de	 kankerregistratie	
en	 longitudinale	 gegevens	 van	 onder	 andere	 de	 afgifte	 van	 geneesmiddelen	 en	
ziekenhuisopnames	zijn	beschikbaar	via	de	PHARMO	databanken.	
Met	behulp	van	de	gegevens	van	de	kankerregistratie	van	het	IKZ	werd	in	patiënten	met	
operabel	 mammacarcinoom	 de	 toename	 van	 behandeling	 met	 chemotherapie	 en/of	
hormoontherapie	bestudeerd	 in	de	periode	1990-2006	 (Hoofdstuk 3).	Het	percentage	
patiënten	met	 operabel	mammacarcinoom	dat	met	 geneesmiddelen	werd	 behandeld	
nam	toe	van	37%	in	1990-1997,	tot	53%	in	2002-2006.	Deze	toename	was	vooral	te	zien	
bij	borstkankerpatiënten	zonder	 lymfekliermetastasen.	De	toediening	van	behandeling	
met	chemotherapie	en/of	hormoontherapie	varieerde	tussen	de	ziekenhuizen	mogelijk	
als	gevolg	van	snelle	en	trage	navolging	van	de	richtlijnen.
Naast	 een	 toename	 van	 het	 aantal	 borstkankerpatiënten	 dat	 met	 geneesmiddelen	
wordt	 behandeld,	 stijgt	 ook	 het	 aantal	 beschikbare	 geneesmiddelen.	 Trends	 in	 de	
chemotherapieschema’s	 verstrekt	 aan	 patiënten	met	 een	 operabel	 of	 gemetastaseerd	
mammacarcinoom	 werden	 beschreven	 met	 behulp	 van	 de	 gegevens	 uit	 het	 IKZ-
PHARMO	 cohort	 (Hoofdstuk 4).	 Patiënten	 met	 primair	 operabel	 mammacarcinoom	
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werden	overwegend	behandeld	volgens	de	richtlijnen.	Bij	patiënten	met	gemetastaseerd	
mammacarcinoom	werd	een	grote	variatie	waargenomen	in	de	toegediende	palliatieve	
chemotherapie.	Dit	hangt	vermoedelijk	samen	met	de	grote	diversiteit	in	patiënten	met	
gemetastaseerd	mammacarcinoom.	Terugkoppeling	van	de	 resultaten	van	deze	 studie	
aan	 de	 specialisten	 in	 de	 regio	 geeft	 inzicht	 in	 de	 manier	 waarop	 zij,	 als	 groep,	 hun	
borstkankerpatiënten	behandelen	 en	draagt	bij	 aan	de	discussie	 over	 de	behandeling	
van	deze	patiënten.	
Adjuvante	 hormoonbehandeling	 wordt	 aanbevolen	 voor	 vrouwen	 met	 hormonaal	
gevoelig	mammacarcinoom.	Het	 belangrijkste	 aandachtspunt	 in	 de	 dagelijkse	 praktijk	
is	dat	deze	patiënten	hun	hormoonbehandeling	moeten	continueren	over	een	periode	
van	 vijf	 jaar.	 In	 observationele	 studies	 kan	worden	 nagegaan	 hoeveel	 procent	 van	 de	
patiënten	 dit	 ook	 daadwerkelijk	 doet,	 aangezien	 verwacht	 wordt	 dat	 dit	 percentage	
lager	 ligt	dan	bij	patiënten	die	geïncludeerd	zijn	 in	klinische	studies.	 In	dit	proefschrift	
werd	het	continueren	van	hormoonbehandeling	door	de	borstkankerpatiënten	uit	het	
IKZ-PHARMO	 cohort	 bepaald	 met	 behulp	 van	 afleveringen	 van	 hormoonrecepten	 uit	
de	PHARMO	openbare	apotheekdatabank	(Hoofdstuk 5).	Van	de	borstkankerpatiënten	
die	 met	 tamoxifen	 startten,	 continueerde	 49%	 hun	 hormoonbehandeling	 (tamoxifen	
en/of	een	aromataseremmer)	over	een	periode	van	5	 jaar.	Patiënten	ouder	dan	70	 jaar	
stopten	vaker	voortijdig	de	behandeling	dan	patiënten	tussen	50	en	69	jaar.	Hoe	meer	
andere	ziekten	een	patiënte	had	ten	tijde	van	borstkankerdiagnose,	hoe	groter	de	kans	
was	dat	ze	de	hormoonbehandeling	voortijdig	zou	staken.	Als	de	behandelend	arts	zich	
ervan	bewust	is	dat	patiënten	met	deze	kenmerken	een	verhoogd	risico	hebben	op	het	
voortijdig	 stoppen	 van	 hormoonbehandeling,	 dan	 kunnen	 deze	 patiënten	 intensiever	
gevolgd	worden	zodat	dit	voorkomen	kan	worden.
Onderzoek	 naar	 het	 ontstaan	 van	 nieuwe	 aandoeningen	 na	 borstkankerdiagnose	 en	
-behandeling	wordt	steeds	belangrijker	door	het	toenemende	aantal	borstkankerpatiënten	
dat	 na	 behandeling	 kankervrij	 is,	 of	 waarbij	 de	 borstkanker	 na	 behandeling	 onder	
controle	is.	In	Hoofdstuk 6	werd	het	optreden	van	hart-	en	vaatziekten	na	toediening	van	
chemotherapie	bestudeerd	voor	de	borstkankerpatiënten	uit	het	IKZ-PHARMO	cohort.	De	
incidentie	van	hart-	en	vaatziekten	anderhalf	 jaar	na	chemotherapiebehandeling	bleek	
niet	 verhoogd	 na	 toediening	 van	 cardiotoxische	 chemotherapeutica	 vergeleken	 met	
niet-cardiotoxische	chemotherapeutica.	Ouderen	of	patiënten	met	hart-	en	vaatziekten	
op	 het	moment	 van	 diagnose	 kregen	minder	 vaak	 cardiotoxische	 chemotherapeutica	
toegediend.	 Specialisten	 lijken	 rekening	 te	houden	met	de	aanwezigheid	van	hart-	 en	
vaatziekten	bij	de	keuze	van	het	soort	chemotherapeutica,	of	verlagen	de	dosis	van	het	
geneesmiddel	als	het	een	cardiotoxisch	chemotherapeutica	betreft.	
In	Hoofdstuk 7	 werd	 bij	 patiënten	met	 een	 ziekenhuisopname	 voor	 borstkanker	 het	
optreden	van	een	ziekenhuisopname	voor	trombose	bepaald	met	behulp	van	gegevens	uit	
de	PHARMO	databanken.	Borstkankerpatiënten	bleken	in	het	jaar	voor	diagnose	een	meer	
dan	twee	keer	verhoogde	kans	te	hebben	op	een	ziekenhuisopname	voor	een	hartinfarct,	
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herseninfarct	 en	 longembolie	 in	 vergelijking	met	patiënten	 zonder	 kanker.	Mogelijk	 is	
dit	 te	verklaren	doordat	 factoren	zoals	overgewicht	het	 risico	op	zowel	borstkanker	als	
trombose	 verhogen.	 Direct	 na	 ziekenhuisopname	 voor	 borstkanker	 hadden	 patiënten	
een	sterk	verhoogd	risico	op	het	krijgen	van	een	longembolie.	Dat	risico	daalde	naarmate	
de	ziekenhuisopname	voor	borstkanker	langer	geleden	was.	Borstkankerbehandeling	en	
factoren	die	een	verband	hebben	met	de	behandeling,	zoals	duur	van	ziekenhuisopname,	
verhogen	de	 kans	op	het	 krijgen	 van	 een	 longembolie.	Deze	 studie	draagt	bij	 aan	de	
bewustwording	van	de	aanwezigheid	van	trombose	in	borstkankerpatiënten	en	het	risico	
op	het	ontstaan	van	trombose	na	behandeling	van	patiënten	met	borstkanker.	
Naast	 de	 studies	 beschreven	 in	 dit	 proefschrift,	 geeft	 de	 IKZ-PHARMO	 koppeling	 de	
mogelijkheid	om	farmaco-epidemiologisch	onderzoek	en	uitkomstenonderzoek	te	doen	
in	veel	andere	kankersoorten,	mits	de	patiëntenaantallen	dit	toestaan.	Om	de	bijzondere	
positie	van	het	IKZ-PHARMO	cohort	in	kaart	te	brengen	werd	deze	koppeling	vergeleken	
met	soortgelijke	registratiekoppelingen	uit	Noord-Amerika	en	Europa	(Hoofdstuk 8.2).	
In	vergelijking	met	de	andere	databronnen	bleek	het	IKZ-PHARMO	cohort	bijzonder	op	
twee	aspecten:	de	aanwezigheid	van	comorbiditeit	 ten	 tijde	van	kankerdiagnose	zoals	
geregistreerd	in	de	kankerregistratie	van	het	IKZ	en	de	gegevens	over	de	toediening	van	alle	
(anti-kanker)geneesmiddelen	(zowel	intra-	als	extramuraal)	beschikbaar	via	de	PHARMO	
databanken.	Deze	data	waren	niet	aanwezig	in	de	andere	registratiekoppelingen.
Dit	 proefschrift	 eindigt	 met	 een	 beschrijving	 van	 de	 representativititeit	 van	 het	
IKZ-PHARMO	 cohort,	 de	 huidige	 beperkingen	 van	 de	 beschikbare	 gegevens	 en	 de	
mogelijkheden	 tot	 verbetering	 en	 uitbreiding	 van	 de	 datacollecties.	 Ook	 wordt	 er	
een	 overzicht	 gegeven	 van	 farmaco-epidemiologische	 studies,	 die	 naast	 de	 studies	
beschreven	in	dit	proefschrift,	uitgevoerd	zouden	kunnen	worden	met	de	gegevens	van	
het	 IKZ-PHARMO	cohort.	Voorbeelden	zijn:	onderzoek	naar	geneesmiddelengebruik	en	
het	risico	op	kanker,	onderzoek	naar	geneesmiddeleninteracties	tussen	kankermedicijnen	
en	andere	medicijnen	en	onderzoek	naar	 vervolgbehandeling	van	kankerpatiënten	na	
primaire	 behandeling.	Daarnaast	worden	 aspecten	belangrijk	 voor	 de	 continuïteit	 van	
het	IKZ-PHARMO	cohort	beschreven,	zoals	regelgeving,	privacy	en	veiligheid	rondom	het	
gebruik	van	de	data.
Concluderend	kan	gesteld	worden	dat	dit	proefschrift	 inzicht	geeft	 in	het	gebruik	van	
geneesmiddelen	door	borstkankerpatiënten	in	de	dagelijkse	praktijk	en	het	ontstaan	van	
andere	ernstige	aandoeningen	na	borstkankerdiagnose	en	-behandeling.	Deze	resultaten	
zijn	verkregen	met	behulp	van	de	van	de	kankerregistratie	van	het	IKZ,	de	databanken	van	
het	PHARMO	Instituut	en	het	gekoppelde	IKZ-PHARMO	cohort.	Dit	IKZ-PHARMO	cohort	
biedt	nieuwe	mogelijkheden	voor	epidemiologen	en	clinici	die	onderzoek	doen	naar	het	
gebruik,	de	effectiviteit	en	veiligheid	van	(nieuwe)	geneesmiddelen	voor	de	behandeling	
van	kanker.	
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64	hrs	(2.3	ECTS)
40	hrs	(1.4	ECTS)
236
Myrthe van Herk-Sukel
Presentations
-	 Poster	presentation	at	International	Conference	on	
Pharmacoepidemiology	&	Therapeutic	Risk	Management	(ICPE)
-	 Oral	presentation	at	Integraal	Kankercentrum	Zuid	(IKZ)	breast	cancer	
seminar
-	 Poster	presentation	at	6th	European	Breast	Cancer	Conference	(EBCC6)
-	 Poster	presentation	at	International	Society	for	Pharmacoeconomics	
and	Outcomes	Research	(ISPOR)
-	 Oral	presentation	at	Breast	Cancer	Symposium,	‘Nieuwe	
Ontwikkelingen	bij	de	Behandeling	van	het	Mammacarcinoom’
-	 Oral	presentation	at	IKZ	medical	oncology	seminar
-	 Oral	and	poster	presentation	at	ICPE
-	 Poster	presentation	at	joint	15th	Congress	of	the	European	CanCer	
Organisation	and	34th	Congress	of	the	European	Society	for	Medical	
Oncology	(ECCO	15	and	34th	ESMO)
-	 Poster	presentation	at	ISPOR
-	 Poster	presentation	at	32nd	Annual	San	Antonio	Breast	Cancer	
Symposium	(SABCS)
-	 Poster	presentation	at	ISPOR
-	 Oral	presentation	at	“Leren	door	registreren”,	55	jaar	regionale	
kankerregistratie
-	 Two	poster	presentations	at	ISPOR
-	 Two	poster	presentations	at	ICPE
-	 Five	oral	presentations	at	PHARMO	seminars
2006
2007
2008
2008
2009
2009
2009
2009
2009
2009
2010
2011
2011
2011
2006-2011
32	hrs	(1.1	ECTS)
32	hrs	(1.1	ECTS)
32	hrs	(1.1	ECTS)
32	hrs	(1.1	ECTS)
32	hrs	(1.1	ECTS)
32	hrs	(1.1	ECTS)
64	hrs	(2.3	ECTS)
32	hrs	(1.1	ECTS)
32	hrs	(1.1	ECTS)
32	hrs	(1.1	ECTS)
32	hrs	(1.1	ECTS)
32	hrs	(1.1	ECTS)
64	hrs	(2.3	ECTS)
64	hrs	(2.3	ECTS)
160	hrs	(5.7	ECTS)
International conferences
-	 United	Kingdom	Association	of	Cancer	Registries	(UKACR)	and	
Netherlands	Cancer	Registry	(NCR)	Conference
-	 ISPOR	9th	Annual	European	Congress
-	 ISPOR	12th	Annual	International	Meeting
-	 6th	European	Breast	Cancer	Conference	(EBCC6)
-	 25th	Anniversary	International	Conference	on	Pharmacoepidemiology	
&	Therapeutic	Risk	Management
2006
2006
2007
2008
2009
24	hrs	(0.9	ECTS)
24	hrs	(0.9	ECTS)
24	hrs	(0.9	ECTS)
32	hrs	(1.1	ECTS)
24	hrs	(0.9	ECTS)
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Dutch conferences
-	 FIGON	Dutch	Medicines	Days
-	 Therapie	op	maat,	2de	interdisciplinaire	congres	van	de	NVCO,	NVMO	
en	NVRO
-	 Symposium	‘Nieuwe	Ontwikkelingen	bij	de	Behandeling	van	het	
Mammacarcinoom’
-	 NVvO-Oncologiedag	Borstkanker
2006
2007
2009
2011
24	hrs	(0.9	ECTS)
16	hrs	(0.6	ECTS)
8	hrs	(0.3	ECTS)
8	hrs	(0.3	ECTS)
2. Teaching activities
Year Workload  
(Hours/ECTS)
Supervising	Bachelor’s	theses
-	 ‘Literature	review	on	cardiotoxicity	and	cancer’,		J.	Kerkvliet,	
Department	of	Pharmaceutical	Sciences,	Utrecht	University	
-	 ‘Voorschrijfgedrag	van	cytostatica	voor	colorectaalkanker	in	
zes	Nederlandse	ziekenhuizen’,	C.	Verkroost,	Department	of	
Pharmaceutical	Sciences,	Utrecht	University
2006
2010
40	hrs	(1.4	ECTS)
40	hrs	(1.4	ECTS)
Supervising	Master’s	theses
-	 ‘Overview	of	databases	utilized	in	published	literature	for	cancer	
surveillance’,	F.Bergsma,	Department	of	Pharmaceutical	Sciences,	
Utrecht	University
-	 ‘NSAID	exposure	and	risk	of	cancer’,	L.M.	Hollestein,	Master	of	Science	
in	Clinical	Epidemiology,	NIHES
2007
2011
40	hrs	(1.4	ECTS)
40	hrs	(1.4	ECTS)
TOTAL 1,392 hrs (50 ECTS)
P h D  p o r t f o l i o  s u m m a r y



Medication Use Among Women With 
Breast Cancer in the Netherlands
Myrthe van Herk-Sukel
Pharmacoepidemiological studies based on data from 
the Eindhoven Cancer Registry-PHARMO linkage
The crab is the symbol for cancer and the pink colour represents 
breast cancer awareness.  The crab is composed of many smaller 
crabs referring to the complexity of cancer and its treatment. 
The medicines used to treat breast cancer are symbolised 
by the pipette and snake; the symbol of medicine. 
The numbers and figures stand for the large, population-
based data sources used for this research.
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